Selective nk-3 receptor antagonist compounds, pharmaceutical composition and drug comprising them

专利摘要:
NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS. The present invention relates to the novel compounds of formula I and their use as therapeutic compounds.
公开号:BR112012025101B1
申请号:R112012025101-5
申请日:2011-04-04
公开日:2021-08-31
发明作者:Hamid Hoveyda；Marie-Odile Roy；Graeme Lovat Fraser；Guillaume Dutheuil
申请人:Ogeda S.A.；
IPC主号:

专利说明:

[001] The present invention relates to novel compounds including their pharmaceutically acceptable salts and solvates, which are selective neurokinin 3 (NK-3) receptor antagonists and are useful as therapeutic compounds, particularly in the treatment and/or prevention of a wide array of CNS and peripheral diseases or disorders. BACKGROUND OF THE INVENTION
[002] Tachykinin receptors are the targets of a family of structurally related peptides that include substance P (SP), neurokinin A (NKA) and neurokinin B (NKB), collectively called "tachykinins". Tachykinins are synthesized in the central nervous system (CNS) and peripheral tissues, where they exert a variety of biological activities. Three tachykinin receptors are known which are called neurokinin-1 (NK-1), neurokinin-2 (NK-2) and neurokinin-3 (NK-3) receptors. Tachykinin receptors belong to the seven rhodopsin-like membrane G protein-coupled receptors. SP has the highest affinity and is believed to be the endogenous ligand for NK-1, NKA for the NK-2 receptor and NKB for the NK-3 receptor, although some cross-reactivity probably exists. NK-1, NK-2 and NK-3 receptors have been identified in different species. NK-1 and NK-2 receptors are expressed in a wide variety of peripheral tissues and NK-1 receptors are also expressed in the CNS; while NK-3 receptors are primarily expressed in the CNS.
[003] Neurokinin receptors mediate a variety of tachykinin-stimulated biological effects that include excitatory neuronal signal transmission in the CNS and periphery (eg, pain), modulation of smooth muscle contractile activity, modulation of immune and inflammatory responses, induction of hypotensive effects through dilation of the peripheral vasculature and stimulation of endocrine and exocrine gland secretions.
[004] In the CNS, the NK-3 receptor is expressed in regions including the medial prefrontal cortex, hippocampus, thalamus and amygdala. Furthermore, NK-3 receptors are expressed on dopaminergic neurons. Activation of NK-3 receptors has been shown to modulate the release of dopamine, acetylcholine and serotonin suggesting a therapeutic utility for NK-3 receptor modulators for the treatment of a variety of disorders including psychotic disorders, anxiety, depression, schizophrenia as well as obesity, pain or inflammation (Exp. Opinion Ther. Patents (2000), 10(6); 939-960 Current Opinion in Investigational Drugs, 2001, 2(7), 950-956 and Current Pharmaceutical Design, 2010, 16, 344-357 ).
[005] Schizophrenia is classified into subgroups. The paranoid type is characterized by delusions and hallucinations and an absence of thought disturbance, disorganized behavior, and affective flattening. In the disorganized type, which is also called 'hebephrenic schizophrenia' in the International Classification of Diseases (ICD), thought disorder and absence or decrease in affect are present together. In the catatonic type, prominent psychomotor disorders are evident, and symptoms may include catatonic stupor and waxy flexibility (stiffness of catalepsy). In the undifferentiated type, psychotic symptoms are present, but the criteria for the paranoid, disorganized, or catatonic types were not met. Schizophrenia symptoms usually manifest themselves into three broad categories, namely, positive, negative, and cognitive symptoms. Positive symptoms are those that represent an "excess" of normal experiences such as hallucinations and delusions. Negative symptoms are those where the patient suffers from a lack of normal experiences such as anhedonia and lack of social interaction. Cognitive symptoms are related to cognitive impairment in schizophrenics, such as sustained lack of attention and decision-making deficits. Current antipsychotic drugs (APDs) are reasonably successful in treating positive symptoms but work far less well for negative and cognitive symptoms. In contrast, NK3 antagonists have been clinically shown to improve both positive and negative symptoms in schizophrenics (Meltzer et al., Am. J. Psychiatry, 161, 975-984, 2004) and to improve cognitive behavior in schizophrenics (Curr. Opion. Invest. Drug, 6, 717-721, 2005).
[006] In the rat, morphological studies provide evidence for putative interactions between NKB neurons and the hypothalamic reproductive axis (Krajewski et al., J. Comp. Neurol., 489(3), 372-386, 2005). In arcuate nucleus neurons, NKB expression colocalizes with the stro estrogen and dynorphin receptor, implicated in progesterone feedback for Gonadotropin Releasing Hormone (GnRH) secretion (Burke et al., J. Comp. Neurol., 498( 5), 712-726, 2006; Goodman et al., Endocrinology, 145, 2959-2967, 2004). Furthermore, the NK-3 receptor is highly expressed in the hypothalamic arcuate nucleus in neurons that are involved in the regulation of GnRH release.
[007] WO 00/43008 describes a method of suppressing gonadotropin and/or androgen production with specific NK-3 receptor antagonists. More particularly, application WO 00/43008 relates to reducing the blood level of luteinizing hormone (LH) by administering an NK-3 receptor antagonist. Concurrently or alternatively with gonadotropin suppression, WO 00/43008 also refers to suppression of androgen production with NK-3 receptor antagonists. It has recently been postulated that NKB acts autosynaptically on kisspeptin neurons in the arcuate nucleus to synchronize and formulate pulsatile kisspeptin secretion and guide GnRH release from fibers at the median eminence (Navarro et al., J. of Neuroscience, 23, 2009 - pp11859- 11866). All these observations suggest a therapeutic utility for NK-3 receptor modulators for sex hormone-dependent diseases.
[008] Non-peptide ligands have been developed for each of the tachykinin receptors. Some of them have been described as dual modulators capable of modulating both NK-2 and NK-3 receptors (WO 06/120478). However, known non-peptide NK-3 receptor antagonists suffer from several limitations such as poor drug bioavailability, poor CNS penetration and poor potency particularly at mouse/rat orthologous receptors, all aspects that limit the potential of evaluating these compounds in preclinical models and/or clinical development. Based on this, novel potent and selective NK-3 receptor antagonists may be of therapeutic value for the preparation of drugs useful in the treatment and/or prevention of CNS and peripheral diseases or disorders in which NKB and NK-3 receptors are involved . SUMMARY OF THE INVENTION
[009] The invention encompasses compounds of general formula I, their pharmaceutically acceptable salts and solvates as well as methods of using such compounds or compositions comprising such compounds as antagonists of NK-3 receptor activity.
[0010] In a general aspect, the invention provides compounds of general formula I:

[0011] and pharmaceutically acceptable salts and solvates thereof, wherein
[0012] Ar1 is a 5- to 6-membered aryl or heteroaryl group, 3 to 6-membered cycloalkyl group, a 3 to 6-membered heterocyclyl group or a C3-C6 alkyl group, each of the aryl, heteroaryl, cycloalkyl or heterocyclyl groups being optionally substituted by one or more group(s) selected from halo, cyano, alkyl, haloalkyl, cycloalkyl, heteroalkyl, heterocyclyl, aryl, aralkyl, heteroaryl, hydroxyl, alkoxy, haloalkoxy, alkoxyalkoxy, alkylamino, carboxy, alkoxycarbonyl, alkylcarbonyloxy, alkylcarbonylamino, haloalkylcarbonylamino, carbohydrate they are linked to, or merged with, the group aryl, heteroaryl, cycloalkyl or heterocycloalkyl may be one or more aryl moiety, each of said substituents being optionally substituted by one or more other substituent(s) selected from halo, cyano, alkyl, haloalkyl, cyclopropyl, alkoxy, haloalkoxy, heterocyclyl, aryl, heteroaryl, aryloxy or heteroaryloxy;
[0013] L1 is C1-C2 alkylene optionally being substituted by one or more group(s) selected from halo, methyl or ethyl under the condition that R2' together with R2form an oxo substituent, or L1is carbonyl or sulfonyl, or L1is -( C=O)-CH2- where C=O is bound to piperazine nitrogen and CH2 to Ar1;
[0014] R 1 is H, a C 1 -C 4 alkyl, aryl or aralkyl group, each of said alkyl, aryl or aralkyl groups being optionally substituted by one or more group(s) selected from halo or hydroxy;
[0015] R1' is H or a C1-C4 alkyl group;
[0016] R2is H or a C1-C4 alkyl group;
[0017] R2' is H or a C1-C4 alkyl group, or, when L1 is C1-C2 alkylene optionally being substituted by one or more group(s) selected from halo, methyl or ethyl, R2' together with R2 form an oxo substituent ;
[0018] R3 is H or a C1-C4 alkyl group optionally substituted by a hydroxy;
[0019] R3' is H or a C1-C4 alkyl group;
[0020] X1and X2are independently selected from N or C-Z wherein Z is H or C1-C2 alkyl under the proviso that X1and X2 cannot both be C-Z;
[0021] L2 is a single bond or carbonyl;
[0022] Ar2 is a 5- to 6-membered aryl or heteroaryl group, each of the aryl, or heteroaryl groups being optionally substituted by one or more group(s) selected from halo, cyano, alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, heteroalkyl, heterocyclyl , aryl, heteroaryl, aralkyl, heteroarylalkyl, hydroxyl, alkoxy, haloalkoxy, alkylamino, carboxy, alkoxycarbonyl, alkylcarbonyloxy, alkylcarbonylamino, haloalkylcarbonylamino, acylamino, carbamoyl, alkylcarbamoyl, carbamoylalkyl, carbamoylalkyl, carbamoylalkylsulfonylalkylsulfamoyl,sulfonylalkylsulfamoyl,sulfonylalkylsulfamoyl,sulfonylalkyl, , haloalkylsulfonylamino, or two substituents form an alkylenedioxy group or a haloalkylenedioxy group, or fused to the aryl or heteroaryl group may be one or more cycloalkyl, aryl, heterocyclyl or heteroaryl moieties, each of said substituents being optionally substituted by one or more other substituents ( s) select halo, cyano, alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, heterocyclyl optionally substituted by alkyl, aryl, heteroaryl, hydroxyl, alkoxyalkyl, hydroxyalkoxy, alkylamino, alkylsulfonylamino, alkoxycarbonylamino, aminoalkoxy, or alkoxycarbonylaminoalkoxy;
[0023] and where, when:
[0024] R1, R1', R2, R2', R3, R3'are H, and
[0025] L1 is carbonyl, and
[0026] L2is single link, and
[0027] X2 is N, and
[0028] Ar1 is a 6-membered aryl optionally substituted by one or more group(s) selected from halo, cyano, C1-C3 alkyl, C1 haloalkyl, and
[0029] Ar2 is a 5- to 6-membered aryl or heteroaryl group optionally substituted by one or more group(s) selected from halo, C1-C3 alkyl, hydroxyl, methoxy, or fused to an aryl or heteroaryl group optionally substituted by one or plus others halo, C1C3 alkyl, hydroxyl, methoxy,
[0030] then,
[0031] Ar1is phenyl, 3-halophenyl, 4-halophenyl, 2,3-dichlorophenyl, 2,4-difluorophenyl, 2,4-dichlorophenyl, 2,5-dihalophenyl, 2,6-difluorophenyl, 2,6- dichlorophenyl, 3,4-dihalophenyl, 3,5-dihalophenyl, 3,4,5-trihalophenyl, 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, 2,3-dicyanophenyl, 2,4- dicyanophenyl, 3,5-dicyanophenyl, 3-cyano-4-halophenyl, 4-(C1-C3 alkyl)phenyl, 3,4-di(C1-C3 alkyl)phenyl, 3,5-di(C1-C3 alkyl) phenyl, 4-(C1 haloalkyl)phenyl, and
Ar2is 2-(C1-C3 alkyl)thiazol-4-yl, 5-(C1-C3 alkyl)thiazol-4-yl, pyridin-2-yl, 4-halopyridin-2-yl, 4-(C1 -C3 alkyl)pyridin-2-yl, 5-(C1-C3 alkyl)pyridin-2-yl, 6-(C1-C3 alkyl)pyridin-2-yl, quinolin-2-yl, isoquinolin-3-yl, 8-haloquinolin-2-yl, benzothiazol-2-yl, 4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl;
[0033] with the following conditions:
[0034] - compounds wherein L1 is CO, L2 is a single bond, X1 is N, X2 is CH and Ar2 is a substituted phenyl are excluded; and
[0035] - Ar1 is neither a substituted or unsubstituted pyrazolo[1,5-a] pyridin-2yl moiety nor a substituted or unsubstituted pyrazolo[1,5-a] pyrimidin-2yl moiety; and
[0036] the compound of formula I is none of:
[0037] 1-methyl-7-[(3-phenyl-5-isoxazolyl)carbonyl]-3-(4-pyridinyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine,
[0038] 7-[(2-benzyl-1,3-thiazol-4-yl)carbonyl]-1-methyl-3-(4-pyridinyl)-5,6,7,8-tetrahydroimidazo[1,5- a] pyrazine,
3-{[1-methyl-3-(1-phenyl-1H-pyrazol-4-yl)-5,6-dihydroimidazo[1,5-a]pyrazin-7(8H)-yl] carbonyl}-1-indanone,
[0040] 7-[5-(4-methoxyphenyl)-2-furoyl]-1-methyl-3-(4-pyridinyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine,
[0041] 1-methyl-3-(4-pyridinyl)-7-(4,5,6,7-tetrahydro-1-benzothien-3-ylcarbonyl)-5,6,7,8-tetrahydroimidazo[1,5 -a] pyrazine,
[0042] 2-{2-[1-methyl-3-(2-methyl-1,3-thiazol-4-yl)-5,6-dihydroimidazo[1,5-a] pyrazin-7(8H) )-yl]-2-oxoethyl}-1,2,3,4-tetrahydroisoquinoline,
[0043] 7-[(1,3-diphenyl-1H-pyrazol-5-yl)carbonyl]-1-methyl-3-(4-pyridinyl)-5,6,7,8-tetrahydroimidazo[1,5- a] pyrazine,
[0044] 8-fluoro-2-{[1-methyl-3-(4-pyridinyl)-5,6-dihydroimidazo[1,5-a] pyrazin-7(8H)-yl]carbonyl}quinoline,
[0045] 1-methyl-3-(2-methyl-1,3-thiazol-4-yl)-7-{[2-(2-thienyl)-1,3-thiazol-4-yl]carbonyl}- 5,6,7,8-tetrahydroimidazo[1,5-a] pyrazine,
[0046] 7-(3-fluoro-4-methoxybenzoyl)-1-methyl-3-(4-pyridinyl)-5,6,7,8-tetrahydroimidazo[1,5-a] pyrazine,
7-[(3-ethyl-5-methyl-4-isoxazolyl)carbonyl]-1-methyl-3-(4-pyridinyl)-5,6,7,8-tetrahydroimidazo[1,5-a] pyrazine,
[0048] 3-{2-[1-methyl-3-(1-phenyl-1H-pyrazol-4-yl)-5,6-dihydroimidazo[1,5-a]pyrazin-7(8H)- yl]-2-oxoethyl}-4(3H)-quinazolinone,
[0049] 3-{[1-methyl-3-(1-phenyl-1H-pyrazol-4-yl)-5,6-dihydroimidazo[1,5-a]pyrazin-7(8H)-yl] carbonyl}-6,7-dihydro-1-benzofuran-4(5H)-one,
[0050] 7-{[3-(2-methoxyphenyl)-1H-pyrazol-5-yl]carbonyl}-1-methyl-3-(4-pyridinyl)-5,6,7,8-tetrahydroimidazo[1, 5-a] pyrazine,
3-{[1-methyl-3-(1-phenyl-1H-pyrazol-4-yl)-5,6-dihydroimidazo[1,5-a]pyrazin-7(8H)-yl] carbonyl}-4H-pyrido[1,2-a]pyrimidin-4-one,
[0052] 1-ethyl-3-(2-methoxyphenyl)-7-[3-(1H-pyrazol-1-yl)benzoyl]-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine,
[0053] 1-methyl-7-[(3-phenyl-1-piperidinyl)acetyl]-3-(4-pyridinyl)-5,6,7,8-tetrahydroimidazo[1,5-a] pyrazine,
[0054] 1-methyl-3-(2-methyl-1,3-thiazol-4-yl)-7-(1,2,5-thiadiazol-3-ylcarbonyl)-5,6,7,8-tetrahydroimidazo [1,5-a] pyrazine,
[0055] (2,3-dihydrobenzo[b][1,4]dioxin-6-yl)(1-methyl-3-(pyridin-4-yl)-5,6-dihydroimidazo[1, 5-a]pyrazin-7(8H)-yl)methanone,
[0056] 3-(1-methyl-3-(pyridin-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a] pyrazine-7-carbonyl)-5,6,7,8 -tetrahydroquinolin-2(1H)-one,
[0057] (2,3-dihydrobenzofuran-2-yl)(1-methyl-3-(pyridin-4-yl)-5,6-dihydroimidazo[1,5-a]pyrazin-7(8H) )-yl)methanone,
[0058] (1-methyl-3-(1-phenyl-1H-pyrazol-4-yl)-5,6-dihydroimidazo[1,5-a] pyrazin-7(8H)-yl)(8- methylimidazo[1,2-a]pyridin-2-yl)methanone,
[0059] (2,3-dihydrothieno[3,4-b][1,4]dioxin-5-yl)(1-methyl-3-(pyridin-4-yl)-5,6-di- hydroimidazo[1,5-a]pyrazin-7(8H)-yl)methanone,
[0060] 2-methyl-6-(1-methyl-3-(pyridin-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a] pyrazine-7-carbonyl)-4,5 -dihydropyridazin-3(2H)-one
[0061] (3-(2-methoxyphenyl)-1H-pyrazol-5-yl)(1-methyl-3-(pyridin-4-yl)-5,6-dihydroimidazo[1,5-a]pyrazin -7(8H)-yl)methanone,
[0062] (2,3-dihydrobenzofuran-2-yl)(1-methyl-3-(pyridin-4-yl)-5,6-dihydroimidazo[1,5-a]pyrazin-7(8H) )-yl)methanone,
[0063] (1-methyl-3-(2-methylthiazol-4-yl)-5,6-dihydroimidazo[1,5-a]pyrazin-7(8H)-yl)(2-(thiophen-2) -yl)thiazol-4-yl)methanone,
[0064] (3,5-dimethyl-1H-pyrrol-2-yl)(1-methyl-3-(pyridin-4-yl)-5,6-dihydroimidazo[1,5-a]pyrazin-7 (8H)-yl)methanone,
[0065] (1-methyl-3-(pyridin-4-yl)-5,6-dihydroimidazo[1,5-a]pyrazin-7(8H)-yl)(4,5,6,7- tetrahydrobenzo[b]thiophen-3-yl)methanone;
[0066] (2,4-dichlorophenyl)(3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H) -yl)methanone;
[0067] (2,4-difluorophenyl)(3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H) -yl)methanone;
[0068] (3-chlorophenyl)(3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl )methanone;
[0069] 2-(3-(pyridin-2-yl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine-7-carbonyl)benzonitrile;
[0070] (2,6-dichlorophenyl)(3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H) -yl)methanone,
[0071] (2,3-dichlorophenyl)(3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H) -yl)methanone,
[0072] (2,3-dichlorophenyl)(3-(5-methylpyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo [4,3-a]pyrazin-7( 8H)-yl)methanone,
[0073] (2,3-dichlorophenyl)(3-(6-methylpyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo [4,3-a]pyrazin-7( 8H)-yl)methanone.
[0074] In another aspect, the present invention provides a pharmaceutical composition comprising at least one compound according to the invention or a pharmaceutically acceptable salt or solvate thereof.
[0075] The invention also relates to the use of the above compounds or their pharmaceutically acceptable salts and solvates as NK-3 receptor modulators, preferably as NK-3 receptor antagonists.
[0076] The invention also provides methods of treating and/or preventing depression, anxiety, psychosis, schizophrenia, psychotic disorders, bipolar disorders, cognitive disorders, Parkinson's disease, Alzheimer's disease, attention deficit hyperactivity disorder (ADHD) , pain, seizure, obesity, inflammatory diseases including irritable bowel syndrome and inflammatory bowel disorders, emesis, pre-eclampsia, airway related diseases including chronic obstructive pulmonary disease, asthma, airway hyperresponsiveness, bronchoconstriction and coughing, reproductive disorders and sex hormone dependent diseases including but not limited to benign prostatic hyperplasia (BPH), metastatic prostatic carninoma, testicular cancer, breast cancer, erogen dependent acne, male pattern baldness, endometriosis, abnormal puberty, uterine fibrosis, dependent cancers of hormone, hyperandrogenism, hirsutism, virilization, ova syndrome polycystic river (PCOS), HAIR-AN syndrome (hyperandrogenism, insulin resistance, and acanthosis nigricans), ovarian hyperthecosis (HAIR-AN with luteinized theca cell hyperplasia in ovarian stroma), other manifestations of elevated intraovarian androgen concentrations (eg, interruption of follicular maturation, atresia, anovulation, dysmenorrhea, dysfunctional uterine bleeding, infertility) and androgen-producing tumor (virilizing adrenal or ovarian tumor) comprising the administration of a therapeutically effective amount of a compound or pharmaceutically acceptable salt or formula solvate ( I), to a patient in need thereof. Preferably the patient is a warm-blooded animal, more preferably a human.
[0077] The invention also provides methods of treatment for gynecological disorders and infertility. In particular, the invention provides methods for suppressing LH surge in assisted conception comprising administering a therapeutically effective amount of a compound or pharmaceutically acceptable salt or solvate of formula (I) to a patient in need thereof. Preferably the patient is a warm-blooded animal, more preferably a woman.
[0078] The invention also provides methods for affecting androgen production to cause male castration and for inhibiting the sex drive in male sex offenders comprising administering a therapeutically effective amount of a compound or pharmaceutically acceptable salt or solvate of formula (I) , to a patient in need of it. Preferably the patient is a warm-blooded animal, more preferably a man.
[0079] The invention also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as a medicine. Preferably, the drug is used for the treatment and/or prevention of depression, anxiety, psychosis, schizophrenia, psychotic disorders, bipolar disorders, cognitive disorders, Parkinson's disease, Alzheimer's disease, attention deficit hyperactivity disorder (ADHD), pain, seizure, obesity, inflammatory diseases including irritable bowel syndrome and inflammatory bowel disorders, emesis, pre-eclampsia, airway related diseases including chronic obstructive pulmonary disease, asthma, airway hyperresponsiveness, bronchoconstriction and coughing, reproductive disorders and sex hormone dependent diseases including, but not limited to benign prostatic hyperplasia (BPH), metastatic prostatic carninoma, testicular cancer, breast cancer, androgen dependent acne, male pattern baldness, endometriosis, abnormal puberty, uterine fibrosis, cancer dependent hormone, hyperandrogenism, hirsutism, virilization, syndrome polycystic ovary (PCOS), HAIR-AN syndrome (hyperandrogenism, insulin resistance and acanthosis nigricans), ovarian hyperthecosis (HAIR-AN with luteinized theca cell hyperplasia in ovarian stroma), other manifestations of elevated intraovarian androgen concentrations (eg , interruption of follicular maturation, atresia, anovulation, dysmenorrhea, dysfunctional uterine bleeding, infertility) and androgen-producing tumor (virilizing adrenal or ovarian tumor). The drug can also be used to treat gynecological disorder, infertility and to affect androgen production to cause male castration. DETAILED DESCRIPTION OF THE INVENTION
[0080] As noted above, the invention relates to the compounds of formula I, as well as their pharmaceutically acceptable salts and solvates.
[0081] Preferred compounds of formula I and pharmaceutically acceptable salts and solvates thereof are those wherein
[0082] Ar1 is a 5- to 6-membered aryl or heteroaryl group, 5- to 6-membered cycloalkyl group, C3-C6 alkyl group, each of the aryl or heteroaryl groups being optionally substituted by one or more group(s) selected from halo, cyano, alkyl, haloalkyl, C3-C6 cycloalkyl, heteroalkyl, heterocyclyl, aryl, heteroaryl, hydroxyl, alkoxy, haloalkoxy, alkylamino, carboxy, alkoxycarbonyl, alkylcarbonyloxy, alkylcarbonylamino, haloalkylcarbonylamino, carbamoyl, alkylcarbaylaminoalkylsulfamoyl, alkylcarbaylaminoalkylsulfamyl, carbamoyl, alkylaminoalkylsulfamoyl, carbamoylsulfamyl , alkylsulfamoyl, alkylsulfonylamino, haloalkylsulfonylamino, or two substituents form an alkylenedioxy group or a haloalkylenedioxy group, or fused to the aryl, heteroaryl, cycloalkyl or heterocycloalkyl group may be an aryl moiety, each of said substituents being optionally substituted by one or more other substituents ( s) selected from halo, cyano, alkyl, haloalkyl, cyclopro pyla, alkoxy, haloalkoxy, heterocyclyl, aryl, heteroaryl, aryloxy or heteroaryloxy, preferably Ar1 is an aryl group, preferably phenyl, 5- to 6-membered heteroaryl preferably pyridinyl, isopropyl, isobutyl, each of the aryl or heteroaryl groups being optionally substituted by one or further group(s) selected from halo, cyano, alkyl, haloalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or fused to the aryl or heteroaryl group may be an aryl moiety, preferably phenyl, each of said substituents optionally being substituted by one or plus other substituent(s) selected from halo, alkyl, haloalkyl, cyclopropyl, haloalkoxy, or aryloxy, more preferably Ar1 is a phenyl, a biaryl, preferably 4-biphenyl, heterobiaryl preferably 4-(thiophen-2-yl)phenyl, 3 -phenyl-1H-pyrazol-5-yl, 5-phenylpyridin-2-yl, 2-phenylpyridin-5-yl, more preferably 4-(thiophen-2-yl)phenyl, each of said biaryl or heterobiaryl being optionally substituted with one or more other substituent(s) selected from halo, alkyl, cyclopropyl, haloalkyl, haloalkoxy or aryloxy; and/or
[0083] L1 is carbonyl; and/or
[0084] R1is H, a C1-C4 alkyl, aryl or aralkyl group, each of said alkyl, aryl or aralkyl groups being optionally substituted by one or more group(s) selected from halo or hydroxy, preferably R1is H, a C1 group -C3 alkyl, preferably methyl or isopropyl, hydroxyethyl, phenyl or benzyl, each of said phenyl or benzyl groups being optionally substituted by one or more group(s) selected from halo, preferably fluorine or chlorine, more preferably R1 is H, methyl or 2 -hydroxyethyl; and/or
[0085] R1' is H or methyl preferably R1' is H; and/or
[0086] R2, R2', R3and R3'are H; and/or
[0087] X1 and X2 are independently selected from N or CZ where Z is H or methyl, under the condition that X1 and X2 cannot both be CZ, preferably X1 and X2 are independently selected from N or CH under the condition that X1 and X2 cannot be both CH, more preferably X1 and X2 are both N; and/or
[0088] L2 is a single bond; and/or
[0089] Ar2 is a 5- to 6-membered heteroaryl group optionally substituted by one or more group(s) selected from halo, cyano, alkyl, haloalkyl, C3-C6 cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, arylsulfonylalkyl, alkoxy , or fused to the heteroaryl group may be a cycloalkyl, aryl, heterocyclyl or heteroaryl moiety, each of said substituents being optionally substituted by one or more other substituent(s) selected from halo, cyano, alkyl, haloalkyl, cyclopropyl, alkoxy, heterocyclyl optionally substituted by alkyl aryl, hydroxy, alkoxyalkyl, hydroxyalkoxy, alkylamino, alkylsulfonylamino, alkoxycarbonylamino, aminoalkoxy, or alkoxycarbonylaminoalkoxy preferably Ar2 is a fused heteroaryl, preferably quinolin-2-yl, benzo[d]thiazol-2-yl, 4,5,6, 7-tetrahydrobenzo[d]thiazol-2-yl, heterocyclylheteroaryl, preferably 2-(pyrrolidin-1-yl)thiazol-4-yl, 2-(piperidin-1-yl)thiazol-4-yl, 2-(morpholin- 4-yl)thiazol-4-yl, 2-(piperazin-1-yl)thiazol-4-yl, heterobiaryl preferably 2-phenylthiazol-4-yl, 2-phenyloxazol-4-yl, 2-phenylthiazol-5-yl , 2-phenyloxazol-5-yl, 2-phenylimidazol-4-yl, 3-phenylpyrazol-5-yl, 5-phenylpyrazol-3-yl, 3-phenyl-1,2,4-oxadiazol-5-yl, 3 -phenyl-1,2,4-thiadiazol-5-yl, 5-phenyl-1,2,4-oxadiazol-3-yl, 5-phenyl-1,2,4-triazol-3-yl, 2-( thiophen-2-yl)thiazol-4-yl, 2-(pyridin-2-yl)thiazol-4-yl, 2-(pyridin-4-yl)thiazol-4-yl, 2-(quinolin-2-yl )thiazol-4-yl, 2-(pyrazin-2-yl)thiazol-4-yl, each of said fused heteroaryl, heterocyclylheteroaryl and heterobiaryl being optionally substituted by one or more other substituent(s) selected from halo, cyano, alkyl , haloalkyl, cyclopropyl, alkoxy, heterocyclyl optionally substituted by alkyl, aryl, hydroxyl, alkoxyalkyl, hydroxyalkoxy, alkylamino, alkylsulfonylamino, aminoalkoxy, or alkoxycarbonylaminoalkoxy; and/or
[0090] where, when:
[0091] R1, R1', R2, R2', R3, R3'are H, and
[0092] L1 is carbonyl, and
[0093] L2is single link, and
[0094] X2 is N, and
[0095] Ar1 is a 6-membered aryl optionally substituted by one or more group(s) selected from halo, cyano, C1-C3 alkyl, C1 haloalkyl, and
[0096] Ar2 is a 5- to 6-membered aryl or heteroaryl group optionally substituted by one or more group(s) selected from halo, C1-C3 alkyl, hydroxyl, methoxy, or fused to an aryl or heteroaryl group optionally substituted by one or plus others halo, C1C3 alkyl, hydroxyl, methoxy,
[0097] then,
[0098] Ar1is phenyl, 3-halophenyl, 4-halophenyl, 2,3-dichlorophenyl 3,4-dihalophenyl, 3,4,5-tri-halophenyl, 4-cyanophenyl, 4-(C1-C3 alkyl)phenyl , 4-(C1 haloalkyl)phenyl, preferably Ar1 is phenyl, 3-fluorophenyl, 3-chlorophenyl, 4-fluorophenyl, 4-chlorophenyl, 3,4-difluorophenyl, 3,4-dichlorophenyl, 4-chloro-3-fluorophenyl, 3 -chloro-4-fluorophenyl, 3,4,5-trifluorophenyl, 4-cyanophenyl, 4-tolyl, 4-trifluoromethylphenyl, and
Ar2is 2-(C1-C3 alkyl)thiazol-4-yl, 5-(C1-C3 alkyl)thiazol-4-yl, pyridin-2-yl, 4-halopyridin-2-yl, 4-(C1 -C3 alkyl)pyridin-2-yl, 5-(C1-C3 alkyl)pyridin-2-yl, 6-(C1-C3 alkyl)pyridin-2-yl, quinolin-2-yl, isoquinolin-3-yl, 8-haloquinolin-2-yl, benzothiazol-2-yl, 4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl, preferably, Ar2 is 2-isopropylthiazol-4-yl, 5-methylthiazol-4 -yl, pyridin-2-yl, 4-chloropyridin-2-yl, 4-methylpyridin-2-yl, 5-methylpyridin-2-yl, 6-methylpyridin-2-yl, quinolin-2-yl, isoquinolin-3 -yl, 8-fluoroquinolin-2-yl, 8-chloroquinolin-2-yl, benzothiazol-2-yl, 4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl.
[00100] In one embodiment, preferred compounds of formula I are those of formula Ia:

[00101] and pharmaceutically acceptable salts and solvates thereof, wherein 1 2 1 1 1’ 2 2’ 3 3’ 1 2
[00102] Ar , Ar , L , R , R , R , R , R , R , X and X are as defined above with respect to formula I.
[00103] Preferred compounds of formula Ia are those of formula Ib:

[00104] and pharmaceutically acceptable salts and solvates thereof, wherein
[00105] Ar1 is as defined above with regard to formula I, preferably Ar1 is a 5- to 6-membered aryl or heteroaryl group, 5- to 6-membered cycloalkyl group, or a C3-C6 alkyl group each of the aryl, heteroaryl or cycloalkyl groups being optionally substituted by one or more group(s) selected from halo, cyano, alkyl, haloalkyl, 3 to 6 membered cycloalkyl, heteroalkyl, heterocyclyl, aryl, heteroaryl, alkoxy, haloalkoxy, alkylamino, carboxy, alkoxycarbonyl, alkylcarbonyloxy, alkylcarbonylamino, carbamoyl, alkylcarbamoyl, alkylsulfonyl, sulfamoyl, alkylsulfamoyl, alkylsulfonylamino, or two substituents form an alkylenedioxy group, or fused to the aryl or heteroaryl group may be one or more aryl moieties, each of said substituents being optionally substituted by one or more other selected substituent(s) from halo, cyano, alkyl, haloalkyl, cyclopropyl, alkoxy, haloalkoxy, heterocyclyl, aryloxy or heteroaryloxy, more preferably nte Ar1 is a 5- to 6-membered aryl group preferably phenyl, or 5- to 6-membered heteroaryl group preferably pyrazolyl, pyridinyl, more preferably pyrazolyl, C3-C6 alkyl group, each of the aryl or heteroaryl groups being optionally substituted by one or more groups (s) selected from halo, cyano, alkyl, haloalkyl, C3-C6 cycloalkyl, heteroalkyl, heterocyclyl, aryl, heteroaryl, alkoxy, haloalkoxy, alkylamino, carboxy, alkoxycarbonyl, alkylcarbonyloxy, alkylcarbonylamino, carbamoyl, alkylcarbamoyl, sulfamoyl, alkylsulfamyl alkylsulfonylamino, or two substituents form an alkylenedioxy group, or fused to the aryl or heteroaryl group may be an aryl moiety, each of said substituents optionally being substituted by one or more other substituent(s) selected from halo, cyano, alkyl, haloalkyl, cyclopropyl , alkoxy, haloalkoxy, heterocyclyl, aryloxy, or heteroaryloxy, even more preferably Ar1 is an ar 5- to 6-membered yl preferably phenyl, or heteroaryl preferably pyrrolyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, more preferably pyrazolyl, isobutyl group, each of the aryl or heteroaryl groups being optionally substituted by one or more group(s) selected from halo preferably chlorine or fluorine, cyano, alkyl preferably methyl, haloalkyl preferably -CF3 or -CHF2, cycloalkyl preferably cyclopropyl, cyclohexyl, aryl preferably phenyl, heteroaryl preferably furanyl, thiophenyl, thiazolyl, isothiazolyl, more preferably thiophen-2-yl, thiophen-3-yl, thiazol-2-yl, thiazol-5-yl, isothiazol-5-yl, even more preferably thiophen-2-yl, thiophen-2-yl, furan-2 -yl, or fused to the aryl or heteroaryl group may be a phenyl moiety, each of said substituents being optionally substituted by one or more other substituent(s) selected from and halo preferably chlorine or fluorine, alkyl preferably methyl, haloalkyl preferably -CF3 or -CHF2, cyclopropyl, haloalkoxy preferably -OCF3 or -OCHF2, or aryloxy preferably phenoxy; and
[00106] R 1 is as defined above with regard to formula I, preferably R 1 is H, C 1 -C 4 alkyl preferably isopropyl, methyl, aryl preferably phenyl, or aralkyl preferably benzyl, each of which is optionally substituted by one or more selected group(s) of halo, preferably chlorine, fluorine, or hydroxy, more preferably R 1 is H, methyl, isopropyl, 2-hydroxyethyl, 4-fluorophenyl or benzyl, even more preferably R 1 is H, methyl or 2-hydroxyethyl, even more preferably R 1 is methyl; and
[00107] R 1' is as defined above with regard to formula I, preferably R 1' is H or methyl, more preferably R 1' is H;
[00108] R2, R2', R3and R3'are as defined above with regard to formula I, preferably R2, R2', R3and R3'are H; and
[00109] X1 and X2 are as defined above with regard to formula I, preferably X1 and X2 are independently selected from N or CZ wherein Z is H or methyl under the proviso that X1 and X2 cannot both be CZ, more preferably X1 and X2 are independently selected from N or CH under the proviso that X1 and X2 cannot both be CH, even more preferably X1 and X2 are N; and
[00110] Ar2 is as defined above with regard to formula I, preferably, Ar2 is a 5- to 6-membered heteroaryl group optionally substituted by one or more group(s) selected from halo, cyano, alkyl, hydroxyalkyl, haloalkyl, C3-C6 cycloalkyl, heteroalkyl, heterocyclyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, hydroxyl, alkoxy, alkylamino, carboxy, alkoxycarbonyl, alkylcarbonyloxy, alkylcarbonylamino, acylamino, carbamoyl, alkylcarbamoyl, alkylsulfonyl, arylsulfonylalkyla, alkylsulfamoyl, form a two-substituted, alkylsulfonyl, or alkylsulfamoyl group or fused to the heteroaryl group may be one or more cycloalkyl, aryl, heterocyclyl or heteroaryl moieties, each of said substituents being optionally substituted by one or more other substituent(s) selected from halo, cyano, alkyl, haloalkyl, cyclopropyl, alkoxy, haloalkoxy , alkoxyalkyl, cycloalkyl, aryl, heterocyclyl optionally substituted by alkyl a, heteroaryl, hydroxyl, alkoxy, alkoxyalkyl, hydroxyalkoxy, alkylamino, alkylsulfonylamino, alkoxycarbonylamino, aminoalkoxy or alkoxycarbonylaminoalkoxy, more preferably Ar2 is a 5- to 6-membered heteroaryl group preferably imidazolyl, pyrazolyl, oxazolyl, thiazolyl, oxayladiazolyl, triazolyl each of the heteroaryl groups optionally being substituted by one or more group(s) selected from halo preferably chlorine or fluorine, cyano, alkyl preferably methyl, isopropyl, isobutyl, haloalkyl preferably -CF3 or -CHF2, C3-C6 cycloalkyl preferably cyclopropyl, heterocyclyl preferably pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, aryl preferably phenyl, aralkyl preferably benzyl, heteroarylalkyl preferably (imidazol-3-yl)methyl, arylsulfonylalkyl preferably phenylsulfonylmethyl, heteroaryl preferably thiophen-2-yl, pyridin-2-yl, pyridin-4-yl , pyrimidin-2-yl, pyrazin-2-yl , quinolin-2-yl, alkoxy preferably methoxy, or fused to the heteroaryl group may be one or more cycloalkyl, aryl, heterocyclyl or heteroaryl moieties, each of said substituents being optionally substituted by one or more other substituent(s) selected from preferably halo bromine, chlorine or fluorine, cyano, alkyl preferably methyl, haloalkyl preferably -CF3 or -CHF2, cyclopropyl, alkoxy preferably methoxy, heterocyclyl optionally substituted by alkyl, preferably pyrrolidin-1yl, piperidin-1-yl, morpholin-4-yl, 4 - methylpiperazin-1-yl, aryl preferably phenyl, hydroxy, alkoxy preferably methoxy, alkoxyalkyl preferably methoxymethyl, methoxyethyl, hydroxyalkoxy preferably hydroxyethoxy, alkylamino preferably dimethylamino, alkylsulfonylamino preferably methylsulfonylamino, alkoxycarbonylamino preferably tert-butyloxyoxycarbonylamino, preferably aminoethyloxycarbonyl and preferably tert-butoxycarbonylaminoethoxy, more preferably Ar2 is a pyrazolyl, oxazolyl, thiazolyl, oxadiazolyl triazolyl, thiadiazolyl or pyridyl group, each of which is optionally substituted by one or more groups selected from chlorine, fluorine, cyano, methyl, isobutyl, C3-C6 cycloalkyl preferably cyclopropyl, heterocyclyl preferably pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, aryl preferably phenyl, heteroaryl preferably thiophen-2-yl, pyridin-2-yl, pyridin-4-yl, or fused to the oxazolyl, thiazolyl or pyridyl group may be one cyclohexyl or phenyl moiety, each of said substituents being optionally substituted by one or more other substituent(s) selected from bromine, chlorine, fluorine, cyano, haloalkyl preferably -CF3, methoxy, cyclopropyl, heterocyclyl optionally substituted by methyl, preferably pyrrolidin-1yl , piperidin-1-yl, morpholin-4-yl, 4-methylpiperazin-1-yl, phenyl, hydroxyl, alkoxy preferably methoxy, alkoxyalkyl preferably methoxyethyl, hydroxyalkoxy preferably hydroxyethoxy, alkylamino preferably dimethylamino, alkylsulfonylamino preferably methylsulfonylamino, aminoalkoxy preferably aminoethyloxy, even more preferably Ar2 is a pyrazolyl, oxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl or pyridyl group, each of which is optionally substituted more groups selected from chlorine, fluorine, cyano, methyl, isobutyl, heterocyclyl preferably pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, 4-phenylpiperazin-1-yl, aryl preferably phenyl, heteroaryl preferably thiophen- 2-yl, pyridin-2-yl, or fused to the oxazolyl, thiazolyl or pyridyl group may be a cyclohexyl or phenyl moiety, each of said substituents being optionally substituted by one or more other substituent(s) selected from chlorine, fluorine, cyano , methyl, cyclopropyl, phenyl, hydroxyl, alkoxy preferably methoxy, or meth xyethyl.
[00111] Preferred compounds of formula Ib are those of formula Ic:

[00112] and pharmaceutically acceptable salts and solvates thereof, wherein a represents the bond linking R1 to the piperazine moiety, and Ar1, Ar2, R1, R1', X1, and X2 are as defined above with respect to formula Ib.
[00113] In one embodiment, compounds of formula Ic are those wherein R 1' is H, and/or X 1 and X 2 are N.
[00114] In another embodiment, compounds of formula Ic are those in which the bond a is drawn as a dotted wedge, R1 is selected from the group consisting of the group C1-C4 alkyl, aryl or aralkyl, each of said alkyl, aryl or aralkyl groups. aralkyl being optionally substituted by one or more group(s) selected from halo or hydroxy, R1' is H, and/or X1 and X2 are N.
[00115] In yet another embodiment, compounds of formula Ic are those in which the bond a is drawn as a solid wedge, R1 is selected from the group consisting of the group C1-C4 alkyl, aryl or aralkyl, each of said alkyl, aryl groups or aralkyl being optionally substituted by one or more group(s) selected from halo or hydroxy, R 1' is H, and/or X 1 and X 2 are N.
[00116] Preferred compounds of formula Ic are those of formulas Id-1, Id-2, Id-3 and Id-4:

[00117] and pharmaceutically acceptable salts and solvates thereof, wherein
[00118] a represents the bond linking R1 to the piperazine moiety; and
[00119] Ar2, R1, X1 and X2 are as defined above for formula Ib; and
[00120] R4, R4', R5, R5'and R6are independently selected from H, halo, cyano, alkyl, haloalkyl, C3-C6 cycloalkyl, heteroalkyl, heterocyclyl, aryl, heteroaryl, hydroxyl, alkoxy, haloalkoxy, alkoxyalkoxy, alkylamino, carboxy, alkoxycarbonyl, alkylcarbonyloxy, alkylcarbonylamino, haloalkylcarbonylamino, carbamoyl, alkylcarbamoyl, carbamoylamino, alkylcarbamoylamino, alkylsulfonyl, haloalkylsulfonyl, sulfamoyl, alkylsulfamoyl, alkylsulfonylamino, alkylsulfonylamino, haloformally or R5' or alkylsulfonylamino grouped with R4' or R4',or together with R5' or alkylsulfonylamino group a haloalkylenedioxy group, or R5 together with R4 or R6, or R5' together with R4' or R6 forms an aryl moiety fused to the phenyl group to which they are attached, each of said substituents being optionally substituted by one or more other substituent(s) selected from halo, cyano, alkyl, haloalkyl, cyclopropyl, preferably R4 and R4' are H and at least one of R5, R5', R6 is independently element selected from halo preferably chlorine or fluorine, cyano, alkyl preferably methyl, haloalkyl preferably -CF3 or -CHF2, more preferably -CF3, cyclopropyl, aryl preferably phenyl, heteroaryl preferably thiophen-2-yl, thiophen-3-yl, or furan -2-yl, the others, if applicable, being H, each of said aryl and heteroaryl groups being optionally substituted by one or more other substituent(s) selected from halo preferably chlorine or fluorine, alkyl preferably methyl, cyclopropyl, or R5 together with R4 or R6, or R5'together with R4'or R6forms a phenyl moiety fused to the phenyl group to which they are attached, more preferably R4, R4', R5, and R5'are H and R6 is selected from cyano, phenyl, thiophen- 2-yl, thiophen-3-yl, or furan-2-yl, each of said groups being optionally substituted by one or more other substituent(s) selected from chlorine, fluorine or methyl, or R4, R4', R5 are H and R5', R6 are independently selected from fluorine or u chlorine, or R4 and R4' are H and R5, R5', R6 are fluorine; and
[00121] R7is H or methyl, preferably R7is H; and
[00122] R7' is H or methyl, preferably R7' is H; and
Ar4 is a cycloalkyl group preferably cyclohexyl or aryl preferably phenyl, each of said cycloalkyl or aryl groups being optionally substituted by one or more group(s) selected from halo preferably chlorine or fluorine, alkyl preferably methyl, haloalkyl preferably -CF3 or - CHF2, more preferably -CF3, cyclopropyl, haloalkoxy preferably -OCF3 or -OCHF2, more preferably -OCF3, aryloxy preferably phenoxy; and
[00124] M1 is N or C-R4''wherein R4''is selected from H, halo, cyano, alkyl, haloalkyl, C3-C6 cycloalkyl, heteroalkyl, heterocyclyl, aryl, heteroaryl, hydroxyl, alkoxy, haloalkoxy, alkoxyalkoxy, alkylamino, carboxy, alkoxycarbonyl, alkylcarbonyloxy, alkylcarbonylamino, haloalkylcarbonylamino, carbamoyl, alkylcarbamoyl, carbamoylamino, alkylcarbamoylamino, alkylsulfonyl, haloalkylsulfonyl, sulfamoyl, alkylsulfamoyl, alkylsulfonylamino, each other optionally substituted by one of the other substituents, each other optionally substituted by haloalkylamino, each other substituted by haloalkylamino. halo, cyano, alkyl, haloalkyl, cyclopropyl, preferably R4'' is H; and
[00125] M2is N or M2is C-R5'' under the proviso that M1is N, where R5'' is selected from H, halo, cyano, alkyl, haloalkyl, C3-C6 cycloalkyl, heteroalkyl, heterocyclyl, aryl, heteroaryl , hydroxy, alkoxy, haloalkoxy, alkoxyalkoxy, alkylamino, carboxy, alkoxycarbonyl, alkylcarbonyloxy, alkylcarbonylamino, haloalkylcarbonylamino, carbamoyl, alkylcarbamoyl, carbamoylamino, alkylcarbamoylamino, alkylsulfonyl, alkylsulfonyl, haloalkylsulfonyl, R6 alkylsulfonyl, forms haloalkylsulfonyl, alkylsulfonyl, or alkylsulfonyl; alkylenedioxy group or a haloalkylenedioxy group, or an aryl moiety fused to the pyridinyl group to which they are attached, each of said substituents being optionally substituted by one or more other substituent(s) selected from halo, cyano, alkyl, haloalkyl, cyclopropyl, preferably R5'' is selected from H, halo preferably chlorine or fluorine, alkyl preferably methyl, haloalkyl preferably -CF3 or -CHF2, more preferably -CF3, most preferably R5' is H; and
[00126] where, in the formula Id-1 when:
[00127] R1 is H, and
[00128] X2 is N, and
[00129] R4, R4', R5, R5'and R6 are independently selected from H, halo, cyano, C1-C3 alkyl, C1 haloalkyl, and
[00130] Ar2 is a 5- to 6-membered aryl or heteroaryl group optionally substituted by one or more group(s) selected from halo, C1-C3 alkyl, hydroxyl, alkoxy, or fused to an aryl group optionally substituted by one or more others halo, C1-C3 alkyl, hydroxyl, methoxy,
[00131] then, 4 4’ 5 5’ 6 4 4’ 5’ 6 5
[00132] R , R , R , R and R are H, or R , R , R , R are H and R is halo, or R4, R4', R5, R5' are H and R6 is halo, cyano, C1- C3 alkyl, C1 haloalkyl, or R4', R5', R6 are H and R4, R5 are halo, or R4, R4', R5' are H and R5, R6 are independently halo, or R4, R4'are H and R5, R5' , R 6 4 4' 5 5' 6 4 4' 5' 6 are halo, preferably, R , R , R , R and R are H, or R , R , R , R are H and R 5 is fluorine, chlorine, or R 4 , R4', R5, R5'are H and R6is fluorine, chlorine, cyano, methyl, trifluoromethyl, or R4, R4', R5'are H and R5, R6are independently fluorine, chlorine, or R4, R4'are H and R5 , R5', R6 are fluorine, and
[00133] Ar2is 2-(C1-C3 alkyl)thiazol-4-yl, 5-(C1-C3 alkyl)thiazol-4-yl, pyridin-2-yl, 4-halopyridin-2-yl, 4-(C1 -C3 alkyl)pyridin-2-yl, 5-(C1-C3 alkyl)pyridin-2-yl, 6-(C1-C3 alkyl)pyridin-2-yl, quinolin-2-yl, isoquinolin-3-yl, 8-haloquinolin-2-yl, benzothiazol-2-yl, 4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl, preferably Ar2 is 2-isopropylthiazol-4-yl, 5-methylthiazol-4-yl yl pyridin-2-yl, 6-methylpyridin-2-yl, 5-methylpyridin-2-yl, 4-methylpyridin-2-yl, 4-chloropyridin-2-yl, quinolin-2-yl, isoquinolin-3-yl , 8-fluoroquinolin-2-yl, 8-chloroquinolin-2-yl, benzothiazol-2-yl, 4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl.
[00134] In one embodiment, compounds of the formulas Id-1, Id-2, Id-3 and Id-4 are those in which X1 and X2 are N.
[00135] In another embodiment, compounds of the formulas Id-1, Id-2, Id-3 and Id-4 are those in which the bond a is drawn as a dotted wedge, R1 is selected from the group consisting of the group C1-C4 alkyl, aryl or aralkyl, each of said alkyl, aryl or aralkyl groups being optionally substituted by one or more group(s) selected from halo or hydroxy, and/or X1 and X2 are N.
[00136] In yet another embodiment, compounds of the formulas Id-1, Id-2, Id-3 and Id-4 are those in which the bond a is drawn as a solid wedge, R1 is selected from the group consisting of the C1-group C4 alkyl, aryl or aralkyl, each of said alkyl, aryl or aralkyl groups being optionally substituted by one or more group(s) selected from halo or hydroxy, and/or X1 and X2 are N.
Preferred compounds of the formulas Id-1, Id-2, Id-3 and Id-4 are those of the formulas Ie-1, Ie-2 and Ie-3:

[00138] and pharmaceutically acceptable salts and solvates thereof, wherein
[00139] a represents the bond linking R1 to the piperazine moiety; and
[00140] Ar2, R1, X1 and X2 are as defined above for formula Ib; and
R5and R6are independently selected from H, halo preferably chlorine or fluorine, cyano, alkyl preferably methyl, cyclopropyl, aryl preferably phenyl, heteroaryl, preferably thiophen-2-yl, thiophen-2-yl, furan-2-yl, each of said aryl and heteroaryl groups being optionally substituted by one or more group(s) selected from halo, preferably chlorine or fluorine, alkyl preferably methyl, cyclopropyl, or R5and R6 together form a phenyl moiety fused to the phenyl ring to which they are attached, preferably R5is H and R6is selected from H, chlorine, fluorine, cyano, methyl, cyclopropyl, phenyl, 4-fluorophenyl, 4-chlorophenyl, 4-cyanophenyl, 4-tolyl, 3-tolyl, 2-tolyl, 2-fluorophenyl, 3, 4-difluorophenyl, 3,4-dichlorophenyl, 3-fluoro-4-chlorophenyl, 3,5-difluorophenyl, thiophen-2-yl, 5-methylthiophen-2-yl, 2-methylthiophen-3-yl, furan-2-yl ila, or R6 is H and R5 is selected from chlorine, fluorine, methyl, cyclopropyl or phenyl, or R5 and R6 are both chlorine, more preferably R5 is H and R6 is selected from H, chlorine, fluorine, phenyl, 4-fluorophenyl, 4-chlorophenyl, 4-cyanophenyl, 4-tolyl, 2-fluorophenyl, 3,4-difluorophenyl, thiophen-2-yl, 5-methylthiophen -2-yl, 2-methylthiophen-3-yl, or R6 is H and R5 is selected from chlorine, fluorine, methyl or phenyl, or R5 and R6 are both chlorine, even more preferably R5 is H and R6 is selected from phenyl, 4-fluorophenyl, thiophen -2-yl, 5-methylthiophen-2-yl, 2-methylthiophen-3-yl, or R5and R6are both chlorine; and
R8, R8', R9, R9' and R10 are independently selected from H, halo preferably fluorine or chlorine, haloalkyl preferably -CF3 or -CHF2, more preferably -CF3, cyclopropyl or haloalkoxy preferably -OCF3 or -OCHF2 more preferably - OCF3, or R8, R8', R9, R9' are H and R10 is phenoxy, preferably R8', R9, R9', R10 are H and R8 is -CF3, or R8, R8', R9', R10 are H and R9 is selected from chlorine or fluorine, or R8, R8', R9, R9' are H and R10 is selected from chlorine, fluorine, -CF3, -OCF3 or -OCHF2, phenoxy, or R8, R9, R9' are H, R8' is selected from chlorine , fluorine -CF3, and R10 is selected from fluorine or chlorine, or R8, R8', R9' are H and R9, R10 are independently selected from fluorine or chlorine, more preferably R8, R8', R9, R9' are H and R10 is selected of chlorine, fluorine or phenoxy, or R8, R9, R9' are H and R8', R10 are both chlorine, or R8, R8', R9' are H and R9, R10 are both chlorine; and
[00143] M1 and M2 are as defined above for formula Id-4; and
[00144] where, in formula Ie-1 when:
[00145] R1 is H, and
[00146] X2 is N, and
[00147] R5and R6are independently selected from H, halo, cyano, C1-C3 alkyl, and
[00148] Ar2 is a 5- to 6-membered aryl or heteroaryl group optionally substituted by one or more group(s) selected from halo, C1-C3 alkyl, hydroxyl, alkoxy, or fused to an aryl group optionally substituted by one or more others halo, C1-C3 alkyl, hydroxyl, methoxy,
[00149] then,
[00150] R6is H and R5is H, halo, or R5is H and R6is halo, cyano, C1-C3 alkyl, C1 haloalkyl, or R5and R6are independently halo, preferably R6is H and R5is fluorine, chlorine, or R5is H and R6is fluorine, chlorine, cyano, methyl, trifluoromethyl or R5 and R6 are independently fluorine, chlorine, and
[00151] Ar2is 2-(C1-C3 alkyl)thiazol-4-yl, 5-(C1-C3 alkyl)thiazol-4-yl, pyridin-2-yl, 4-halopyridin-2-yl, 4-(C1 -C3 alkyl)pyridin-2-yl, 5-(C1-C3 alkyl)pyridin-2-yl, 6-(C1-C3 alkyl)pyridin-2-yl, quinolin-2-yl, isoquinolin-3-yl, 8-haloquinolin-2-yl, benzothiazol-2-yl, 4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl, preferably Ar2 is 2-isopropylthiazol-4-yl, 5-methylthiazol-4-yl yl, pyridin-2-yl, 6-methylpyridin-2-yl, 5-methylpyridin-2-yl, 4-methylpyridin-2-yl, 4-chloropyridin-2-yl, quinolin-2-yl, isoquinolin-3- yl, 8-fluoroquinolin-2-yl, 8-chloroquinolin-2-yl, benzothiazol-2-yl, 4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl.
[00152] In one embodiment, compounds of formulas Ie-1, Ie-2 and Ie-3 are those wherein X1and X2are N.
[00153] In another embodiment, compounds of formulas Ie-1, Ie-2 and Ie-3 are those in which the bond a is drawn as a dotted wedge, R1 is selected from the group consisting of the group C1-C4 alkyl, aryl or aralkyl, each of said alkyl, aryl or aralkyl groups being optionally substituted by one or more group(s) selected from halo or hydroxyl, and/or X1 and X2 are N.
[00154] In yet another embodiment, compounds of formulas Ie-1, Ie-2 and Ie-3 are those in which bond a is drawn as a solid wedge, R1 is selected from the group consisting of the group C1-C4 alkyl, aryl or aralkyl, each of said alkyl, aryl or aralkyl groups being optionally substituted by one or more group(s) selected from halo or hydroxy, and/or X1 and X2 are N.
[00155] Other preferred compounds of formula Ic are those of formulas If-1, If-2, If-3, If-4, If-5, If-6, If-7 and If-8:

[00156] and pharmaceutically acceptable salts and solvates thereof, wherein
[00157] a designates the bond that connects R1 to the piperazine moiety; and
[00158] Ar1, R1, X1 and X2 are as defined above for formula Ib; and
[00159] R11, R12, R12'and R13are independently selected from H, halo, cyano, alkyl, hydroxyalkyl, haloalkyl, C3-C6 cycloalkyl, heteroalkyl, heterocyclyl, aryl, heteroaryl, hydroxyl, alkoxy, haloalkoxy, alkylamino, carboxy, alkoxycarbonyl , alkylcarbonyloxy, alkylcarbonylamino, haloalkylcarbonylamino, acylamino, carbamoyl, alkylcarbamoyl, carbamoylalkyl, carbamoylamino, alkylcarbamoylamino, alkylsulfonyl, haloalkylsulfonyl, sulfamoyl, alkylsulfamoyl, alkylsulfonyl, or R12 or R12 or haloalkylsulfonyl together with an R12 or R12 or haloalkylsulfonyl group together with R12 or R12 or haloalkylsulfonylamino group haloalkylenedioxy, or R12 together with R11 or R13 forms the cycloalkyl, aryl, heterocyclyl or heteroaryl moiety fused to the pyridyl group to which they are attached, each of said groups being optionally substituted by one or more group(s) selected from halo, cyano, alkyl, haloalkyl, cyclopropyl, alkoxy, haloalkoxy or hydroxy, preferably R11, R12, R12' and R13 are independently selected from H, halo preferably chlorine or fluorine, alkyl preferably methyl, haloalkyl preferably -CF3 or -CHF2, more preferably -CF3, C3-C6 cycloalkyl, preferably cyclopropyl, heterocyclyl preferably pyrrolidin-1- yl, morpholin-4-yl, aryl preferably phenyl, or R 12 together with R 11 or R 13 forms an aryl moiety preferably phenyl fused to the pyridyl group to which they are attached, each of said groups being optionally substituted by one or more group(s) selected from halo , cyano, alkyl, haloalkyl, alkoxy or haloalkoxy more preferably R12, R12' and R13 are H and R11 is selected from methyl, -CF3, cyclopropyl, pyrrolidin-1-yl, morpholin-4-yl or phenyl, or R11, R12' , R13 are H and R12 is methyl, cyclopropyl, or R11, R12, R12' are H and R13 is selected from chloro or methyl, cyclopropyl, or R12 together with R11or R13forms an aryl moiety preferably phenyl fused to the pyridyl group to which they are linked, thereby forming a fused ring system, each of said fused ring system and phenyl being optionally substituted by one or more halo preferably chlorine or fluorine, even more preferably R12, R12' and R13 are H and R11 is selected from methyl , pyrrolidin-1-yl or morpholin-4-yl, or R12 together with R11 forms a phenyl moiety fused to the pyridyl group to which they are attached, thereby forming a quinoline moiety, each of said phenyl and quinoline groups being optionally substituted by a or more group(s) selected from halo preferably chlorine or fluorine, even more preferably R12, R12' and R13 are H and R11 is methyl, or R12 together with R11 forms a phenyl moiety fused to the pyridyl group to which they are attached, thereby forming a moiety quinoline; and
[00160] Ar5is a heterocyclyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, or arylsulfonylalkyl group, each of which is optionally substituted by one or more group(s) selected from halo, cyano, alkyl, haloalkyl, cyclopropyl, alkoxy, haloalkoxy, heterocyclyl optionally substituted by alkyl, aryl, hydroxy, alkoxy, alkoxyalkyl, hydroxyalkoxy, alkylamino, alkylsulfonylamino, aminoalkoxy, or alkoxycarbonylaminoalkoxy preferably tert-butyloxycarbonylaminoethoxy, preferably Ar5 is pyrrolidin-1-yl, morpholin-4-yl, piperidin-1-yl, 4- methylpiperazin-1-yl, each of which optionally substituted by one or more halo preferably fluorine, alkyl preferably methyl, alkoxyalkyl preferably methoxymethyl, methoxyethyl, or Ar5 is 4-phenyl-piperazin-1-yl or a phenyl group optionally substituted by one or more group(s) selected from halo preferably bromine, chlorine or fluorine, cyano, haloalkyl preferably -CF3 or -CHF2, more preferred preferably -CF3, cyclopropyl, hydroxy, alkoxy preferably methoxy, heterocyclyl optionally substituted by alkyl, preferably pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, 4-methylpiperazin-1-yl, hydroxyalkoxy preferably hydroxyethoxy, alkylamino preferably dimethylamino, alkylsulfonylamino preferably methylsulfonylamino, aminoalkoxy preferably aminoethoxy, or Ar5 is thiophen-2-yl, pyridin-2-yl, pyridin-4-yl, pyrimidin-2-yl, pyrazin-2-yl, quinolin-2-yl, 4 -chlorobenzyl, 4,5-dichloro(imidazol-3-yl)methyl, 4-chlorophenylsulfonylmethyl more preferably Ar5 is a phenyl optionally substituted by one or more group(s) selected from chlorine or fluorine, cyano, -CF3, hydroxyl, methoxy, 4-methylpiperazin-1-yl hydroxyethoxy or Ar5 is thiophen-2-yl, pyridin-2-yl even more preferably Ar5 is phenyl, 2-fluorophenyl, 4-fluorophenyl, 4-chlorophenyl, 3-fluorophenyl, 3-chlorophenyl, 2-chlorophenyl , 2,4-difluorophenyl or 2,4-dichlorophenyl, 4-cyanophenyl; and
[00161] X3 is O or S, preferably X3 is S; and
[00162] R14is H or methyl, preferably R14is H; and
[00163] Ar6 is a heterocyclyl, aryl or heteroaryl group, each of which is optionally substituted by one or more group(s) selected from halo, cyano, alkyl, haloalkyl, cyclopropyl, alkoxy, haloalkoxy, aryl or hydroxy, preferably Ar6 is a group phenyl optionally substituted by one or more group(s) selected from halo preferably chlorine or fluorine, haloalkyl preferably -CF3 or -CHF2, cyclopropyl, more preferably -CF3, or alkoxy preferably methoxy, more preferably Ar6 is phenyl, 4-fluorophenyl, 2, 4-difluorophenyl; and
[00164] R15is H or methyl, preferably R15is methyl; and
[00165] R16 is a heterocyclyl, aryl or heteroaryl group, each of said groups being optionally substituted by one or more group(s) selected from halo, cyano, alkyl, haloalkyl, cyclopropyl, alkoxy, haloalkoxy or hydroxy, preferably R16 is a phenyl group optionally substituted by one or more group(s) selected from halo preferably chlorine or fluorine, haloalkyl preferably -CF3 or -CHF2, more preferably -CF3, alkoxy preferably methoxy, most preferably R16 is phenyl; and
[00166] R17is H, methyl or R17together with R16forms a cycloalkyl or aryl moiety fused to the thiazolyl group to which they are attached, thereby forming a fused ring system, said fused ring system being optionally substituted by one or more groups( s) selected from halo, cyano, alkyl, haloalkyl, cyclopropyl, alkoxy, haloalkoxy or hydroxy, preferably R17 is H or R17 together with R16 forms a cyclohexyl or phenyl moiety fused to the thiazolyl group to which they are attached, more preferably R17 together with R16 forms a moiety cyclohexyl or phenyl fused to the thiazolyl group to which they are attached; and
[00167] X5is O or S, or N-R36wherein R36is H or C1-C3 alkyl, preferably X5is O or S, more preferably X5is O; and
[00168] Ar7 is a heterocyclyl, aryl or heteroaryl group, each of which is optionally substituted by one or more group(s) selected from halo, cyano, alkyl, haloalkyl, cyclopropyl, alkoxy, haloalkoxy, aryl or hydroxyl, preferably Ar7 is a group phenyl optionally substituted by one or more group(s) selected from halo preferably chlorine or fluorine, haloalkyl preferably -CF3 or -CHF2, more preferably -CF3, or alkoxy preferably methoxy, more preferably Ar7 is phenyl, 4-fluorophenyl, 2,4- difluorophenyl; and
[00169] X6is O, S or N-R36'wherein R36'is H or C1-C3 alkyl, preferably X6is O or NH, more preferably X6is O; and
[00170] R14' is H or methyl, preferably R14' is H; and
R34 is H, alkyl, alkoxyalkyl, hydroxyalkyl, alkoxycarbonylaminoalkyl, preferably R34is H, methyl, ethyl, hydroxyethyl, methoxyethyl, tert-butoxycarbonylaminoethyl, more preferably R34is H, methyl, hydroxyethyl, methoxyethyl; and
R35 is H, alkyl, alkoxyalkyl, hydroxyalkyl, alkoxycarbonylaminoalkyl, preferably R35is H, methyl, ethyl, hydroxyethyl, methoxyethyl, tert-butoxycarbonylaminoethyl, more preferably R35is H, methyl, hydroxyethyl; and
[00173] in which,
[00174] - in the If-1 formula when:
[00175] R1 is H, and
[00176] X2 is N, and
[00177] Ar1 is a 6-membered aryl optionally substituted by one or more group(s) selected from halo, cyano, C1-C3 alkyl, C1-haloalkyl, and
[00178] R11, R12, R12' and R13 are independently selected from H, halo, C1-C3 alkyl, hydroxyl, methoxy, or R12 together with R11 or R13 forms an aryl or heterocyclyl or heteroaryl moiety fused to the pyridyl group to which they are attached and being optionally substituted by one or more group(s) selected from halo, C1-C3 alkyl, methoxy or hydroxy,
[00179] then,
[00180] Ar1is phenyl, 3-halophenyl, 4-halophenyl, 2,3-dichlorophenyl, 3,4-dihalophenyl, 3,4,5-tri-halophenyl, 4-cyanophenyl, 4-(C1-C3 alkyl) phenyl, 4-(C1 haloalkyl)phenyl, preferably Ar1 is phenyl, 4-fluorophenyl, 4-chlorophenyl, 3-chlorophenyl, 3-fluorophenyl, 3,4-dichlorophenyl, 3,4-difluorophenyl, 3,4,5-trifluorophenyl, 4-chloro-3-fluorophenyl, 3-chloro-4-fluorophenyl, 4-cyanophenyl, 4-tolyl, 4-trifluoromethylphenyl, and
[00181] R11, R12, R12'and R13are H, or R11, R12, R12'are H and R13is halo, C1-C3 alkyl, or R11, R12', R13are H and R12is C1-C3 alkyl, or R12, R12 ', R13 are H and R11 is C1-C3 alkyl, or R11, R12, R12' and R13 together with the pyridyl group to which they are attached form a quinolin-2-yl, isoquinolin-3-yl or 8-haloquinolin-2 moiety -yl, preferably R11, R12, R12'and R13are H, or R11, R12, R12'are H and R13 is chloro, methyl, or R11, R12', R13are H and R12is methyl, or R12, R12', R13 are H and R11 is methyl, or R11, R12, R12' and R13 together with the pyridyl group to which they are attached form a quinolin-2-yl, isoquinolin-3-yl, 8-fluoroquinolin-2-yl or 8-chloroquinolin- moiety. 2-yl; and
[00182] - in the If-4 formula when:
[00183] R1 is H, and
[00184] X2 is N, and
[00185] Ar1 is a 6-membered aryl optionally substituted by one or more group(s) selected from halo, cyano, C1-C3 alkyl, C1-haloalkyl, and
[00186] R17 together with R16 forms a cycloalkyl or aryl moiety fused to the thiazolyl group to which they are attached, thereby forming a fused ring system, said fused ring system being optionally substituted by one or more group(s) selected from halo , C1-3 alkyl, methoxy or hydroxyl,
[00187] then,
[00188] Ar1is phenyl, 3-halophenyl, 4-halophenyl, 2,3-dichlorophenyl, 3,4-dihalophenyl, 3,4,5-tri-halophenyl, 4-cyanophenyl, 4-(C1-C3 alkyl) phenyl, 4-(C1 haloalkyl)phenyl, preferably Ar1 is phenyl, 4-fluorophenyl, 4-chlorophenyl, 3-chlorophenyl, 3-fluorophenyl, 3,4-dichlorophenyl, 3,4-difluorophenyl, 3,4,5-trifluorophenyl, 4-chloro-3-fluorophenyl, 3-chloro-4-fluorophenyl, 4-cyanophenyl, 4-tolyl, 4-trifluoromethylphenyl, and
[00189] R17and R16form together with the thiazolyl group to which they are attached a benzothiazol-2-yl or 4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl moiety.
[00190] In one embodiment, compounds of the formulas If-1, If-2, If-3, If-4, If-5, If-6, If-7 and If-8 are those where X1 and X2 are N.
[00191] In another embodiment, compounds of the formulas If-1, If-2, If-3, If-4, If-5, If-6, If-7 and If-8 are those in which a bond is drawn as a dotted wedge, R1 is selected from the group consisting of the C1-C4 alkyl, aryl or aralkyl group, each of said alkyl, aryl or aralkyl groups being optionally substituted by one or more group(s) selected from halo or hydroxyl, and/ or X1 and X2 are N.
[00192] In yet another embodiment, compounds of the formulas If-1, If-2, If-3, If-4, If-5, If-6, If-7 and If-8 are those in which the bond a is drawn as a solid wedge, R1 is selected from the group consisting of the C1-C4 alkyl, aryl or aralkyl group, each of said alkyl, aryl or aralkyl groups being optionally substituted by one or more group(s) selected from halo or hydroxyl, and /or X1 and X2 are N.
Preferred compounds of formulas If-1, If-2, If-3, If-4, If-5, If-6, If-7 and If-8 are those of formulas Ig-1, Ig-2, IgG-3, IgG-4, IgG-5, IgG-6, IgG-7 and IgG-8 respectively:
[00194] and pharmaceutically acceptable salts, and solvates of
themselves, in which
[00195] a represents the bond linking R1 to the piperazine moiety; and
[00196] Ar1, R1, X1 and X2 are as defined above for formula Ib; and
[00197] R12' and R13are independently selected from H, halo, cyano, alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, heteroalkyl, hydroxyl, alkoxy, haloalkoxy, carboxy, alkoxycarbonyl, alkylcarbonyloxy, alkylcarbonylamino, haloalkylcarbonylamino, acylamino, carbamoyl, alkylcarbamoyl, alkyl carbamoylamino, alkylcarbamoylamino, alkylsulfonyl, haloalkylsulfonyl, sulfamoyl, alkylsulfamoyl, alkylsulfonylamino, haloalkylsulfonylamino, or R13 together with R12' forms an alkylenedioxy group or a haloalkylenedioxy group, each of said groups being optionally substituted by one or more halo group(s) cyano, alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxy or oxo, preferably, R12' and R13 are independently selected from H, halo preferably chlorine or fluorine, alkyl preferably methyl, haloalkyl preferably -CF3 or -CHF2, more preferably -CF3, more preferably R12' and R13 are H; and
[00198] X3 is as defined above with regard to formula If-2, preferably X3 is S; and
[00199] R18, R19, R19'and R20are independently selected from H, halo, cyano, alkyl, haloalkyl, cyclopropyl, alkoxy, haloalkoxy, preferably R19, R19'and R20are H and R18is selected from H, fluorine or chlorine, more preferably R18, R19, R19' and R20 are H; and
[00200] R14 is as defined above for formula If-2; and
R21, R21', R22, R22'and R23 are independently selected from H, halo preferably bromine, chlorine or fluorine, cyano, alkyl, haloalkyl preferably -CF3 or -CHF2, more preferably -CF3, cyclopropyl, heterocyclyl optionally substituted by alkyl, preferably pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, 4-methylpiperazin-1-yl, hydroxy, alkoxy preferably methoxy, haloalkoxy, hydroxyalkoxy preferably hydroxyethoxy, alkylamino preferably dimethylamino, alkylsulfonylamino preferably methylsulfonylamino, aminoalkoxy preferably aminoethoxy, alkoxycarbonylaminoalkoxy preferably tert-butyloxycarbonylaminoethoxy, preferably R21, R21', R22and R22' are H and R23 is selected from bromine, fluorine, chlorine, cyano, methyl -CF3, pyrrolidin-1-yl, piperidin-1-yl, morpholin- 4-yl, 4-methylpiperazin-1-yl methoxy, dimethylamino or methylsulfonylamino, or R21, R21', R22' and R23 are H and R22 is selected from fluorine, chlorine, bromine, cyano, -CF3, dimethylamino or methylsulfonylamino or R21', R22, R22'and R23 are H and R21 is fluorine, chlorine, bromine, cyano, hydroxyl, methoxy, hydroxyethoxy, dimethylamino, methylsulfonylamino, aminoethoxy or tert-butoxycarbonylaminoethoxy or R21', R22, R22' are H and R21 independently selected from H, chlorine or fluorine, or R21', R22', and R23 are H and R21 and R22 are chlorine, or R21, R21' and R23 are H and R22e R22' are chlorine, more preferably R21, R21', R22and R22'are H and R23 is selected from fluorine or chlorine, cyano, or R21, R21', R22' and R23 are H and R22 is chloro, or R21', R22, R22' and R23 are H and R21 is chlorine, or R21', R22, R22' are H and R21and R23are independently selected from H, chlorine or fluorine, even more preferably R21, R21', R22and R22'are H and R23is selected from H, fluorine, chlorine, cyano, or R21', R22, R22'are H and R21 and R23 are independently selected from H, chlorine or fluorine; and
[00202] R15 is as defined above with regard to formula If-3, preferably R15 is methyl; and
R24, R24', R25, R25'and R26 are independently selected from H, halo preferably chlorine or fluorine, haloalkyl preferably -CF3 or -CHF2, more preferably -CF3, cyclopropyl, preferably R24, R24', R25, R25' are H and R26 is selected from H, chlorine or fluorine, more preferably R24, R24', R25, R25' and R26 are H; and
[00204] R27, R28, R29and R30are independently selected from H, halo, cyano, alkyl, haloalkyl, cyclopropyl, alkoxy, haloalkoxy, preferably R28, R29and R30are H and R27is selected from H, fluorine or chlorine, more preferably R27, R28, R29 and R30 are H; and
[00205] R27', R28', R29'and R30'are absent, or R27', R28', R29'and R30' are H with the proviso that R28, R29and R30 are H and that R27 is selected from H, chlorine or fluorine preferably R27', R28', R29'and R30' are absent or H under the proviso that R27, R28, R29and R30are H; and
[00206] the two bonds represented by the dotted lines in formula Ig-4 are either absent, or both present under the condition that R27', R28', R29'and R30'are absent; and
[00207] X5 is as defined above with regard to formula If-5, preferably X5 is O; and
[00208] R31, R31', R32, R32'and R33are independently selected from H, halo preferably chlorine or fluorine, cyano, alkyl, haloalkyl preferably -CF3 or -CHF2, more preferably -CF3, cyclopropyl, alkoxy preferably methoxy, haloalkoxy, preferably R31, R31', R32 and R32' are H and R33 is selected from fluorine, chlorine, cyano, -CF3 or methoxy, or R31, R31', R32' and R33 are H and R32 is selected from chlorine or -CF3, or R31', R32, R32' and R33 are H and R31 is chlorine, or R31', R32, R32' are H and R31 and R33 are independently selected from H, chlorine or fluorine, or R31', R32', and R33 are H and R31 and R32 are chlorine, or R31 or R31', R32, R32'and R33are H and R31 is chloro, or R31', R32, R32'are H and R31and R33are independently selected from H, chlorine or fluorine, even more preferably R31, R31', R32and R32'are H and R33 is selected from H, fluorine or chlorine, or R31', R32, R32'are H and R31and R33are fluorine; and
[00209] X6 is as defined above for formula If-6; and
[00210] R14' is as defined above with regard to formulas If-7 and If-8, preferably R14' is H; and
[00211] R34 and R35 are as defined above for formula If-7; and
[00212] in which,
[00213] - in the formula Ig-1 when:
[00214] R1 is H, and
[00215] X2 is N, and
[00216] Ar1 is a 6-membered aryl optionally substituted by one or more group(s) selected from halo, cyano, C1-C3 alkyl, C1-haloalkyl, and
[00217] R12', R13, R18, R19, R19'and R20 are independently selected from H, halo, C1-3 alkyl, hydroxyl, methoxy,
[00218] then,
[00219] Ar1is phenyl, 3-halophenyl, 4-halophenyl, 2,3-dichlorophenyl, 3,4-dihalophenyl, 3,4,5-tri-halophenyl, 4-cyanophenyl, 4-(C1-C3 alkyl) phenyl, 4-(C1 haloalkyl)phenyl, preferably Ar1 is phenyl, 4-fluorophenyl, 4-chlorophenyl, 4-trifluoromethylphenyl, 3-chlorophenyl, 3-fluorophenyl, 3,4-dichlorophenyl, 3,4-difluorophenyl, 3,4, 5-trifluorophenyl, 4-chloro-3-fluorophenyl, 3-chloro-4-fluorophenyl, 4-cyanophenyl, 4-tolyl, 4-trifluoromethylphenyl, and 12' 13 18 19 19' 20 12' 13 19 19'
[00220] R , R , R , R , R and R are H, or R , R , R , R , R20 are H and R18 is fluorine, chlorine, and
[00221] - in the formula Ig-4 when
[00222] R1 is H, and
[00223] X2 is N, and
[00224] Ar1 is a 6-membered aryl optionally substituted by one or more group(s) selected from halo, cyano, C1-C3 alkyl, C1-haloalkyl, and
[00225] R27, R28, R29and R30 are independently selected from H, halo, C1-3 alkyl, methoxy, and
[00226] R27', R28', R29'and R30'are absent or H under the condition that R28, R29and R30are H and R27is selected from H, chlorine or fluorine,
[00227] then
Ar1is phenyl, 3-halophenyl, 4-halophenyl, 2,3-dichlorophenyl, 3,4-dihalophenyl, 3,4,5-tri-halophenyl, 4-cyanophenyl, 4-(C1-C3 alkyl) phenyl, 4-(C1 haloalkyl)phenyl, preferably Ar1 is phenyl, 4-fluorophenyl, 4-chlorophenyl, 3-chlorophenyl, 3-fluorophenyl, 3,4-dichlorophenyl, 3,4-difluorophenyl, 3,4,5-trifluorophenyl, 4-chloro-3-fluorophenyl, 3-chloro-4-fluorophenyl, 4-cyanophenyl, 4-tolyl, 4-trifluoromethylphenyl, and
[00229] R27, R28, R29 and R30 are H, and
[00230] R27', R28', R29'and R30'are absent or H under the condition that R27, R28, R29and R30are H.
In one embodiment, compounds of the formulas Ig-1, Ig-2, Ig-3, Ig-4, Ig-5, Ig-6, Ig-7 and Ig-8 are those wherein X1 and X2 are N.
[00232] In another embodiment, compounds of the formulas Ig-1, Ig-2, Ig-3, Ig-4, Ig-5, Ig-6, Ig-7 and Ig-8 are those in which the α bond is traced. as a dotted wedge, R1 is selected from the group consisting of the C1-C4 alkyl, aryl or aralkyl group, each of said alkyl, aryl or aralkyl groups being optionally substituted by one or more group(s) selected from halo or hydroxyl, and/ or X1 and X2 are N.
In yet another embodiment, compounds of the formulas Ig-1, Ig-2, Ig-3, Ig-4, Ig-5, Ig-6, Ig-7 and Ig-8 are those in which the a-bond is drawn as a solid wedge, R1 is selected from the group consisting of the C1-C4 alkyl, aryl or aralkyl group, each of said alkyl, aryl or aralkyl groups being optionally substituted by one or more group(s) selected from halo or hydroxyl, and /or X1 and X2 are N.
[00234] Other preferred compounds of formulas If-1 and If-2 are those of formulas Ih-1 and Ih-2 respectively:

[00235] and pharmaceutically acceptable salts and solvates thereof, wherein
[00236] a designates the bond that connects R1 to the piperazine moiety; and
[00237] Ar1, R1, X1 and X2 are as defined above for formula Ib; and
[00238] R12, R12' and R13 are as defined above with regard to formula If-1, preferably R12, R12' and R13 are H; and
[00239] R14" is H or methyl; and
[00240] X3 is as defined above with regard to formula If-2, preferably X3 is S; and
[00241] X4is O, CH2, CF2, C(CH3)2, N-(C1-C3 alkyl)N-phenyl, preferably X4is O, CH2, CF2, N-methyl or N-phenyl; and
[00242] R36a, R36b, R36a, R37a and R37'a are independently selected from H, C1-C3 alkyl, alkoxyC1-C3 alkyl, preferably R36a, R36b, R37a and R37a are H and R36'a is H, methyl, methoxyethyl, or R36a, R36b, R37's are H and R37a and R36's are methyl, or R36b, R37a, R37's are H and R36a and R36's are methyl, or R36'a, R37a, R37's are H and R36a and R36b are methyl, or R36a , R36b, R36'a, R37a are H and R37'a is methoxymethyl.
[00243] In one embodiment, compounds of formula Ih-1 are those in which X1 and X2 are N.
[00244] In another embodiment, compounds of formula Ih-1 are those in which the bond a is drawn as a dotted wedge and/or X1 and X2 are N.
[00245] In another embodiment, compounds of formula Ih-1 are those in which bond a is drawn as a solid wedge and/or X1 and X2 are N.
[00246] In another embodiment, compounds of formula Ih-2 are those in which X1 and X2 are N.
[00247] In another embodiment, compounds of formula Ih-2 are those in which the bond a is drawn as a dotted wedge and/or X1 and X2 are N. In a variant of this embodiment, compounds of formula Ih-2 are those in which a bond a is drawn as a dotted wedge, X1e X2are N and R36a, R36b, R36'a, R37a and R37'ason H.
[00248] In yet another embodiment, compounds of formula Ih-2 are those in which the bond a is drawn as a solid wedge and/or X1 and X2 are N. In a variant of this embodiment, compounds of formula Ih-2 are those in that bond a is drawn as a solid wedge, X1 and X2 are N and R36a, R36b, R36'a, R37a and R37'a are H.
Other preferred compounds of formula Ic are those of formulas II-1, II-2, II-3, II-4, II-5, II-6, II-7, II-8, Ij-1, Ij -2, Ij-3, Ij-4, Ij-5, Ij-6, Ij-7, Ij-8, Ik-1, Ik-2, Ik-3, Ik-4 Ik-5, Ik-6, Ik-7, Ik-8, Ii'-1, Ii'-2, Ii'-3, Ii'-4, Ii'-5, Ii'-6, Ii'-7 and Ii'-8,



[00250] and pharmaceutically acceptable salts and solvates thereof, wherein
[00251] a represents the bond linking R1 to the piperazine moiety; and
[00252] R1, X1 and X2 are as defined above with respect to formula Ib; and
[00253] R4, R4', R5, R5'and R6 are as defined above with respect to formula Id-1; and
[00254] Ar4, R7and R7' are as defined above for formulas Id-2 and Id-3; and
[00255] M1 and M2 are as defined above with respect to formula Id-4; and
[00256] R11, R12, R12' and R13 are as defined above for formula If-1; and
[00257] Ar5, R14 and X3 are as defined above for formula If-2; and
[00258] Ar6 and R15 are as defined above for formula If-3; and
[00259] R16 and R17 are as defined above for formula If-4: and
[00260] Ar7 and X5 are as defined above for formula If-5; and
[00261] X6 is as defined above for formula If-6; and
[00262] R14', R34and R35 are as defined above for formulas If-7 and If-8.
Among the compounds of the formulas II-1, II-2, II-3, II-4, II-5, II-6, II-7, II-8, Ij-1, Ij-2, Ij- 3, Ij-4, Ij-5, Ij-6, Ij-7, Ij-8, Ik-1, Ik-2, Ik-3, Ik-4 Ik-5, Ik-6, Ik-7, Ik -8, Ii'-1, Ii'-2, Ii'-3, Ii'-4, Ii'-5, Ii-6, Ii'-7 and II'-8, the compounds of the formulas Ii-1, II-2, II-3, II-4, II-5, II-6, II-7, II-8, II'-1, II'-2, II'-3, II'-4, II' -5, II-6, II'-7 and II'-8 are preferred.
[00264] In one embodiment, compounds of Ii-1, Ii-2, Ii-3, Ii-4, Ii-5, Ii-6, Ii-7, Ii-8, Ij-1, Ij-2, Ij -3, Ij-4, Ij-5, Ij-6, Ij-7, Ij-8, Ik-1, Ik-2, Ik-3, Ik-4 Ik-5, Ik-6, Ik-7, Ik-8, Ii'-1, Ii'-2, Ii'-3, Ii'-4, Ii'-5, Ii-6, Ii'-7 and Ii'-8 are those where X1 and X2 are N.
[00265] In another embodiment, compounds of the formulas II-1, II-2, II-3, II-4, II-5, II-6, II-7, II-8, Ij-1, Ij-2, Ij-3, Ij-4, Ij-5, Ij-6, Ij-7, Ij-8, Ik-1, Ik-2, Ik-3, Ik-4 Ik-5, Ik-6, Ik-7 , Ik-8, Ii'-1, Ii'-2, Ii'-3, Ii'-4, Ii'-5, Ii-6, Ii-7 and Ii-8 are those in which the a bond is drawn as a dotted wedge, R1 is selected from the group consisting of the C1-C4 alkyl, aryl or aralkyl group, each of said alkyl, aryl or aralkyl groups being optionally substituted by one or more group(s) selected from halo or hydroxyl, and/ or X1 and X2 are N.
[00266] In yet another embodiment, compounds of the formulas II-1, II-2, II-3, II-4, II-5, II-6, II-7, II-8, Ij-1, Ij-2 , Ij-3, Ij-4, Ij-5, Ij-6, Ij-7, Ij-8, Ik-1, Ik-2, Ik-3, Ik-4 Ik-5, Ik-6, Ik- 7, Ik-8, Ii'-1, Ii'-2, Ii'-3, Ii'-4, Ii'-5, Ii-6, Ii-7 and Ii-8 are those where bond a is drawn as a solid wedge, R1 is selected from the group consisting of the C1-C4 alkyl, aryl or aralkyl group, each of said alkyl, aryl or aralkyl groups being optionally substituted by one or more group(s) selected from halo or hydroxyl, and /or X1 and X2 are N.
Preferred compounds of formulas II-1, II-2, II-3, II-4, II-5, II-6, II-7, II-8, II'-1, II'-2, Ii '-3, Ii'-4, Ii'-5, Ii'-6, Ii'-7 and Ii'-8 are those of the formulas Il-1, Il-2, Il-3, Il-4, Il- 5, Il-6, Il-7, Il-8, Il'-1, Il'-2, Il'-3, Il'-4, Il'-5, Il'-6, Il'-7 and Il '-8 respectively:

[00268] and pharmaceutically acceptable salts and solvates thereof, in which:
[00269] a represents the bond linking R1 to the piperazine moiety; and
[00270] R1, X1 and X2 are as defined above for formula Ib; and
[00271] R4, R4', R5, R5'and R6 are as defined above with respect to formula Id-1; and
[00272] M1 and M2 are as defined above for formula Id-4; and
[00273] R12' 13 14 14' 15 18 19 19' 20 21 21' 22 22' , R , R , R , R , R , R , R , R , R , R , R , R , R25 25' 26 27 27' 28 28' 29 29' 30 30' 31, R, R, R, R, R, R, R, R, R, R, R, R, R32', R33, R34, R35, X3, X5; X6; and the two bonds , , , ,, represented by the dotted lines are as defined above for the formulas Ig-1, Ig-2, Ig-3, Ig-4, Ig-5, Ig-6, Ig-7 and Ig- 8.
[00274] In one embodiment, compounds of formulas Il-1, Il-2, Il-3, Il-4, Il-5, Il-6, Il-7, Il-8, Il'-1, Il'- 2, Il'-3, Il'-4, Il'-5, Il'-6, Il'-7 and Il'-8 are those where X1 and X2 are N.
[00275] In another embodiment, compounds of formulas Il-1, Il-2, Il-3, Il-4, Il-5, Il-6, Il-7, Il-8, Il'-1, Il'- 2, Il'-3, Il'-4, Il'-5, Il'-6, Il'-7 and Il'-8 are those where bond a is drawn as a dotted wedge, R1 is selected from the group which consists of the C1-C4 alkyl, aryl or aralkyl group, each of said alkyl, aryl or aralkyl groups being optionally substituted by one or more group(s) selected from halo or hydroxyl, and/or X1and X2are N.
[00276] In yet another embodiment, compounds of formulas Il-1, Il-2, Il-3, Il-4, Il-5, Il-6, Il-7, Il-8, Il'-1, Il' -2, Il'-3, Il'-4, Il'-5, Il'-6, Il'-7 and Il'-8 are those where bond a is drawn as a solid wedge, R1 is selected from group consisting of the C1-C4 alkyl, aryl or aralkyl group, each of said alkyl, aryl or aralkyl groups being optionally substituted by one or more group(s) selected from halo or hydroxyl, and/or X1and X2are N.
[00277] Preferred compounds of formulas Il-1, Il-2, Il-3, Il-4, Il-5, Il-6, Il-7, Il-8, Il'-1, Il'-2, Il '-3, Il'-4, Il'-5, Il'-6, Il'-7 and Il'-8 are those of the formulas Im-1, Im-2, Im-3, Im-4, Im- 5, Im-6, Im-7, Im-8, Im'-1, Im'-2, Im'-3, Im'-4, Im'-5, Im'-6, Im'-7 and Im '-8 respectively:
and pharmaceutically acceptable salts and solvates thereof, wherein:
[00278] a designates the bond that connects R1 to the piperazine moiety; and
[00279] R1, X1 and X2 are as defined above for formula Ib; and
[00280] R5and R6are as defined above for formula Ie-1; and
[00281] M1 and M2 are as defined above for formula Ie-3; and
[00282] R12' 13 14 14' 15 18 19 19' 20 21 21' 22 22' , R , R , R , R , R , R , R , R , R , R , R , R , R 23 24 24 ' 25 25' 26 27 27' 28 28' 29 29' 30 30' 31 , R , R , R , R , R , R , R , R , R , R , R , R , R , R , R31', R32, R32', R33, R34, R35, X3, X5, X6; and the two bonds , , , , , ,, , represented by the dotted lines are as defined above with respect to the formulas Ig-1, Ig-2, Ig-3, Ig-4, Ig-5, Ig-6, Ig-7 and IgG-8.
[00283] In one embodiment, compounds of the formulas Im-1, Im-2, Im-3, Im-4, Im-5, Im-6, Im-7, Im-8, Im'-1, Im'- 2, Im'-3, Im'-4, Im'-5, Im'-6, Im'-7 and Im'-8 are those where X1 and X2 are N.
[00284] In another embodiment, compounds of the formulas Im-1, Im-2, Im-3, Im-4, Im-5, Im-6, Im-7, Im-8, Im'-1, Im'- 2, Im'-3, Im'-4, Im'-5, Im'-6, Im'-7 and Im'-8 are those where the bond a is drawn as a dotted wedge, R1is selected from the group that consists of the C1-C4 alkyl, aryl or aralkyl group, each of said alkyl, aryl or aralkyl groups being optionally substituted by one or more group(s) selected from halo or hydroxyl, and/or X1and X2are N.
[00285] In yet another embodiment, compounds of Im-1, Im-2, Im-3, Im-4, Im-5, Im-6, Im-7, Im-8, Im'-1, Im'- 2, Im'-3, Im'-4, Im'-5, Im'-6, Im'-7 and Im'-8 are those where bond a is drawn as a solid wedge, R1is selected from the group that consists of the C1-C4 alkyl, aryl or aralkyl group, each of said alkyl, aryl or aralkyl groups being optionally substituted by one or more group(s) selected from halo or hydroxyl, and/or X1and X2 are N.
[00286] Other preferred compounds of formula I are those of formulas In, Io, Ip and In'

[00287] and pharmaceutically acceptable salts and solvates thereof, wherein: 2 1 2 1 1’ 2 2’ 3 3’ 1 2
[00288] Ar , L , L , R , R , R , R , R , R , X and X , are as defined above with respect to formula I.
[00289] R4, R4', R5, R5'and R6 are as defined above with respect to formula Id-1;
[00290] Ar4, R7and R7' are as defined above for formulas Id-2 and Id-3;
[00291] M1 and M2 are as defined above for formula Id-4;
[00292] Preferred compounds of formulas In, Io and Ip are those wherein R2, R2', R3and R3'are H.
[00293] Still other preferred compounds of formula I are those of formulas Iq, Ir, Is and It

[00294] and pharmaceutically acceptable salts and solvates thereof, wherein: 1 1 2 1 1’ 2 2’ 3 3’ 1 2
[00295] Ar , L , L , R , R , R , R , R , R , X and X , are as defined above with respect to formula I;
[00296] R11, R12, R12' and R13 are as defined above for formula If-1;
[00297] Ar5, R14 and X3 are as defined above for formula If-2;
[00298] Ar6 and R15 are as defined above for formula If-3;
[00299] R16 and R17 are as defined above for formula If-4.
Preferred compounds of the formulas Iq, Ir, Is and It are those wherein R2, R2', R3and R3'are H.
[00301] Other preferred compounds of formula I are those of formulas Iu and Iv

[00302] and pharmaceutically acceptable salts and solvates of the same 1 2 1 2 1 1' 2 2' 3 3' 1 2 , wherein Ar , Ar , L , L , R , R , R , R , R , R , X and X are as defined above for formula I, and R1 and R1' are different.
Preferred compounds of formulas Iu and Iv are those wherein X1 and X2 are both N.
[00304] Still other preferred compounds of formula I are those of formula Iw:

[00305] and pharmaceutically acceptable salts and solvates of the same 1 1 2 1 1' 2 2' 3 3' 1 2 , wherein Ar , L , L , R , R , R , R , R , R , X and X , are as defined above with respect to formula I;
[00306] Ar7 and X5 are as defined above for formula If-5;
Preferred compounds of formula Iw are those wherein R2, R2', R3and R3'are H.
Still other preferred compounds of formula I are those of formulas Ix, Iy and Iz:

[00309] and pharmaceutically acceptable salts and solvates of the same 1 1 2 1 1' 2 2' 3 3' 1 2 , wherein Ar , L , L , R , R , R , R , R , R , X and X , are as defined above with respect to formula I;
[00310] Ar5, Ar7, R14', R34, R35, and X6 are as defined above for formulas If-6, If-7 and If-8.
Preferred compounds of formulas Ix, Iy and Iz are those wherein R2, R2', R3and R3'are H and/or R14'is H.
[00312] Particularly preferred compounds of the invention are those listed in Table 1 below: TABLE 1:































The compounds in Table 1 were named using ChemDraw Ultra 12 purchased from CambridgeSoft (Cambridge, MA, USA).
[00314] The compounds of formula I can be prepared in different ways with reactions known to the person skilled in the art. Reaction schemes as described in the example section illustrate by way of example different possible methods.
The invention also provides the use of the compounds of the invention or pharmaceutically acceptable salts, or solvates thereof as NK-3 receptor antagonists.
Accordingly, in a particularly preferred embodiment, the invention relates to the use of compounds of formula I and sub-formula in particular those of table 1 above, or pharmaceutically acceptable salts and solvates thereof, as NK-3 receptor antagonists. APPLICATIONS
The compounds of the invention are therefore useful as medicines, in particular in the prevention and/or treatment of depression, anxiety, psychosis, schizophrenia, psychotic disorders, bipolar disorders, cognitive disorders, Parkinson's disease, Alzheimer's disease, of attention deficit hyperactivity disorder (ADHD), pain, seizure, obesity, inflammatory diseases including irritable bowel syndrome and inflammatory bowel disorders, emesis, pre-eclampsia, airway related diseases including chronic obstructive pulmonary disease, asthma, airway hyperresponsiveness airways, bronchoconstriction and coughing, reproductive disorders and sex hormone dependent diseases including but not limited to benign prostatic hyperplasia (BPH), metastatic prostatic carninoma, testicular cancer, breast cancer, erogen-dependent acne, male pattern baldness, endometriosis , abnormal puberty, uterine fibrosis, hormone dependent cancers, hyperandrogen ism, hirsutism, virilization, polycystic ovary syndrome (PCOS), HAIR-AN syndrome (hyperandrogenism, insulin resistance and acanthosis nigricans), ovarian hyperthecosis (HAIR-AN with luteinized theca cell hyperplasia in ovarian stroma), other manifestations of concentrations elevated levels of intraovarian androgen (eg, disruption of follicular maturation, atresia, anovulation, dysmenorrhea, dysfunctional uterine bleeding, infertility) and androgen-producing tumor (virilizing ovarian or adrenal tumor).
The invention also provides a method for delaying in the patient the onset of depression, anxiety, psychosis, schizophrenia, psychotic disorders, bipolar disorders, cognitive disorders, Parkinson's disease, Alzheimer's disease, attention deficit hyperactivity disorder (ADHD ), pain, seizure, obesity, inflammatory diseases including irritable bowel syndrome and inflammatory bowel disorders, emesis, pre-eclampsia, airway related diseases including chronic obstructive pulmonary disease, asthma, airway hyperresponsiveness, bronchoconstriction and coughing, reproduction and sex hormone dependent diseases including but not limited to benign prostatic hyperplasia (BPH), metastatic prostatic carninoma, testicular cancer, breast cancer, erogen dependent acne, male pattern baldness, endometriosis, abnormal puberty, uterine fibrosis, cancers hormone dependents, hyperandrogenism, hirsutism, virilization, syndrome me of polycystic ovary (PCOS), HAIR-AN syndrome (hyperandrogenism, insulin resistance, and acanthosis nigricans), ovarian hyperthecosis (HAIR-AN with luteinized theca cell hyperplasia in ovarian stroma), other manifestations of elevated intraovarian androgen concentrations (by example, interruption of follicular maturation, atresia, anovulation, dysmenorrhea, dysfunctional uterine bleeding, infertility) and androgen-producing tumor (virilizing adrenal or ovarian tumor) comprising the administration of a pharmaceutically effective amount of a compound of formula (I) or salt pharmaceutically acceptable thereof to a patient in need thereof.
[00319] Preferably, the patient is a warm-blooded animal, more preferably a human.
The compounds of the invention are also useful in the treatment of gynecological disorders and infertility. In particular, the invention provides methods for suppressing LH surge in assisted conception.
The compounds of the invention are also useful to cause male castration and to inhibit sex drive in men. This is of particular interest in the treatment of male sex offenders.
[00322] The invention also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof for the manufacture of a medicament for treating and/or preventing depression, anxiety, psychosis, schizophrenia, psychotic disorders, disorders bipolar disorders, cognitive disorders, Parkinson's disease, Alzheimer's disease, attention deficit hyperactivity disorder (ADHD), pain, seizure, obesity, inflammatory diseases including irritable bowel syndrome and inflammatory bowel disorders, emesis, pre-eclampsia, related diseases to airways including chronic obstructive pulmonary disease, asthma, airway hyperresponsiveness, bronchoconstriction and coughing, reproductive disorders and sex hormone dependent diseases including but not limited to benign prostatic hyperplasia (BPH), metastatic prostatic carninoma, testicular cancer, cancer breast cancer, erogen-dependent acne, male pattern baldness, endometriosis, puberty an normal, uterine fibrosis, hormone-dependent cancers, hyperandrogenism, hirsutism, virilization, polycystic ovary syndrome (PCOS), HAIR-AN syndrome (hyperandrogenism, insulin resistance and acanthosis nigricans), ovarian hyperthecosis (HAIR-AN with theca cell hyperplasia luteinized in ovarian stroma), other manifestations of elevated intraovarian androgen concentrations (eg, disruption of follicular maturation, atresia, anovulation, dysmenorrhea, dysfunctional uterine bleeding, infertility) and androgen-producing tumor (virilizing adrenal or ovarian tumor) in a patient.
[00323] Preferably, the patient is a warm-blooded animal, more preferably a human.
[00324] The invention also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof for the manufacture of a medicament for suppressing LH surge in assisted conception in a patient. Preferably the patient is a warm-blooded animal, more preferably a woman.
[00325] The invention also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof for the manufacture of a medicament for causing male castration and for inhibiting the sex drive in men. This is of particular interest in the treatment of male sex offenders.
[00326] According to another aspect of the present invention there is provided a method for modulating NK-3 receptor activity, in a patient, preferably a warm-blooded animal, and even more preferably a human, in need of such treatment, who comprises administering to said patient an effective amount of the compound of the present invention, or a pharmaceutically acceptable salt or solvate thereof.
According to one embodiment, the compounds of the invention, their pharmaceutically acceptable salts or solvates can be administered as part of a combination therapy. Thus, modalities comprising co-administration of, and compositions and medicaments which contain, in addition to a compound of the present invention, a pharmaceutically acceptable salt or solvate thereof as active ingredient, additional therapeutic agents and/or active ingredients are included within the scope of the present invention. . Such multiple drug regimens, often referred to as combination therapy, can be used in the treatment and/or prevention of any of the diseases or conditions mediated by or associated with NK-3 receptor modulation. The use of such combinations of therapeutic agents is especially pertinent with respect to the treatment of the disorders mentioned above within a patient in need of treatment or a patient at risk of becoming such a patient.
[00328] In addition to the requirement for therapeutic efficacy, which may require the use of active agents in addition to NK-3 receptor modulating compounds of formula I or pharmaceutically acceptable salts or solvates thereof, there may be additional rationales that compel or highly recommend the use of drug combinations involving active ingredients that represent adjunct therapy, that is, that complement and supplement the function performed by the NK-3 receptor modulating compounds of the present invention. Suitable supplementary therapeutic agents used for the purpose of adjunctive treatment include drugs that, rather than directly treating or preventing a disease or condition mediated by or associated with NK-3 receptor modulation, treat diseases or conditions that directly result from or indirectly accompany the basic or underlying NK-3 receptor-modulated disease or condition.
[00329] According to another aspect of the present invention the compound of formula I, a pharmaceutically acceptable salt or solvate thereof can be used in combination therapy with antipsychotic drugs (APD), to improve efficacy and to minimize associated side effects with APD including but not limited to Dopamine 2/3 and 5-HT2 receptor antagonists. More particularly, the compound of formula I, a pharmaceutically acceptable salt or solvate thereof can be used as an adjunct therapy in combination with an atypical antipsychotic drug, including but not limited to risperidone, clozapine, olanzapine, where the NK receptor modulator -3 may play a dose-limiting role for the atypical antipsychotic and therefore spare the patient from some of the side effects of those atypical antipsychotic drugs.
[00330] Thus, the methods of treatment and pharmaceutical compositions of the present invention may employ the compounds of formula I or pharmaceutically acceptable salts or solvates thereof in the form of monotherapy, however said methods and compositions may also be used in the form of therapy a multiple wherein one or more compounds of formula I or their pharmaceutically acceptable salts or solvates are co-administered in combination with one or more other therapeutic agents.
[00331] In combinations of the above-described embodiment of the present invention, the compound of formula I, a pharmaceutically acceptable salt or solvate thereof and other active therapeutic agents may be administered in terms of dosage forms separately or in conjunction with each other, and in terms of your administration time, serially or simultaneously. Thus, administration of one component agent may be prior to, concomitant with, or subsequent to administration of the other component agent(s).
The invention also provides pharmaceutical compositions comprising a compound of formula I or a pharmaceutically acceptable salt or solvate thereof and at least one pharmaceutically acceptable carrier, diluent, excipient and/or adjuvant. As indicated above, the invention also encompasses pharmaceutical compositions which contain, in addition to a compound of the present invention, a pharmaceutically acceptable salt or solvate thereof as an active ingredient, additional therapeutic agents and/or active ingredients.
[00333] Another object of this invention is a medicine comprising at least one compound of the invention, or a pharmaceutically acceptable salt or solvate thereof, as an active ingredient.
[00334] According to another aspect of the present invention there is provided the use of a compound of formula I or a pharmaceutically acceptable salt or solvate thereof for the manufacture of a medicament for modulating NK-3 receptor activity in a patient, in in need of such treatment, which comprises administering to said patient an effective amount of the compound of the present invention, or a pharmaceutically acceptable salt or solvate thereof.
[00335] Preferably, the patient is a warm-blooded animal, more preferably a human.
As set out above, the compounds of the invention, their pharmaceutically acceptable salts or solvates can be used in monotherapy or in combination therapy. Thus, according to an embodiment, the invention provides the use of a compound of the invention for the manufacture of a medicament for at least one of the purposes described above, wherein said medicament is administered to a patient in need thereof, preferably a warm-blooded animal, and even more preferably a human, in combination with at least one additional therapeutic agent and/or active ingredient. The benefits and advantages of such a multiple drug regimen, possible administration regimens as well as additional therapeutic agents and/or suitable active ingredients are those described above.
Generally, for pharmaceutical use, the compounds of the inventions may be formulated as a pharmaceutical preparation comprising at least one compound of the invention and at least one pharmaceutically acceptable carrier, diluent, excipient and/or adjuvant, and optionally one or more other compounds pharmaceutically actives.
[00338] By way of non-limiting examples, such a formulation may be in a form suitable for oral administration, for parenteral administration (such as by intravenous, intramuscular or subcutaneous injection or intravenous infusion), for topical administration (including ocular), for administration by inhalation, by a skin patch, by an implant, by a suppository, etc. Such suitable forms of administration - which may be solid, semi-solid or liquid, depending on the mode of administration - as well as methods and vehicles, diluents and excipients for use in preparing the same, will be clear to the person skilled in the art; reference is made to the latest edition of Remington's Pharmaceutical Sciences.
Some preferred, but non-limiting examples of such preparations include tablets, pills, powders, lozenges, sachets, seals, elixirs, suspensions, emulsions, solutions, syrups, aerosols, ointments, creams, lotions, soft and hard gelatin capsules , suppositories, drops, sterile injectable solutions and sterile packaged powders (which are usually reconstituted before use) for administration as a bolus and/or for continuous administration, which can be formulated with vehicles, excipients, and diluents that are suitable on their own for such formulations, such as lactose, dextrose, sucrose, sorbitol, mannitol, starches, acacia gum, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, polyethylene glycol, cellulose, water (sterile), methylcellulose, methyl- and propylhydroxybenzoates, talc, magnesium stearate, edible oils, vegetable oils and mineral oils or suitable mixtures thereof. The formulations may optionally contain other substances that are commonly used in pharmaceutical formulations, such as lubricating agents, wetting agents, emulsifying and suspending agents, dispersing agents, disintegrating agents, bulking agents, fillers, preserving agents, sweetening agents, flavoring agents, regulators flux agents, release agents, etc. The compositions may also be formulated in order to provide quick, sustained or delayed release of the active compound(s) contained therein.
[00340] The pharmaceutical preparations of the invention are preferably in a unit dosage form, and may be suitably packaged, for example, in a box, blister, vial, bottle, sachet, ampoule or in any other single-dose container or carrier or multiple doses suitable (which can be appropriately labeled); optionally with one or more leaflets containing product information and/or instructions for use. Generally, such unit dosages will contain between 0.05 and 1000 mg, and usually between 1 and 500 mg, of the at least one compound of the invention, for example about 10, 25, 50, 100, 200, 300 or 400 mg per unit dosage.
Usually, depending on the condition to be prevented or treated and the routine of administration, the active compound of the invention will usually be administered between 0.01 to 100 mg per kilogram, more often between 0.1 and 50 mg, such as between 1 and 25 mg, for example about 0.5, 1, 5, 10, 15, 20 or 25 mg, per kilogram of patient body weight per day, which can be administered as a single daily dose, divided into one or more doses daily, or essentially continuously, for example, using a drip infusion. DEFINITIONS
[00342] The definitions and explanations below are for the terms as used throughout the entire application, including both the specification and claims.
When describing the compounds of the invention, terms used should be construed in accordance with the following definitions, unless otherwise indicated.
[00344] Where groups may be substituted, such groups may be substituted with one or more substituents, and preferably with one, two or three substituents. Substituents can be selected from, but not limited to, for example, the group comprising halogen, hydroxyl, oxo, nitro, starch, carboxy, amino, cyanohaloalkoxy, and haloalkyl.
[00345] As used herein terms such as "alkyl, aryl, or cycloalkyl, each being optionally substituted with..." or "alkyl, aryl, or cycloalkyl, optionally substituted with." encompass "alkyl optionally substituted with.", "aryl optionally substituted with." and "cycloalkyl optionally substituted with.".
[00346] The term "halo" or "halogen" means fluorine, chlorine, bromine, or iodine. Preferred halo groups are fluorine and chlorine.
[00347] The term "alkyl" by itself or as part of another substituent refers to a hydrocarbyl radical of the formula CnH2n+1 where n is a number greater than or equal to 1. Generally, alkyl groups of this invention comprise from 1 to 6 carbon atoms, preferably from 1 to 4 carbon atoms, more preferably from 1 to 3 carbon atoms, even more preferably 1 to 2 carbon atoms. Alkyl groups can be linear or branched and can be substituted as indicated herein.
Suitable alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl and t-butyl, pentyl and its isomers (eg, n-pentyl, iso-pentyl ), and hexyl and its isomers (eg n-hexyl, isohexyl). Preferred alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl and t-butyl. Cx-y-alkyl and Cx-Cy-alkyl refer to alkyl groups comprising from x to y carbon atoms.
When the suffix "ene" ("alkylene") is used in conjunction with an alkyl group, this is intended to mean the alkyl group as defined herein having two single bonds as points of attachment to other groups. The term "alkylene" includes methylene, ethylene, methylmethylene, propylene, ethylethylene, and 1,2-dimethylethylene.
[00350] The term "haloalkyl", alone or in combination, refers to an alkyl radical having the meaning as defined above wherein one or more hydrogens are replaced with a halogen as defined above. Non-limiting examples of such haloalkyl radicals include chloromethyl, 1-bromoethyl, fluoromethyl, difluoromethyl, trifluoromethyl, 1,1,1-trifluoroethyl and the like. Cx-y-haloalkyl and Cx-Cy-alkyl refer to alkyl groups that comprise from x to y carbon atoms. Preferred haloalkyl groups are difluoromethyl, trifluoromethyl.
[00351] The term "cycloalkyl" as used herein is a cyclic alkyl group, that is, a monovalent, saturated, or unsaturated hydrocarbyl group having 1 or 2 cyclic structures. Cycloalkyl includes monocyclic or bicyclic hydrocarbyl groups. Cycloalkyl groups may comprise 3 or more ring carbon atoms and generally, according to this invention comprise from 3 to 10, more preferably from 3 to 8 carbon atoms, even more preferably from 3 to 6 carbon atoms. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, with cyclopropyl being particularly preferred.
When the suffix "ene" is used in conjunction with a cyclic group, this is intended to mean the cyclic group as defined herein having two single bonds as points of attachment to other groups.
[00353] Therefore, "cycloalkylene" herein refers to a saturated homocyclic hydrocarbyl biradical of formula CnH2n-2. Suitable cycloalkylene groups are a C3-6 cycloalkylene group, preferably a C3-5 cycloalkylene (i.e. 1,2-cyclopropylene, 1,1-cyclopropylene, 1,1-cyclobutylene, 1,2-cyclobutylene, 1,3-cyclobutylene, 1,3-cyclopentylene, or 1,1-cyclopentylene), more preferably a C3-4 cycloalkylene (i.e., 1,2-cyclopropylene, 1,1-cyclopropylene, 1,1-cyclobutylene, 1,2-cyclobutylene).
[00354] Where at least one carbon atom in a cycloalkyl group is replaced with a heteroatom, the resulting ring is referred to herein as "heterocycloalkyl" or "heterocyclyl".
The terms "heterocyclyl", "heterocycloalkyl" or "heterocycle" as used herein by itself or as part of another group refer to fully saturated or partially unsaturated, non-aromatic cyclic groups (e.g., monocyclics from 3 to 7-membered, 7- to 11-membered bicyclic, or containing a total of 3 to 10 ring atoms) which have at least one heteroatom in at least one carbon-containing ring. Each ring of the heterocyclic group containing a heteroatom may have 1, 2, 3 or 4 heteroatoms selected from nitrogen, oxygen and/or sulfur atoms, where the nitrogen and sulfur heteroatoms can optionally be oxidized and the nitrogen heteroatoms can optionally be quaternized . Any of the carbon atoms of the heterocyclic group can be replaced by oxo (eg piperidone, pyrrolidinone). The heterocyclic group can be attached at any heteroatom or carbon atom of the ring or ring system, where valence allows. Rings of multi-ring heterocycles can be fused, bridged and/or joined through one or more spiro atoms. Exemplary non-limiting heterocyclic groups include oxetanyl, piperidinyl, azetidinyl, 2-imidazolinyl, pyrazolidinyl, imidazolidinyl, isoxazolinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, piperidinyl, 3H-indolyl, indolinyl, homoindolinyl, perazineyl, 2-oxy 2-pyrazolinyl, 3-pyrazolinyl, tetrahydro-2H-pyranyl, 2H-pyranyl, 4H-pyranyl, 3,4-dihydro-2H-pyranyl, 3-dioxolanyl, 1,4-dioxanyl, 2,5-dioximidazolidinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, indolinyl, tetrahydropyranyl, tetrahydrofuranyl, tetrahydroquinolinyl, tetrahydroisoquinolin-1-yl, tetrahydroisoquinolin-2-yl, tetrahydroisoquinolin-3-yl, tetrahydroisoquinolin-4-yl, thiomorpholin-4-yl, thiomorpholin-4-yl ylsulfoxide, thiomorpholin-4-ylsulfone, 1,3-dioxolanyl, 1,4-oxathianyl, 1H-pyrrolizinyl, tetrahydro-1,1-dioxothiophenyl, N-formylpiperazinyl, and morpholin-4-yl.
[00356] The ring atoms of the selected heterocyclyl and heterocyclylene moieties are numbered based on the scheme
low
[00357] The fused piperazine ring atoms of the invention are numbered based on the scheme below

[00358] The term "aryl" as used herein refers to an aromatic, polyunsaturated hydrocarbyl group having a single ring (i.e., phenyl) or multiple aromatic rings fused together (e.g., naphthyl) or covalently linked , typically containing 5 to 12 atoms; preferably 6 to 10, wherein at least one ring is aromatic. The aromatic ring may optionally include one to two additional rings (cycloalkyl, heterocyclyl or heteroaryl) fused thereto. Aryl is also intended to include the partially hydrogenated derivatives of the carbocyclic systems enumerated herein. Non-limiting examples of aryl include phenyl, biphenylyl, biphenylenyl, 5- or 6-tetralinyl, naphthalen-1- or -2-yl, 4-, 5-, 6 or 7-indenyl, 1-2-, 3-, 4 - or 5-acenaphthylene, 3-, 4- or 5- acenaphthenyl, 1- or 2-pentalenyl, 4- or 5-indanyl, 5-, 6-, 7- or 8-tetrahydronaphthyl, 1,2,3,4 -tetrahydronaphthyl, 1,4-dihydronaphthyl, 1-, 2-, 3-, 4- or 5-pyrenyl.
[00359] The term "arylene" as used herein is intended to include divalent carbocyclic aromatic ring systems such as phenylene, biphenylylene, naphthylene, indenylene, pentalenylene, azulenylene and the like. Arylene is also intended to include the partially hydrogenated derivatives of the carbocyclic systems enumerated above. Non-limiting examples of such partially hydrogenated derivatives are 1,2,3,4-tetrahydronaphthylene, 1,4-dihydronaphthylene and the like.
[00360] Where at least one carbon atom in an aryl group is replaced with a heteroatom, the resulting ring is referred to herein as a heteroaryl ring.
[00361] The term "heteroaryl" as used herein by itself or as part of another group refers to, but is not limited to, aromatic rings having 5 to 12 carbon atoms or ring systems containing 1 to 2 rings that are fused to each other or covalently bonded, typically containing 5 to 6 atoms; at least one of which is aromatic, wherein one or more carbon atoms in one or more of these rings is replaced by oxygen, nitrogen and/or sulfur atoms where the nitrogen and sulfur heteroatoms can optionally be oxidized and the nitrogen heteroatoms can optionally be quaternized. Such rings can be fused to an aryl, cycloalkyl, heteroaryl or heterocyclyl ring. Non-limiting examples of such heteroaryl include: furanyl, thiophenyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, oxatriazolyl, thiadiazolyl, pyridinyl, pyrimidyl, pyrazinyl, pyrazinyl, , triazinyl, imidazo[2,1-b][1,3]thiazolyl, thieno[3,2-b] furanyl, thieno[3,2-b]thiophenyl, thieno[2,3-d][1,3 ]thiazolyl, thieno[2,3-d]imidazolyl, tetrazolo[1,5-a]pyridinyl, indolyl, indolizinyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, isobenzothiophenyl, indazolyl, benzimidazolyl, 1,3-benzoxazolyl, 1,2 -benzisoxazolyl, 2,1-benzisoxazolyl, 1,3-benzothiazolyl, 1,2-benzoisothiazolyl, 2,1-benzoisothiazolyl, benzotriazolyl, 1,2,3-benzoxadiazolyl, 2,1,3-benzoxadiazolyl, 1,2,3 -benzothiadiazolyl, 2,1,3-benzothiadiazolyl, thienopyridinyl, purinyl, imidazo[1,2-a]pyridinyl, 6-oxo-pyridazin-1(6H)-yl, 2-oxopyridin-1(2H)-yl, 6 -oxo-pyridazin-1(6H)-yl, 2-oxo pyridin-1(2H)-yl, 1,3-benzodioxolyl, quinolinyl, isoquinolinyl, cinolinyl, quinazolinyl, quinoxalinyl.
[00362] The term "heteroarylene" as used herein means divalent carbocyclic aromatic ring systems including pyridinylene and the like.
[00363] The ring atoms of the selected heteroaryl or heteroarylene moieties are numbered in the scheme below:

The term "biaryl" as used herein designates two aryl moieties as defined herein linked by means of a single bond. Non-limiting examples of such biaryl moieties all include 2-biphenyl, 3-biphenyl and 4-biphenyl biphenyl regioisomers.

The term "heterobiaryl" as used herein designates two heteroaryl moieties as defined herein or a heteroaryl moiety and an aryl moiety as defined herein linked via a single bond. Non-limiting examples of such heterobiaryl moieties are provided below.

[00366] The term "carbamoyl" as used herein means a group of formula

[00367] where the arrow defines the connection point.
[00368] The term "carbamimidoyl" as used herein means a group of formula

[00369] where the arrow defines the connection point.
The compounds of formula I and subformulas thereof contain at least one asymmetric center and thus can exist as different stereoisomeric forms. Consequently, the present invention includes all possible stereoisomers and includes not only racemic compounds, but the individual enantiomers and their non-racemic mixtures as well. When a compound is desired as a single enantiomer, this can be obtained by stereospecific synthesis, by resolution of the final product or any convenient intermediate, or by chiral chromatographic methods as each is known in the art. Resolution of the final product, an intermediate, or a starting material can be performed by any suitable method known in the art. See, for example, Stereochemistry of Organic Compounds by E.L. Eliel, S.H. Wilen, and L.N. Mander (Wiley-Interscience, 1994), incorporated by reference for stereochemistry.
Bonds of an asymmetric carbon in compounds of the present invention may be depicted herein using a solid line (— ), a zigzag line (— ), a solid wedge ( — ), or a dotted wedge ( ). The use of a solid line to represent the bonds of an asymmetric carbon atom is intended to indicate that all possible stereoisomers in any relative relationship are intended to be included, unless it is clear from the context that a specific stereoisomer is intended. As a non-limiting example, a solid line representing bonds of an asymmetric carbon atom in a compound containing an asymmetric carbon encompasses a racemic mixture of both enantiomers. The racemic term used here indicated a 1/1 relationship between the two enantiomers. The use of a solid or dotted wedge to represent the bonds of an asymmetric carbon atom is intended to indicate that only the stereoisomer shown is intended to be included.
As a non-limiting example, compounds of formula Ic where R1' is H, R1 is not H and bond a, which designates the bond connecting R1 to the piperazine moiety, is drawn as a dotted wedge are stereoisomers of formula A. Compounds of formula Ic where R1' is H, R1 is not H and bond a is drawn as a solid wedge are stereoisomers of formula B.

[00373] The compounds of the invention may also contain more than one asymmetric carbon atom. In those compounds, the use of a solid line to represent asymmetric carbon atom bonds is intended to indicate that all possible stereoisomers in any relative relationship are intended to be included, unless it is clear from the context that a specific stereoisomer is intended. .
The compounds of the invention may be in the form of pharmaceutically acceptable salts. Pharmaceutically acceptable salts of the compounds of formula I include the base and acid addition salts thereof. Suitable acid addition salts are formed from acids which form non-toxic salts. Examples include acetate, adipate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulfate/sulfate, borate, cansylate, citrate, cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride salts /chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulfate, naphthylate, 2-napsilate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/phosphate of dihydrogen, pyroglutamate, saccharate, stearate, succinate, tannate, tartrate, tosylate, trifluoroacetate and xinofoate. Suitable base salts are formed from bases which form non-toxic salts. Examples include the salts of aluminum, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine, 2-(diethylamino)ethanol, ethanolamine, morpholine, 4-(2 -hydroxyethyl)morpholine and zinc. Acid and base hemissals can also be formed, for example hemisulfate and hemicalcium salts. Preferred pharmaceutically acceptable salts include hydrochloride/chloride, hydrobromide/bromide, bisulfate/sulfate, nitrate, citrate, and acetate.
When the compounds of the invention contain an acidic group as well as a basic group, the compounds of the invention may also form inner salts, and such compounds fall within the scope of the invention. When the compounds of the invention contain a hydrogen donor heteroatom (eg NH), the invention also encompasses salts and/or isomers formed by transfer of said hydrogen atom to a basic group or atom within the molecule.
[00376] Pharmaceutically acceptable salts of compounds of formula I can be prepared by one or more of these methods
[00377] (i) by reacting the compound of formula I with the desired acid;
[00378] (ii) by reacting the compound of formula I with the desired base;
[00379] (iii) by removing an acid- or base-labile protecting group from a suitable precursor of the compound of formula I or by ring-opening a suitable cyclic precursor, e.g., a lactone or lactam, using the desired acid ; or
[00380] (iv) by converting one salt of the compound of formula I into another by reaction with an appropriate acid or by means of a suitable ion exchange column.
[00381] All these reactions are typically carried out in solution. The salt can precipitate out of solution and be collected by filtration or can be recovered by evaporation of the solvent. The degree of ionization in the salt can range from fully ionized to almost non-ionized.
The term "solvate" is used herein to describe a molecular complex comprising the compound of the invention and one or more pharmaceutically acceptable solvent molecules, for example, ethanol. The term 'hydrate' is used when said solvent is water.
All references to compounds of formula I include references to salts, solvates, multi-component complexes and liquid crystals thereof.
The compounds of the invention include compounds of formula I as defined above, including all polymorphs and crystal habits thereof, prodrugs and isomers thereof (including optical, geometric and tautomeric isomers) and isotopically labeled compounds of formula I .
[00385] Furthermore, although generally, with respect to salts of the compounds of the invention, pharmaceutically acceptable salts are preferred, it should be noted that the invention in its broadest sense also included pharmaceutically unacceptable salts, which may, for example, be used in the isolation and/or purification of the compounds of the invention. For example, salts formed with optically active acids or bases can be used to form diastereoisomeric salts which can facilitate the separation of optically active isomers from the compounds of formula I above.
The invention also generally encompasses all pharmaceutically acceptable predrugs and prodrugs of the compounds of formula I.
The term "prodrug", as used herein, means the pharmacologically acceptable derivatives of the compounds of formula I such as esters whose in vivo biotransformation product is the active drug. Prodrugs are characterized by increased bioavailability and are easily metabolized to active compounds in vivo.
[00388] The term "predrug", as used herein, means any compound that will be modified to form a kind of drug, wherein the modification may occur inside or outside the body, and before or after the predrug reaches the area of the body where drug administration is indicated.
The term "patient" refers to a warm-blooded animal, most preferably a human, who/who is awaiting or receiving medical care or is or will be the subject of a medical procedure.
[00390] The term "human" refers to the individual of both genders and at any stage of development (ie, neonate, infant, juvenile, adolescent, adult).
The terms "treating", "treating" and "treatment, as used herein, are intended to include alleviating or abolishing a condition or disease and/or its accompanying symptoms.
[00392] The terms "prevent", "preventing" and "prevention", as used herein, refer to a method of delaying or preventing the onset of a condition or disease and/or its accompanying symptoms, blocking a patient from acquiring a condition or disease, or reduce a patient's risk of acquiring a condition or disease.
The term "therapeutically effective amount" (or more simply an "effective amount"), as used herein, means the amount of active agent or active ingredient (e.g., NK-3 antagonist) that is sufficient to obtain the desired therapeutic or prophylactic effect on the individual to which it is administered.
[00394] The term "administering", or a variant thereof (eg "administering"), means providing the active agent or active ingredient (eg an NK-3 antagonist), alone or as part of a composition pharmaceutically acceptable, to the patient in whom/that the condition, symptom, or illness is to be treated or prevented.
[00395] By "pharmaceutically acceptable" it is meant that the ingredients of a pharmaceutical composition are compatible with one another and not harmful to the patient thereof.
[00396] The term "antagonist", as used herein, means a compound that competitively or non-competitively binds to a receptor at the same site as an agonist (eg, the endogenous ligand), but does not activate an intracellular response initiated by an active form of the receiver. An antagonist thereby inhibits the intracellular response induced by an agonist.
The term "sex hormone dependent disease", as used herein, means a disease that is exacerbated by, or caused by, excessive, inappropriate, or unregulated sex hormone production. Examples of such diseases in men include, but are not limited to benign prostatic hyperplasia (BPH), metastatic prostatic carninoma, testicular cancer, breast cancer, erogen-dependent acne, male pattern baldness. Examples of such diseases in women include, but are not limited to, endometriosis, abnormal puberty, uterine fibrosis, hormone-dependent cancers (ovarian cancer, breast cancer), hyperandrogenism, hirsutism, virilization, polycystic ovary syndrome (PCOS), HAIR syndrome -AN (hyperandrogenism, insulin resistance and acanthosis nigricans), ovarian hyperthecosis (HAIR-AN with luteinized theca cell hyperplasia in ovarian stroma), other manifestations of elevated intraovarian androgen concentrations (eg, disruption of follicular maturation, atresia, anovulation , dysmenorrhea, dysfunctional uterine bleeding, infertility) and androgen-producing tumor (virilizing adrenal or ovarian tumor).
[00398] The term "psychotic disorders", as used herein, means a group of ailments that affect the mind. These disorders alter a patient's ability to think clearly, make good judgments, respond emotionally, communicate effectively, understand reality, and behave appropriately. When symptoms are severe, patients with psychotic disorders have difficulty staying in touch with reality and are often unable to cope with the ordinary demands of daily life. Psychotic disorders include, and are not limited to, schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorder due to a general medical condition, substance-induced psychotic disorder, or unspecified psychotic disorder of another method (Diagnostic and Statistical Manual of Mental Disorders, 4th Ed., American Psychiatric Association, Washington, DC 1994).
The term "pharmaceutical carrier", as used herein, means an inert vehicle or medium used as a solvent or diluent in which the pharmaceutically active agent is formulated and/or administered. Non-limiting examples of pharmaceutical carriers include creams, gels, lotions, solutions, and liposomes.
[00400] The present invention will be better understood with reference to the following examples. These examples are intended to be representative of specific embodiments of the invention, and are not intended to limit the scope of the invention. CHEMISTRY EXAMPLES
[00401] All temperatures are expressed in °C and all reactions were performed at room temperature (RT) unless otherwise noted.
[00402] Analytical thin layer chromatography (TLC) was used to monitor reactions, establish flash chromatography conditions and verify the purity of intermediates or final products. TLC plates used were Merck TLC aluminum foil silica gel 60 F254. TLC plates were developed using ultraviolet irradiation (wavelength = 254 nm) at room temperature or 0.1% bromocresol green spray reagent in propan-2-ol purchased from VWR International under heating at 160°C or the developer KMnO4 under heating at 160°C. TLC developing agent KMnO4 was prepared by dissolving 3 g potassium permanganate, 20 g sodium carbonate, 0.5 g sodium hydroxide in 100 ml distilled water.
HPLC-MS spectra were obtained under Agilent LCMS using electrospray ionization (ESI). The Agilent instrument includes a 1200 Autosampler, a 1100 binary pump, a 1100 5-wavelength detector and a 6100 Single Quad. The column used was an XBridge C18, 4.6 x 50 mm, 3.5 µm.
[00404] The eluent was a mixture of solution A (TFA 0.1% in H2O) and solution B (TFA 0.1% in ACN). The gradient was applied at a flow rate of 2 mL min-1 as follows: gradient A: maintained initial conditions of 5% solution B for 1 min, linearly increased to 95% solution B in 4 min, maintained at 95% for 1 min, returned to initial conditions in 0.5 min and held for 1 min; gradient B: initial conditions of 5% solution B maintained for 1 min, linearly increased to 60% in 10 min, linearly increased to 95% in 0.5 min, maintained at 95% for 3 min, returned to initial conditions in 0.5 min and held for 1 min.
[00405] The determination of ee was performed under an Agilent 1100 (binary pump and 5-wavelength detector) with manual or automatic injection (Autosampler 1100). The columns used were CHIRALPAK IA, CHIRALPAK IB or CHIRALPAK IC in isocratic mode. The eluent mixtures were selected depending on the obtained separation of enantiomers or diastereoisomers. The usual mixtures were:
[00406] - hexane and ethanol (0.1% DEA)
[00407] - hexane and isopropanol (0.1% DEA)
[00408] - hexane and ethyl acetate (0.1% DEA)
[00409] - hexane and dichloromethane (0.1% DEA)
[00410] - heptane and THF (0.1% DEA)
[00411] Preparative HPLC purifications were performed under the Fractionlynx instrument, from Waters. This instrument consists of a Fraction Collector, a 2767 Sample Handler, a Pump Control a Module II, a 515 HPLC Pump, a 2525 Binary Gradient Module, a Switch Valve, a 2996 Photodiode Disposition Detector and a Micromass ZQ. The column used was a Waters Sunfire C18. The eluent was a mixture of solution A (0.1% TFA in H2O) and solution B (0.1% TFA in ACN). The gradient was adapted depending on the impurities present in the samples, to allow sufficient separation between the impurities and the target compound.
[00412] Preparative chiral HPLC purification was performed under an Agilent 1100 instrument (binary pump and 5-wavelength detector) with manual injection using a CHIRALPAK IA or CHIRALPAK IB column in isocratic mode. The eluent mixtures were selected depending on the separation of enantiomers or diastereoisomers obtained with the analytical method. The usual mixtures were the same as those used for the determination of ee.
[00413] 1H and 13C NMR spectra were recorded on a Bruker Avance DRX 300 MHz. Chemical shifts are expressed in parts per million, (ppm, δ units). Coupling constants are expressed in Hertz units (Hz). Division patterns describe apparent multiplicities and are described as s (singlet), d (doublet), t (triplet), q (quadruplet), m (multiplet), or br (broad).
[00414] Solvents, reagents and starting materials were purchased from well known chemical suppliers such as, for example, Sigma Aldrich, Acros Organics, Fluorochem, Eurisotop, VWR International, Sopachem and Polimer labs and the following abbreviations are used:


The intermediates and compounds described below were named using ChemDraw Ultra 12 purchased from CambridgeSoft (Cambridge, MA, USA). general synthetic scheme
Most of the compounds of the invention were synthesized using the methodology described in scheme 1. The chiral compounds were obtained by purification using chiral HPLC, or employing the appropriate chiral ketopiperazine building block.
Scheme 1: General synthetic scheme for the preparation of most compounds in the present invention
Ketopiperazine 1.1 was protected with a Boc group and converted to iminoether 1 using the Meerwein reagent (ie Et3OBF4). Ester 1.2 was subsequently converted to acyl hydrazide 2 via its reaction with hydrazine, in N-Boc protected form (ie 1.2 ^ 2, condition a), or unprotected (ie 1.2 ^ 2, condition b) . The condensation reaction between the acyl hydrazide thus generated and the iminoether mentioned above was conducted under thermal reflux conditions, or by applying microwave irradiation. In the case of reactions conducted using microwave irradiation, N-Boc deprotection occurred during the condensation reaction, thus a deprotection step was not necessary to carry out (ie, 1 + 2 ^ 3 in Scheme 1). However, when the condensation reaction was carried out under thermal conditions, it was necessary to introduce a deprotection step (ie, 1 + 2 ^ 1.3 ^ 3). Acylation of the amine to the triazolopiperazine intermediate 1.5, via reaction with the appropriate acid chloride or via reaction with the appropriate activated ester, ie, conditions A and B respectively, provided the final target structure. This synthetic method has been used for most of the compounds described in the present invention. General Method A:
[00418] General Method A is the general procedure used for the synthesis of the iminoether intermediates 1 (as per Scheme 1) and is detailed below using the example of 3-ethoxy-5,6-dihydropyrazine-1(2H)-carboxylate of tert-butyl 1a.
Scheme 2: Synthesis of tert-butyl 3-ethoxy-5,6-dihydropyrazine-1(2H)-carboxylate Step 1: Synthesis of tert-butyl 3-oxopiperazine-1-carboxylate 2.2
[00419] Boc2O (10.9 g, 0.05 mol) was added in portions with stirring and cooling under an ice bath to a suspension of piperazin-2-one 2.1 (5 g, 0.05 mol) in anhydrous dichloromethane (100ml). The reaction mixture was stirred at 20 oC overnight (gas evolution was observed at the beginning of the reaction), during which time a homogeneous solution formed. The solvent was evaporated, and the solid residue was dried in vacuo (10 - 15 mm Hg) at 40 - 50°C to constant weight to give 2.2. Production: 100 g (100%). Step 2: Synthesis of tert-butyl 5-ethoxy-3,6-dihydropyrazine-1(2H)-carboxylate 1a
[00420] Solid triethyloxonium tetrafluoroborate (2.3 g, 0.012 mol) was added in portions with stirring and cooling under an ice bath to a solution of 2.2 (2 g, 0.01 mol) in anhydrous dichloromethane (20 ml) . After the addition was complete, the cooling was removed, and the reaction mixture was stirred at room temperature overnight. Then an aqueous 20% K2CO3 solution was added in portions under cooling under an ice bath to the slightly cloudy solution obtained to obtain pH 8 to 9. The formed precipitate of potassium tetrafluoroborate was filtered off and washed on the filter with dichloromethane. . The filtrate was placed in a separatory funnel, and the organic layer was separated. The aqueous layer was extracted with dichloromethane (3 x 10 mL), and the combined organic extracts were washed with water (20 mL), dried over Na2SO4 and concentrated on a rotary evaporator. Hexane was added to the residue, and the obtained mixture was allowed to rest in a refrigerator for ~4 h. The formed precipitate was filtered off using a thin pad of Celita, and the filtrate was evaporated. The viscous yellowish oil obtained was vacuum dried (10 to 15 mm Hg) at 40 to 50 °C for ~6 h to provide the title intermediate 1a. Yield: 2.03 g (88%). 1HRMN (CDCl3): δ: 4.1 ppm (q, 2H), 3.85 (s, 2H), 3.5 ppm (m, 1H), 3.35 ppm (t, 2H), 1.45 ppm (s, 9H), 1.3ppm (t, 3H).
[00421] Alternatively, General Method A was carried out as follows: Step 1: Synthesis of tert-butyl 3-oxopiperazine-1-carboxylate 2.2
To a solution of piperazin-2-one 2.1 (5.0 g, 33.2 mmols) in commercial anhydrous CH2Cl2 (100 mL) under N2 at RT was added NEt3 (5.1 mL, 35.5 mmols) . After 10 min of stirring, the RM was cooled to 0°C with an ice bath and Boc2O (8.33 g, 38.2 mmols) was added in one portion. RM was then stirred at RT for 1 h. The mixture was diluted with 50 mL of CH2Cl2 and washed with 0.5M HCl (30 mL), brine (30 mL), dried over magnesium sulfate, filtered and concentrated to constant weight providing 2.2 as a yellow oil. Yield: 7.1 g (100%). LCMS and 1HRMN data are compatible with those described above. Step 2: Synthesis of tert-butyl 5-ethoxy-3,6-dihydropyrazine-1(2H)-carboxylate 1a
To a pre-prepared solution of triethyloxonium tetrafluoroborate (2.3 g, 0.012 mol) in anhydrous dichloromethane (20 ml) was added 2.2 (2 g, 0.01 mol) at 0°C. After the addition was complete, the ice bath was removed, and the reaction mixture was allowed to warm to room temperature and stirred for an additional hour (reaction progress monitored by LC-MS). Upon completion of the reaction, a saturated solution of NaHCO3 (500 mL) was slowly added to the reaction mixture and stirred for 5 min. The organic layer was separated and the aqueous layer was also extracted with dichloromethane. The combined organic layers were subsequently washed with brine, dried over MgSO4, filtered and also dried in vacuo to obtain the title intermediate 1a as a viscous yellow oil. Yield: 2.03 g (88%). 1HRMN (CDCl3): δ: 4.1 ppm (q, 2H), 3.85 (s, 2H), 3.5 ppm (m, 1H), 3.35 ppm (t, 2H), 1.45 ppm (s, 9H), 1.3ppm (t, 3H).
[00424] The following intermediates were also prepared from the ad hoc reagents using General Method A:
Intermediate 1b: (R)-tert-butyl 3-ethoxy-2-methyl-5,6-dihydropyrazine-1(2H)-carboxylate,
Intermediate 1c: (S)-tert-butyl 3-ethoxy-2-methyl-5,6-dihydropyrazine-1(2H)-carboxylate,
[00427] intermediate 1d: tert-butyl 3-ethoxy-2-methyl-5,6-dihydropyrazine-1(2H)-carboxylate,
Intermediate 1e: tert-butyl 3-ethoxy-2-(4-fluorophenyl)-5,6-dihydropyrazine-1(2H)-carboxylate,
[00429] intermediate 1f: tert-butyl 3-ethoxy-2-isopropyl-5,6-dihydropyrazine-1(2H)-carboxylate,
[00430] intermediate 1g: tert-butyl 3-ethoxy-2-(2-hydroxyethyl)-5,6-dihydropyrazine-1(2H)-carboxylate,
[00431] intermediate 1h: tert-butyl 3-ethoxy-2,2-dimethyl-5,6-dihydropyrazine-1(2H)-carboxylate,
[00432] intermediate 1i: tert-butyl 3-ethoxy-6-methyl-5,6-dihydropyrazine-1(2H)-carboxylate,
Intermediate 1j: tert-butyl 3-ethoxy-5-methyl-5,6-dihydropyrazine-1(2H)-carboxylate. General Method B:
[00434] General Method B is the general procedure used for the synthesis of hydrazide intermediates 2 and is detailed below using the example of quinoline-2-carbohydrazide 2nd
Scheme 3: Synthesis of quinoline-2-carbohydrazide 2a Step 1: Synthesis of methyl quinoline-2-carboxylate 3.2
To an ice-cooled solution of quinoline-2-carboxylic acid 3.1 (10 g, 0.0578 mol) in 100 mL of absolute methanol was added dropwise thionyl chloride (20 g, 0.173 mol). After the addition was complete, the mixture was heated to reflux for 2 h. The solvent was then evaporated to dryness under reduced pressure and treated with 100 ml of 10% aqueous K2CO3 solution. The mixture was extracted with ethyl acetate; combined organic extracts were dried over sodium sulphate and evaporated to dryness to give methyl quinoline-2-carboxylate. Production: 10.1 g (93%). Step 2: Synthesis of quinoline-2-carbohydrazide 2a
Methyl quinoline-2-carboxylate 3.2 (10.1 g, 0.054 mol) was dissolved in 50 mL of ethanol and hydrazine hydrate (8.1 g, 0.16 mol) was added. The mixture was heated to reflux for 1 h and cooled to RT at which point a precipitate formed. The mixture was concentrated to approximately 1/3 volume and the precipitate was filtered, washed with small volumes of ethanol to provide intermediate 2a solvated by equivalent % ethanol. Yield 10 g (99%). 1 HRMN (DMSO-d6): δ: 9.95 ppm (s, 1H), 8.55 (d, 1H), 8.1 ppm (d, 2H), 8.05 ppm (d, 1H), 8. 85 ppm (t, 1H), 7.65 ppm (t, 1H), 4.6 ppm (s, 2H), 4.3 ppm (t, 0.5H), 4.4 ppm (q, 1H), 1.05 ppm (q, 1.5H).
[00437] In one embodiment 5 to 20 equivalents of hydrazine hydrate were used to carry out this reaction.
[00438] The following intermediates were also prepared from the ad hoc reagents using General Method B:
[00439] intermediate 2b: 6-chloropicolinyl-hydrazide,
[00440] intermediate 2c: 6-methylpicolinyl hydrazide,
[00441] 2d intermediate: isoquinoline-3-carbohydrazide,
[00442] intermediate 2e: 8-fluoroquinoline-2-carbohydrazide,
[00443] intermediate 2f: 8-chloroquinoline-2-carbohydrazide,
[00444] intermediate 2g: 2-(4-(trifluoromethyl)phenyl)thiazole-4-carbohydrazide,
[00445] 2h intermediate: 6-phenylpicolinohydrazide,
[00446] intermediate 2i: 4,5,6,7-tetrahydrobenzo[d]thiazol-2-carbohydrazide,
[00447] intermediate 2j: benzo[d]thiazol-2-carbohydrazide,
[00448] intermediate 2k: 2-(2,4-difluorophenyl)thiazole-4-carbohydrazide,
[00449] intermediate 21: 2-(4-chlorophenyl)thiazole-4-carbohydrazide,
[00450] 2m intermediate: 2-(4-fluorophenyl)thiazole-4-carbohydrazide,
[00451] 2n intermediate: 2-(piperidin-1-yl)thiazole-4-carbohydrazide,
[00452] intermediate 2o: 2-(4-phenylpiperazin-1-yl)thiazol-4-carbohydrazide,
[00453] intermediate 2p: 2-(2,4-dichlorophenyl)thiazole-4-carbohydrazide,
[00454] intermediate 2q: 2-(3,5-dichlorophenyl)thiazole-4-carbohydrazide,
[00455] intermediate 2r: 6-(pyrrolidin-1-yl)picolinoidrazide,
[00456] intermediate 2s: 6-morpholinopicolinohydrazide,
[00457] intermediate 2t: 6-(trifluoromethyl)picolinohydrazide,
[00458] intermediate 2u: 2-(3,4-dimethoxyphenyl)thiazole-4-carbohydrazide,
[00459] intermediate 2v: 2-(3-chlorophenyl)thiazole-4-carbohydrazide,
[00460] intermediate 2w: 2-phenyloxazole-4-carbohydrazide,
[00461] 2x intermediate: 2-(2-chlorophenyl)thiazole-4-carbohydrazide,
[00462] intermediate 2y: 5-methyl-2-phenylthiazol-4-carbohydrazide,
[00463] 2z intermediate: 3-phenyl-1,2,4-oxadiazol-5-carbohydrazide,
[00464] intermediate 2a1: 5-phenyl-1,2,4-oxadiazol-3-carbohydrazide,
[00465] intermediate 2b1: 3-(4-fluorophenyl)-1,2,4-oxadiazol-5-carbohydrazide,
[00466] intermediate 2c1: 3-(2,4-difluorophenyl)-1,2,4-oxadiazol-5-carbohydrazide, was synthesized from intermediate 5a obtained using General Method E,
[00467] Intermediate 2d1: 5-phenyl-1H-1,2,4-triazol-3-carbohydrazide, was synthesized from methyl 5-phenyl-1H-1,2,4-triazol-3-carboxylate whose preparation is described in J. Med. Chem. 1995, 38, 2196,
[00468] intermediate 2e1: 2-((4,5-dichloro-1H-imidazol-1-yl)methyl)thiazole-4-carbohydrazide,
[00469] intermediate 2f1: 2-(4-chlorobenzyl)thiazole-4-carbohydrazide
[00470] intermediate 2g1: 2-(p-tolyl)thiazole-4-carbohydrazide,
[00471] intermediate 2h1: 2-(2-methoxyphenyl)thiazole-4-carbohydrazide,
[00472] intermediate 2i1: 2-(3-fluorophenyl)thiazole-4-carbohydrazide,
[00473] intermediate 2j1: 3-(4-fluorophenyl)-1,2,4-oxadiazol-5-carbohydrazide,
[00474] intermediate 2k1: 3-phenyl-1,2,4-thiadiazol-5-carbohydrazide,
[00475] intermediate 211: 2-(4-bromophenyl)thiazole-4-carbohydrazide,
[00476] intermediate 2m1: 2-(pyridin-4-yl)thiazole-4-carbohydrazide, was synthesized from intermediate 6b obtained using General Method F,
[00477] intermediate 2n1: 2-(quinolin-2-yl)thiazole-4-carbohydrazide,
[00478] intermediate 2o1: 1-methyl-3-phenyl-1H-pyrazol-5-carbohydrazide,
[00479] intermediate 2p1: 2-(4-(dimethylamino)phenyl)thiazole-4-carbohydrazide,
[00480] intermediate 2q1: 1-methyl-5-phenyl-1H-pyrazol-3-carbohydrazide,
[00481] intermediate 2r1: 2-(pyridin-2-yl)thiazole-4-carbohydrazide,
[00482] intermediate 2s1: 2-(pyrimidin-2-yl)thiazole-4-carbohydrazide, was synthesized from intermediate 6d obtained using General Method F
[00483] intermediate 2t1: 2-(pyrazin-2-yl)thiazole-4-carbohydrazide, was synthesized from intermediate 6e obtained using General Method F,
[00484] intermediate 2u1: 2-(4-morpholinophenyl)thiazole-4-carbohydrazide, was synthesized from intermediate 7b obtained using General Method G,
[00485] intermediate 2v1: 2-(4-(4-methylpiperazin-1-yl)phenyl)thiazol-4-carbohydrazide,
[00486] intermediate 2w1: 2-(4-(piperidin-1-yl)phenyl)thiazole-4-carbohydrazide, was synthesized from intermediate 7c obtained using General Method G,
[00487] intermediate 2x1: 2-(4-(pyrrolidin-1-yl)phenyl)thiazole-4-carbohydrazide, was synthesized from intermediate 7d obtained using General Method G,
[00488] intermediate 2y1: 2-(piperidin-1-yl)thiazole-4-carbohydrazide, was synthesized from intermediate 7e obtained using General Method G,
[00489] intermediate 2z1: 2-(pyrrolidin-1-yl)thiazole-4-carbohydrazide, was synthesized from intermediate 7f obtained using General Method G,
[00490] intermediate 2a2: 2-(4-methylpiperazin-1-yl)thiazole-4-carbohydrazide, was synthesized from intermediate 7g obtained using General Method G,
[00491] intermediate 2b2: 1-methyl-2-phenyl-1H-imidazol-4-carbohydrazide,
[00492] intermediate 2c2: 1-(2-methoxyethyl)-3-phenyl-1H-pyrazol-5-carbohydrazide, was synthesized from intermediate 8a obtained using General Method H,
Intermediate 2d2: 2-isobutylthiazole-4-carbohydrazide, was synthesized from ethyl 2-isobutylthiazole-4-carboxylate, which was obtained from 3-methylbutanethioamide using the methodology reported by Ciufolini, et al. in Journal of Organic Chemistry, 1997 , vol. 62, issue 12, p. 3804 - 3805,
[00494] intermediate 2e2: 2-(2-(2-methoxyethyl)morpholino)thiazole-4-carbohydrazide, was synthesized from intermediate 7h obtained using General Method G,
[00495] intermediate 2f2: 2-(4,4-difluoropiperidin-1-yl)thiazole-4-carbohydrazide, was synthesized from intermediate 7i obtained using General Method G,
[00496] intermediate 2g2: 2-(2,5-dimethylmorpholino)thiazole-4-carbohydrazide, was synthesized from intermediate 7i obtained using General Method G,
[00497] intermediate 2h2: 2-(2-hydroxyphenyl)thiazol-4-carbohydrazide, was synthesized from ethyl 2-(2-hydroxyphenyl)thiazol-4-carboxylate, which was obtained from 2-hydroxybenzothioamide using the methodology reported by Ciufolini , et al. in Journal of Organic Chemistry, 1997, vol. 62, issue 12, p. 3804 - 3805,
[00498] intermediate 2i2: 2-(2,6-dimethylmorpholino)thiazole-4-carbohydrazide, was synthesized from intermediate 7k obtained using General Method G,
[00499] intermediate 2j2: 2-(2,2-dimethylmorpholino)thiazole-4-carbohydrazide, was synthesized from intermediate 7l obtained using General Method G,
[00500] 2k2 intermediate: 3-phenyl-1H-pyrazol-5-carbohydrazide,
[00501] intermediate 2l2: 2-(2-methylmorpholino)thiazole-4-carbohydrazide, was synthesized from intermediate 7m obtained using General Method G,
[00502] intermediate 2m2: 2-(4,4-dimethylpiperidin-1-yl)thiazole-4-carbohydrazide, was synthesized from intermediate 7n obtained using General Method G,
[00503] 2n2 intermediate: 5-methylthiazole-4-carbohydrazide,
[00504] intermediate 2o2: 2-(2-(methoxymethyl)piperidin-1-yl)thiazole-4-carbohydrazide, was synthesized from intermediate 7o obtained using General Method G,
[00505] Intermediate 2p2: 2-(2-bromophenyl)thiazol-4-carbohydrazide, was synthesized from ethyl 2-(2-bromophenyl)thiazole-4-carboxylate, which was obtained from 2-bromobenzothioamide using the methodology reported by Ciufolini , et al. in Journal of Organic Chemistry, 1997, vol. 62, issue 12, p. 3804 - 3805,
[00506] intermediate 2q2: 2-(3-bromophenyl)thiazole-4-carbohydrazide, was synthesized from ethyl 2-(3-bromophenyl)thiazole-4-carboxylate, which was obtained from 3-bromobenzothioamide using the methodology reported by Ciufolini , et al. in Journal of Organic Chemistry, 1997, vol. 62, issue 12, p. 3804 - 3805. General Method C:
[00507] General Method C is the general procedure used for the synthesis of the intermediates of triazolopiperazine 3 and is detailed below with the synthesis of (R)-4-(8-methyl-5,6,7,8-tetrahydro) hydrochloride - [1,2,4]triazolo[4,3-a]pyrazin-3-yl)-2-phenylthiazol 3a.
Scheme 4: Synthesis of (R)-4-(8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl hydrochloride salt )-2-phenylthiazole Step 1: Synthesis of 8-methyl-3-(2-phenylthiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a] pyrazine-7(8H) -(R)-tert-butyl carboxylate 4.2
To a solution of hydrazide 4.1 2-phenylthiazole-4-carbohydrazide (100 mg, 0.4 mmol) in ethanol (7 mL) was added 3-ethoxy-2-methyl-5,6-dihydropyrazine- (2R)-tert-butyl 1(2H)-carboxylate 1b (75 mg, 0.34 mmol). To this reaction mixture was applied microwave radiation (110°C, 15.46 kg/cm 2 (220 psi)) for 25 h. The solvent was then evaporated to dryness and the residue was purified on silica gel using CH2Ch-ethyl acetate (5:1^5:2 + 1% to 5% MeOH). Production: 50 mg of 4.2 + 40 mg of de-Boc 3a product. Combined production: 76%. LCMS: P=96%, TR=1.86 min, m/z=398, 298. Step 2: Synthesis of (R)-4-(8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)-hydrochloride- 2-phenylthiazole 3a
[00509] Compound 4.2 (50 mg, 0.125 mmol) obtained in the previous step was dissolved in isopropyl alcohol (10 mL) to which 0.3 mL of 4M HCl in dioxane was added. The mixture was stirred at 50 °C overnight. After cooling to RT, 10 mL of diethyl ether was added. The precipitate was filtered to furnish the title intermediate. Yield: 42mg, 99%. LCMS: P = 100%, RT = 1.08 min, m/z = 298. 1H NMR (DMSO-d6): δ: 8.3 ppm (s, 1H), 8.05 ppm (m, 2H), 7.55 ppm (m, 3H), 4.5 ppm (m, 1H), 4.25-4.05 ppm (m, 2H), 3.3 ppm (m, 1H), 2.95-3, 1ppm (m, 1H), 2.8ppm (br s, 1H), 1.95ppm (d, 3H).
[00510] General Method variant C is detailed below using the example of 2-(4-fluorophenyl)-4-(8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4 ,3-a]pyrazin-3-yl)thiazole 3q1.
Scheme 4: Synthesis of 2-(4-fluorophenyl)-4-(8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl )thiazole Step 1: Synthesis of 3-(2-(4-fluorophenyl)thiazol-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a] pyrazine -7(8H)-tert-butyl 4 carboxylate
[00511] To a solution of 2m hydrazide (1.65 g, 6.95 mmols) in anhydrous ethanol (15 mL, ~0.5 M) was added iminoether 1d (1.69 g, 6.95 mmols) in one batch. portion. The reaction mixture was then stirred under reflux. After 45 h (almost complete conversion by LC-MS), the solvent was evaporated to dryness and the residue was purified on silica gel using a mixture of CH2Cl2/MeOH (0% to 4% MeOH) as eluent, providing 4 ' as a yellow solid. Production: 2.1 g (73%). LCMS: P = 92%, RT = 4.4 min, m/z = 416. 1HRMN (CDCl3): δ: 8.11 ppm (s, 1H), 7.97 ppm (t, 2H), 7.20 ppm (t, 2H), 4.75 (m, 1H), 4.52 (m, 1H), 4.23 (dt, 1H), 4.17 (m, 1H), 3.48 (dt, 1H) ), 1.64 ppm (d, 3H), 1.51 ppm (s, 9H). Step 2 Synthesis of 2-(4-fluorophenyl)-4-(8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl) thiazole 3q1
To a solution of Boc-triazole-piperazine 4' (2.17 g, 5.22 mmols) in iso-propanol (150 mL) was added 4M HCl solution in 1,4-dioxane (26, 1 mL, 104 mmol) in one portion. The reaction mixture was stirred at 60°C and the reaction progress was monitored by LC-MS.
[00513] After 1 h (complete conversion by LC-MS), the reaction mixture was allowed to cool to room temperature and then also cooled to 0°C with an ice bath. Soon after, 150 mL of Et2O was added. After 15 min of stirring, the precipitate was filtered and dried in vacuo to give 3q1 as an off-white solid. Yield: 1.313 g (72%). LCMS: P = 98%, RT = 3.3 min, m/z = 316. 1HRMN (CD3OD): δ: 8.57 ppm (s, 1H), 8.15 ppm (t, 2H), 7.30 ppm (t, 2H), 5.22 (m, 1H), 5.08 (q, 1H), 4.13 (m, 1H), 3.77 (m, 1H), 3.12 (m, 1H) ), 1.94 ppm (d, 3H).
[00514] As noted in scheme 4' above, an alternative procedure to thermal reflux to perform the condensation step to form the triazolopiperazine intermediate entailed the use of microwave irradiation. Such reactions were conducted in anhydrous ethanol and the following conditions were typically applied (CEM Discover): 300 W μ wave (143°C) with air cooling.
[00515] The following intermediates were also prepared from the ad hoc reagents and intermediates using General Method C:
[00516] intermediate 3b: 3-(pyridin-2-yl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine dihydrochloride salt,
[00517] intermediate 3c: 4-(4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)thiazol-2 dihydrochloride salt -yl)morpholine,
[00518] intermediate 3d: 3-(5-chloropyridin-2-yl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine dihydrochloride salt,
[00519] intermediate 3e: 3-(6-methylpyridin-2-yl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine dihydrochloride salt,
[00520] intermediate 3f: 8-methyl-3-(pyridin-2-yl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine dihydrochloride salt ,
[00521] intermediate 3g: 3-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)isoquinoline hydrochloride salt,
[00522] intermediate 3h: 2-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)quinoline hydrochloride salt,
[00523] intermediate 3i: 8-fluor-2-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)quinoline hydrochloride salt,
[00524] intermediate 3j: 8-chloro-2-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)quinoline hydrochloride salt,
[00525] intermediate 3k: hydrochloride salt of 4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)-2-(4- (trifluoromethyl)phenyl)thiazole,
[00526] intermediate 3l: 3-(6-phenylpyridin-2-yl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine dihydrochloride salt,
[00527] intermediate 3m: 2-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)-4,5,6 hydrochloride salt ,7-tetrahydrobenzo[d]thiazole,
[00528] intermediate 3n: 2-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)benzo[d]thiazole hydrochloride salt,
[00529] intermediate 3o: 2-phenyl-4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)thiazole hydrochloride salt,
[00530] intermediate 3p: hydrochloride salt of 4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)-2-(3- (trifluoromethyl)phenyl)thiazole,
[00531] intermediate 3q: 2-(2,4-difluorophenyl)-4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a] pyrazin-hydrochloride salt 3-yl)thiazole,
[00532] intermediate 3r: 2-(2,3-dichlorophenyl)-4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-hydrochloride salt 3-yl)thiazole,
[00533] intermediate 3s: 2-(4-chlorophenyl)-4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-a] hydrochloride salt il)thiazole,
[00534] intermediate 3t: 2-(4-fluorophenyl)-4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a] pyrazin-3-a] hydrochloride salt il)thiazole,
[00535] intermediate 3u: 2-(piperidin-1-yl)-4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-dihydrochloride salt 3-yl)thiazole,
[00536] intermediate 3v: 2-(4-phenylpiperazin-1-yl)-4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a] dihydrochloride salt pyrazin-3-yl)thiazole,
[00537] intermediate 3w: 2-(2,4-dichlorophenyl)-4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-hydrochloride salt 3-yl)thiazole,
[00538] intermediate 3x: 2-(3,5-dichlorophenyl)-4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-hydrochloride salt 3-yl)thiazole,
[00539] intermediate 3y: 3-(6-(pyrrolidin-1-yl)pyridin-2-yl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4, dihydrochloride salt 3-a] pyrazine,
Intermediate 3z: 4-(6-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)pyridin-2 dihydrochloride salt -yl)morpholine,
Intermediate 3a1: 3-(6-(trifluoromethyl)pyridin-2-yl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a] dihydrochloride salt pyrazine,
[00542] intermediate 3b1: 2-(3,4-dimethoxyphenyl)-4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-hydrochloride salt) 3-yl)thiazole,
[00543] intermediate 3c1: 4-(8-(4-fluorophenyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a] pyrazin-3-hydrochloride salt yl)-2-phenylthiazole,
[00544] intermediate 3d1: 2-(3-chlorophenyl)-4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a] pyrazin-3-hydrochloride salt il)thiazole,
[00545] intermediate 3e1: 4-(8-isopropyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)-2 hydrochloride salt -phenylthiazole,
[00546] intermediate 3f1: (R)-8-methyl-3-(pyridin-2-yl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3] dihydrochloride salt -a] pyrazine,
[00547] intermediate 3g1: 4-(4-(8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl) dihydrochloride salt )thiazol-2-yl)morpholine,
[00548] intermediate 3h1: 2-phenyl-4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)oxazole hydrochloride salt,
[00549] intermediate 3i1: 4-(8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)-2-phenyloxazole,
[00550] intermediate 3j1: 2-(3-(2-phenylthiazol-4-yl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a] hydrochloride salt pyrazin-8-yl)ethanol,
[00551] intermediate 3k1: 4-phenyl-2-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)thiazole hydrochloride salt,
[00552] intermediate 311: 2-(2-chlorophenyl)-4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-hydrochloride salt il)thiazole,
[00553] intermediate 3m1: 4-(8,8-dimethyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl) hydrochloride salt -2-phenylthiazole,
[00554] intermediate 3n1: 2-(8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)quinoline hydrochloride salt,
[00555] intermediate 3o1: 4-(8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo [4,3-a] pyrazin-3-yl)-2 hydrochloride salt -phenylthiazole,
[00556] intermediate 3p1: (R)-2-(4-chlorophenyl)-4-(8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,) hydrochloride salt 3-a]pyrazin-3-yl)thiazole,
Intermediate 3q1: 2-(4-fluorophenyl)-4-(8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a] hydrochloride salt pyrazin-3-yl)thiazole,
[00558] intermediate 3r1: (R)-2-(4-fluorophenyl)-4-(8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,) hydrochloride salt 3-a]pyrazin-3-yl)thiazole,
[00559] intermediate 3s1: 5-methyl-4-(8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a] pyrazin-3-hydrochloride salt yl)-2-phenylthiazole,
Intermediate 3t1: 2-(2-chlorophenyl)-4-(8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a] hydrochloride salt pyrazin-3-yl)thiazole,
[00561] intermediate 3u1: 2-(2,4-difluorophenyl)-4-(8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-) hydrochloride salt a]pyrazin-3-yl)thiazole,
[00562] intermediate 3v1: 5-(8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)-3 hydrochloride salt -phenyl-1,2,4-oxadiazole,
Intermediate 3w1: 2-(4-fluorophenyl)-4-(6-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a] hydrochloride salt pyrazin-3-yl)thiazole,
Intermediate 3x1: 2-(4-fluorophenyl)-4-(5-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a] hydrochloride salt pyrazin-3-yl)thiazole,
[00565] Intermediate 3y1: (S)-8-methyl-3-(pyridin-2-yl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine ,
[00566] Intermediate 3z1: (S)-2-(4-fluorophenyl)-4-(8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazole [4,3-a] pyrazin-3-yl)thiazole,
[00567] intermediate 3a2: (S)-4-(4-(8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a] pyrazin-3-yl )thiazol-2-yl)morpholine,
[00568] intermediate 3b2: 5-phenyl-3-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)-1 hydrochloride salt ,2,4-oxadiazole,
[00569] intermediate 3c2: 3-phenyl-5-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)-1 hydrochloride salt ,2,4-oxadiazole,
[00570] intermediate 3d2: 3-(4-fluorophenyl)-5-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-hydrochloride salt) il)-1,2,4-oxadiazole,
[00571] intermediate 3e2: 3-(2,4-difluorophenyl)-5-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-hydrochloride salt) 3-yl)-1,2,4-oxadiazole,
[00572] intermediate 3f2: 3-(5-phenyl-1H-1,2,4-triazol-3-yl)-5,6,7,8-tetrahydro-[1,2,4]triazole hydrochloride salt [4,3-a] pyrazine,
[00573] intermediate 3g2: 2-(2-fluorophenyl)-4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a] pyrazin-3-hydrochloride salt il)thiazole,
[00574] intermediate 3h2: 2-((4,5-dichloro-1H-imidazol-1-yl)methyl)-4-(5,6,7,8-tetrahydro-[1,2,4) dihydrochloride salt ]triazolo[4,3-a]pyrazin-3-yl)thiazole,
[00575] intermediate 3i2: 2-(4-chlorobenzyl)-4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-hydrochloride salt il)thiazole,
[00576] intermediate 3j2: 4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)-2-(p- hydrochloride salt tolyl)thiazole,
[00577] intermediate 3k2: 4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)-2-(thiophen-hydrochloride salt 2-yl)thiazole,
[00578] intermediate 3l2: 2-(((4-chlorophenyl)sulfonyl)methyl)-4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3- a]pyrazin-3-yl)thiazole,
[00579] intermediate 3m2: 2-(2-methoxyphenyl)-4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a] pyrazin-3-hydrochloride salt il)thiazole,
[00580] intermediate 3n2: 2-(3-fluorophenyl)-4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a] pyrazin-3-hydrochloride salt il)thiazole,
[00581] intermediate 3o2: 2-isopropyl-4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)thiazole hydrochloride salt,
Intermediate 3p2: 3-(4-fluorophenyl)-5-(8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a] hydrochloride salt pyrazin-3-yl)-1,2,4-oxadiazole,
[00583] intermediate 3q2: 3-phenyl-5-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)-1 hydrochloride salt ,2,4-thiadiazole,
[00584] intermediate 3r2: 2-(4-bromophenyl)-4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-hydrochloride salt il)thiazole,
[00585] intermediate 3s2: 2-(pyridin-4-yl)-4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-dihydrochloride salt 3-yl)thiazole,
[00586] intermediate 3t2: 2-(quinolin-2-yl)-4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-dihydrochloride salt 3-yl)thiazole,
[00587] intermediate 3u2: 3-(1-methyl-3-phenyl-1H-pyrazol-5-yl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4] hydrochloride salt ,3-a] pyrazine,
[00588] intermediate 3v2: N,N-dimethyl-4-(4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3) dihydrochloride salt -yl)thiazol-2-yl)aniline,
[00589] intermediate 3w2: 3-(1-methyl-5-phenyl-1H-pyrazol-3-yl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4] hydrochloride salt ,3-a] pyrazine,
[00590] intermediate 3y2: 2-(pyridin-2-yl)-4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-dihydrochloride salt 3-yl)thiazole,
[00591] intermediate 3z2: 2-(pyrimidin-2-yl)-4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-dihydrochloride salt 3-yl)thiazole,
[00592] intermediate 3a3: 2-(pyrazin-2-yl)-4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-dihydrochloride salt 3-yl)thiazole,
[00593] intermediate 3b3: 4-(4-(4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl) hydrochloride salt) thiazol-2-yl)phenyl)morpholine,
Intermediate 3c3: 2-(4-(4-methylpiperazin-1-yl)phenyl)-4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4] dihydrochloride salt ,3-a]pyrazin-3-yl)thiazole,
Intermediate 3d3: 2-(4-(piperidin-1-yl)phenyl)-4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3] hydrochloride salt -a]pyrazin-3-yl)thiazole,
Intermediate 3e3: 2-(4-(pyrrolidin-1-yl)phenyl)-4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3] hydrochloride salt -a]pyrazin-3-yl)thiazole,
[00597] intermediate 3f3: 2-(piperidin-1-yl)-4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-hydrochloride salt 3-yl)thiazole,
[00598] intermediate 3g3: 2-(pyrrolidin-1-yl)-4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-hydrochloride salt 3-yl)thiazole,
Intermediate 3h3: 2-(4-methylpiperazin-1-yl)-4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a] dihydrochloride salt pyrazin-3-yl)thiazole,
[00600] intermediate 3i3: 3-(1-methyl-2-phenyl-1H-imidazol-4-yl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4] dihydrochloride salt ,3-a] pyrazine,
[00601] intermediate 3j3: 3-(1-(2-methoxyethyl)-3-phenyl-1H-pyrazol-5-yl)-5,6,7,8-tetrahydro-[1,2,4 hydrochloride salt ]triazolo[4,3-a] pyrazine,
[00602] intermediate 3k3: 2-isobutyl-4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)thiazole hydrochloride salt,
Intermediate 313: 2-(2-Methoxyethyl)-4-(4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin) hydrochloride salt -3-yl)thiazol-2-yl)morpholine,
[00604] intermediate 3m3: 2-(4,4-difluoropiperidin-1-yl)-4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-) hydrochloride salt a]pyrazin-3-yl)thiazole,
[00605] intermediate 3n3: 2,5-dimethyl-4-(4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3) hydrochloride salt -yl)thiazol-2-yl)morpholine,
[00606] intermediate 3o3: 2-(4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)thiazol-2 hydrochloride salt -yl)phenol,
[00607] intermediate 3p3: 2,6-dimethyl-4-(4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3) hydrochloride salt -yl)thiazol-2-yl)morpholine,
[00608] intermediate 3q3: 2,2-dimethyl-4-(4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3) hydrochloride salt -yl)thiazol-2-yl)morpholine,
[00609] intermediate 3r3: 3-(3-phenyl-1H-pyrazol-5-yl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a] dihydrochloride salt ] pyrazine,
Intermediate 3s3: 2-methyl-4-(4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl) hydrochloride salt )thiazol-2-yl)morpholine,
[00611] intermediate 3t3: 2-(4,4-dimethylpiperidin-1-yl)-4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-) hydrochloride salt a]pyrazin-3-yl)thiazole,
[00612] intermediate 3u3: 5-methyl-4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)thiazole hydrochloride salt,
[00613] intermediate 3v3: 2-(2-(methoxymethyl)piperidin-1-yl)-4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3] hydrochloride salt -a]pyrazin-3-yl)thiazole,
[00614] intermediate 3w3: 8-methyl-3-(6-methylpyridin-2-yl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a] dihydrochloride salt ] pyrazine,
[00615] intermediate 3x3: 2-(2-bromophenyl)-4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)thiazole,
[00616] intermediate 3y3: 2-(3-bromophenyl)-4-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)thiazole. General Method D:
[00617] General Method D is the general procedure used for the synthesis of 3-phenyl-pyrazole-5-carboxylic acid intermediates 4 and is exemplified below using the synthesis of 3-(3,4-dichlorophenyl)-1- acid methyl-1H-pyrazole-5-carboxylic acid 4a and 5-(3,4-dichlorophenyl)-1-methyl-1H-pyrazole-3-carboxylic acid 4b.
Scheme 5: Synthesis of intermediates 4a and 4b Step 1: Synthesis of ethyl 4-(3,4-dichlorophenyl)-2,4-dioxobutanoate 5.2
To a solution of t-BuOK (0.05 mol, 5.6 g) in benzene (200 ml) was added dropwise a benzene solution (50 ml) of 3,4-dichloroacetophenone 5.1 (0, 05 mol, 9.45 g) and diethyl oxalate (0.055 mol, 8.1 g). The resulting mixture was stirred for 8 h at room temperature, then 10% aqueous HCl solution (100 ml) was added to the mixture. The organic layer was separated and washed with brine, dried over sodium sulfate and concentrated in vacuo. The crude product was purified by column chromatography using dichloromethane as eluant to yield the title compound. Production: 7.5 g (52%). Step 2: Synthesis of ethyl 3-(3,4-dichlorophenyl)-1-methyl-1H-pyrazol-5-carboxylate 5.3 and 5-(3,4-dichlorophenyl)-1-methyl-1H-pyrazol-3- ethyl carboxylate 5.4
To a solution of compound 5.2 (0.035 mol, 10.2 g) in ethanol (100 ml) was added monomethyl hydrazine (0.0353 mol, 1.63 g) and the resulting mixture was refluxed for 2 h, and subsequently stirred overnight at RT. The mixture was then evaporated to dryness and the crude product thus obtained was subjected to column chromatography (eluent: ethyl acetate/hexane 2:3). This provided 3.68 g of compound 5.3 (Rf = 0.8) and 3.28 g of compound 5.4 (Rf = 0.6). The structure designation of the regioisomers thus obtained was performed on the basis of NOE in 2D-NOESY spectra and 1H-13C cross-coupling constants in 2D-1H-13C-HMBC spectra between N-methyl protons and quaternary carbons on the pyrazole rings. Step 3: Synthesis of 3-(3,4-dichlorophenyl)-1-methyl-1H-pyrazole-5-carboxylic acid 4a and 5-(3,4-dichlorophenyl)-1-methyl-1H- acid hydrochloride salt pyrazole-3-carboxylic acid 4b
[00620] Synthesis of 3-(3,4-dichlorophenyl)-1-methyl-1H-pyrazol-5-carboxylate 4a
Compound 5.3 (0.0123 mol, 3.68 g) and sodium hydroxide (2 g) were dissolved in water-ethanol solution (1:1 v/v, 300 ml). The mixture was refluxed for 3 h and then most of the ethanol was evaporated. The pH of the mixture thus obtained was adjusted to pH 3 by addition of 10% HCl after which a precipitate formed, which was filtered, washed with water and air-dried to furnish compound 5.5. Yield: 3.05 g (91.6%). LCMS: P = 97.5%, RT = 1.86 min, m/z = 271. 1HRMN (DMSO-d6): δ: 13.5 ppm (br s, 1H), 8.05 ppm (s, 1H ), 7.8 ppm (d, 1H), 7.6 ppm (d, 1H), 7.4 ppm (s, 1H), 4.15 ppm (s, 3H).
[00622] Synthesis of 5-(3,4-dichlorophenyl)-1-methyl-1H-pyrazole-3-carboxylate 4b
Compound 5.4 (10.08 mmols, 3.24 g) was refluxed in a mixture of conc. 50 ml/water 75 ml/dioxane 125 ml for 3h. Volatiles were evaporated until a precipitate formed, which was filtered, washed with water and air dried to provide the product 5.6 as the HCl salt. Production: 2.79 g (90%). LCMS: P = 95%, RT = 1.67 min, m/z = 271. 1H NMR (DMSO-d6): δ: 7.9 ppm (s, 1H), 7.75 ppm (d, 1H), 7.6 ppm (d, 1H), 6.95 ppm (s, 1H), 3.9 ppm (s, 3H).
[00624] The following intermediates were also prepared from the ad hoc reagents and intermediates using General Method D:
[00625] Intermediate 4c: 3-(4-chlorophenyl)-1H-pyrazole-5-carboxylic acid,
[00626] Intermediate 4d: 3-(3,4-dichlorophenyl)-1H-pyrazole-5-carboxylic acid,
[00627] Intermediate 4e: 3-(2,4-dichlorophenyl)-1H-pyrazole-5-carboxylic acid,
[00628] Intermediate 4f: 3-(4-trifluoromethylphenyl)-1H-pyrazole-5-carboxylic acid,
[00629] Intermediate 4g: 3-(4-phenoxyphenyl)-1H-pyrazole-5-carboxylic acid,
[00630] Intermediate 4h: 3-(4-chlorophenyl)-1-methyl-1H-pyrazole-5-carboxylic acid,
Intermediate 4i: 5-(4-chlorophenyl)-1-methyl-1H-pyrazole-3-carboxylic acid. General Method E:
[00632] General Method E is the general procedure used for the synthesis of the intermediates of ethyl 3-phenyl-1,2,4-oxadiazol-5-carboxylate 1.2 and is exemplified below with the synthesis of 3-(2,4- ethyl difluorophenyl)-1,2,4-oxadiazol-5-carboxylate 5a.
Scheme 6: Synthesis of Intermediate 5a
[00633] Step 1: Synthesis of 2,4-difluoro-N'-hydroxybenzimidamide 5.2
To a solution of 2,4-difluorobenzonitrile 5.1 (1 g, 7.2 mmols) and hydroxylamine hydrochloride (1 g, 14.4 mmols) in commercial dry EtOH (5 mL) under N2 was added NEt3 (2 mL, 14.4 mmols) dropwise over 2 min at RT. The mixture was stirred under reflux overnight. The mixture was then allowed to cool to RT and concentrated. The white solid obtained was used raw in the next step. Yield: 3.52 g (quantitative). LCMS: P = 33%, TR = 0.84 min, m/z = 173.
[00635] Step 2: Synthesis of ethyl 3-(2,4-difluorophenyl)-1,2,4-oxadiazol-5-carboxylate 5a
To a solution of 2,4-difluoro-N'-hydroxybenzimidamide 5.2 (3.52 g, 33% purity, max. 7.2 mmols) and pyridine (2.32 mL, 28.7 mmols) in Anhydrous CH 2 Cl 2 under N 2 was added ethyl chlorooxoacetate (1.27 g, 9.32 mmols) dropwise over 5 min at RT. The mixture was stirred under reflux. After 1 h and 30 min, the xn mixture was concentrated and purified on silica gel using CH 2 Cl 2 , providing 1.414 g of the title product 5a as a colorless oil. Yield: 1.414 g (78%). LCMS: P = 94%, TR = 4.21 min, m/z = 255, 277 (M+Na). General Method F:
[00637] General Method E is the general procedure used for the synthesis of methyl 2-pyridyl-thiazol-4-carboxylate intermediates 1.2 and is exemplified below with the synthesis of 2-(pyridin-2-yl)thiazol-4- methyl carboxylate 6a.
Scheme 7: Synthesis of Intermediate 6a
[00638] Step 1: Synthesis of tert-butyl thiazole-4-carboxylate 7.2
A solution of thiazole-4-carboxylic acid 7.1 (1 g, 7.2 mmols) and carbonyldiimidazole (6.3 g, 38.7 mmols) in commercial dry DMF (50 mL) under N2 was stirred at 50°C for 20 min. Tert-butanol (8.6 g, 116.0 mmols) and DBU (5.8 mL, 38.7 mmols) were then successively added at once and the reaction was heated at 60°C for 48 h. The RM was then allowed to cool to RT and the pH was adjusted to 4 with a solution of HCl (2M, ~80 mL). The mixture was diluted with water (250 ml) and extracted with Et2O (3 x 100 ml). The combined organic layers were washed with brine (250 mL), dried over MgSO4, concentrated and purified on silica gel using DCM to give the title product as yellowish oil (47%). Production: 3.37 g (47%). LCMS: P = 98%, TR = 3.65 min, m/z = 186.
[00640] Step 2: Synthesis of tert-butyl 2-(pyridin-2-yl)thiazole-4-carboxylate 7.3
To a solution of tert-butyl thiazole-4-carboxylate 7.2 (256 mg, 1.62 mmol), anhydrous cesium carbonate (1 g, 3.24 mmol) and 2-bromo-pyridine (300 mg, 1.62 mmol) sequentially added in commercial anhydrous DMF (6 mL) at RT under N2 were added Pd(OAc)2 (18 mg, 0.08 mmol) and (2-biphenyl)dicyclohexyl phosphine (57 mg, 0.16 mmol). RM was heated to 110°C overnight. The RM was then allowed to cool to RT, filtered over Celita pad and concentrated. The residue was purified on silica gel using cyclohexane/EtOAc (5% to 20% EtOAc), providing 7.3 as a yellow oil. Production: 340 mg (80%). LCMS: P = 96%, TR = 4.28 min, m/z = 263.
[00642] Step 3: Synthesis of 2-(pyridin-2-yl)thiazole-4-carboxylic acid 7.4
To a solution of tert-butyl 2-(pyridin-2-yl)thiazol-4-carboxylate 7.3 (340 mg, 1.3 mmol) in commercial anhydrous CH 2 Cl 2 (5 mL) at RT was added TFA (0 .93 mL, 13 mmols) under N2. The mixture was stirred at RT overnight. The mixture was diluted with CH 2 Cl 2 (25 mL), washed with a 10% aqueous NaHSO 3 solution (5 x 25 mL), brine (25 mL) and then water (25 mL). The organic layer was dried over MgSO4 and evaporated to give the title product as a yellow oil. Production: 250 mg (94%). LCMS: P = 93%, TR = 3.03 min, m/z = 207.
[00644] Step 4: Synthesis of methyl 2-(pyridin-2-yl)thiazole-4-carboxylate 6a
To a solution of 2-(pyridin-2-yl)thiazole-4-carboxylic acid 7.4 (500 mg, 2.425 mmols) in commercial anhydrous methanol (10 mL) was added TMS-Cl (0.77 mL, 6 .06 mmols) at once. RM was heated to 50°C overnight. The RM was concentrated under reduced pressure and the residue was used crude in the next step. Production: 649 mg (quantitative). LCMS: P = 94%, TR = 4.07 min, m/z = 221.
[00646] The following intermediates were also prepared from the ad hoc reagents and intermediates using General Method F:
[00647] intermediate 6b: methyl 2-(pyridin-4-yl)thiazole-4-carboxylate,
[00648] intermediate 6c: methyl 2-(quinolin-2-yl)thiazole-4-carboxylate,
[00649] intermediate 6d: methyl 2-(pyrimidin-2-yl)thiazole-4-carboxylate,
Intermediate 6e: Methyl 2-(pyrazin-2-yl)thiazole-4-carboxylate. General Method G:
General Method G is the general procedure used for the synthesis of methyl 2-(4-heterocyclylphenyl)thiazole-4-carboxylate intermediates 1.2 and is exemplified below with the synthesis of 2-(4-(4-methylpiperazin-). methyl 1-yl)phenyl)thiazole-4-carboxylate 7a.
Scheme 8: Synthesis of Intermediate 7a
[00652] Into a tube previously dried in an oven heated to 113°C overnight were successively introduced 2-(4-bromophenyl)thiazole-4-carboxylate 8.1 (500 mg, 1.6 mmol), 1-methylpiperazine (0 .21 mL, 1.9 mmol) and anhydrous cesium carbonate (1.04 g, 3.0 mmol) under N 2 . Commercial anhydrous toluene (10 mL) was then added and the RM was degassed (argon bubbling for ~5 min).
[00653] Pd2(dba)3 (73 mg, 0.08 mmol) and X-Phos (76 mg, 0.16 mmol) were quickly added successively and the mixture was heated under reflux overnight. The reaction mixture was then allowed to cool to RT and EtOAc (50ml) was added. This mixture was washed with brine (30 ml) and the aqueous layer was also extracted twice with EtOAc (30 ml). The combined organic layers were dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified on silica gel using CH 2 Cl 2 /MeOH (2% MeOH) to furnish the title product as a yellow solid. Yield: 374 mg (71%). LCMS: P=92%, TR=3.31 min, m/z=332.
This General Method has also been applied to the synthesis of methyl 2-heterocyclylthiazole-4-carboxylate intermediates, starting from methyl 2-bromothiazole-4-carboxylate.
[00655] The following intermediates were also prepared from the ad hoc reagents and intermediates using General Method G
[00656] intermediate 7b: methyl 2-(4-morpholinophenyl)thiazole-4-carboxylate,
[00657] intermediate 7c: methyl 2-(4-(piperidin-1-yl)phenyl)thiazole-4-carboxylate,
[00658] intermediate 7d: methyl 2-(4-(pyrrolidin-1-yl)phenyl)thiazole-4-carboxylate,
[00659] intermediate 7e: methyl 2-(piperidin-1-yl)thiazole-4-carboxylate,
[00660] intermediate 7f: methyl 2-(pyrrolidin-1-yl)thiazole-4-carboxylate,
[00661] intermediate 7g: methyl 2-(4-methylpiperazin-1-yl)thiazole-4-carboxylate,
[00662] intermediate 7h: methyl 2-(2-(2-methoxyethyl)morpholino)thiazole-4-carboxylate,
[00663] intermediate 7i: methyl 2-(4,4-difluoropiperidin-1-yl)thiazole-4-carboxylate,
[00664] intermediate 7j: methyl 2-(2,5-dimethylmorpholino)thiazole-4-carboxylate,
[00665] intermediate 7k: methyl 2-(2,6-dimethylmorpholino)thiazole-4-carboxylate,
[00666] intermediate 7l: methyl 2-(2,2-dimethylmorpholino)thiazole-4-carboxylate,
[00667] intermediate 7m: methyl 2-(2-methylmorpholino)thiazole-4-carboxylate,
[00668] intermediate 7n: methyl 2-(4,4-dimethylpiperidin-1-yl)thiazole-4-carboxylate,
Intermediate 7o: Methyl 2-(2-(methoxymethyl)piperidin-1-yl)thiazole-4-carboxylate. General Method H:
[00670] General Method H is the general procedure used for the synthesis of the intermediates of methyl 3-phenylpyrazole-5-carboxylate and methyl 5-phenylpyrazole-3-carboxylate 1.2 and is exemplified below with the synthesis of 1-(2- methyl methoxyethyl)-3-phenyl-1H-pyrazol-5-carboxylate 8a and methyl 1-(2-methoxyethyl)-5-phenyl-1H-pyrazole-3-carboxylate 8b.
Scheme 9: Synthesis of intermediates 8a and 8b
To a solution of methyl 3-phenyl-1H-pyrazol-5-carboxylate 9.1 (250 mg, 1.24 mmol) in commercial anhydrous acetone (30 mL) at RT under N2 was added cesium carbonate all at once (806mg, 2.47mmols). After 10 min of stirring, 2-bromoethyl-methylether (258 mg, 1.85 mmol) was added at once. The reaction mixture was refluxed for 2h then allowed to cool and concentrated, diluted with CH2Cl2 (50ml) and washed with water (50ml). The organic layer was then dried over MgSO4, filtered and evaporated to dryness. The residue was purified on silica gel using CH 2 Cl 2 /MeOH (1% MeOH) to provide a mixture of 8a side by side with 8b (~ 10%) as a pale yellow oil. Yield: 359 mg (71%). LCMS: P=100%, ratio 8a/8b=9/1, 8a: TR=4.41 mn, m/z=261; 8b: TR = 3.95 mn, m/z = 261. Additional Synthetic Schemes
[00672] The synthesis of compounds No. 283, 289, 290, 291, 292 was carried out according to scheme 10
Scheme 10: Synthesis of compounds no. 283, 289, 290, 291,292
[00673] Thioamide 10.1 is condensed with ethyl 3-bromo-2-oxopropanoate to yield the thiazole ester intermediate 10.2 which has also been converted to the thiazolyl hydrazide 10.3. Condensation of 10.3 with iminoether 1 gave aniline 10.4 which could also be converted to N-methylsulfonylaniline 10.5a or dimethylaniline 10.5b. Boc deprotection followed by acylation yielded compounds 10.7a and 10.7b. The diacylated product 10.7a can be deacylated on the aniline part to the target compound provided 10.8.
[00674] The synthesis of compound No. 293 was carried out according to scheme 11
Scheme 11: Synthesis of Compound No. 293
[00675] Boronic acid 12.1 is reacted with 12.2 using Suzuki coupling to provide 12.3. The latter is reduced by hydrogenation in the presence of Pd/C to provide 12.4, which is also acylated to provide the desired compound No. 293. Example 1: Synthesis of Compound No. 45
The general procedure used for the synthesis of the triazolopiperazine compounds of the invention is detailed below using the synthesis of compound No. 45: (R)-(4-fluorophenyl)(8-methyl-3-(2-phenylthiazol-4) -yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone
Scheme 12: Synthesis of (R)-(4-fluorophenyl)(8-methyl-3-(2-phenylthiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4, 3-a]pyrazin-7(8H)-yl)methanone (compound no.45).
[00677] To a solution of intermediate 3a (80 mg, 0.27 mmol) in 7 mL of DCM was added Et3N (68 mg, 0.67 mmol) and then a solution of 4-fluorobenzoyl chloride 6.1 in DCM ( 43mg, 0.27mmol). The solution was allowed to stir at room temperature for 2 h. The reaction mixture was washed with water, brine, dried over sodium sulphate and approximately % of the volatiles were evaporated. Diethyl ether was added and the precipitate was filtered and dried to yield the title compound. Production: 68mg, 60%. LCMS: P = 100%, TR = 1.96 min, (M+H)+: 420.1; chiral: 7.22 min, ee = 91%. 1 HRMN (DMSO-d6): δ: 8.4 ppm (s, 1H), 8.05 ppm (m, 2H), 7.6 ppm (m, 2H), 7.5 ppm (m, 3H), 7 .35 ppm (t, 2H), 5.7 ppm (br m, 1H), 4.8 ppm (dd, 1H), 4.3 ppm (m, 1H), 4.1 ppm (br m, 1H) , 3.7 ppm (m, 1H), 1.6 ppm (d, 3H). Examples 2 to 84:
The general procedure detailed in example 1 was used for the preparation of the compounds in examples 2 to 84 starting from the appropriate intermediates or commercially available reagents. Example no., compound no., compound names, triazolopiperazine intermediates 3 and acyl chloride intermediates 4 are listed in table 2A below. TABLE 2nd





Example 85: Compound #87 was synthesized by reacting intermediate 3h and 4-fluorophenylsulfonyl chloride using well known sulfonylation conditions. Examples 87 to 111:
The general procedure detailed in example 1 was used for the preparation of the compounds in examples 87 to 111 starting from the appropriate intermediates or commercially available reagents. Example no., compound no., compound names, triazolopiperazine intermediates 3 and carboxylic acidacyl chloride intermediates 4 are listed in table 2B below. TABLE 2B



[00681] It has been observed that the synthesis of chiral intermediate 3 can result in compounds with low enantiomeric excess. It may therefore be advantageous to prepare the synthesis of the compounds of the invention from racemic building block 3 and also to carry out purification by chiral preparative HPLC. Example 112: Synthesis of Compound No. 166
A variant of the general procedure used for the synthesis of the triazolopiperazine compounds of the invention is detailed below using the synthesis of compound No. 166: (4-fluorophenyl)(8-methyl-3-(2-phenylthiazol-4-yl) )-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone:
Scheme 13: Synthesis of (4-fluorophenyl)(8-methyl-3-(2-phenylthiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a] pyrazin-7(8H)-yl)methanone (compound no.166).
To a solution of intermediate 3o1 (500 mg, 1.50 mmol) in 20 mL of anhydrous DCM were added 4-fluorobenzoyl chloride 6.1 (261 mg, 1.65 mmol) and Et3N (0.625 mL, 455 mg, 4.49 mmols). The reaction mixture was stirred for 2 h. Soon after, the reaction mixture was washed with water, and the organic layer extracted also washed with brine, dried over sodium sulfate. Therefore, volatiles were concentrated and diethyl ether was added to precipitate the product. The filtered precipitate was then dried in vacuo. Production: 630mg, 100%. LCMS: P = 100%, TR = 8.2 min, (M+H)+: 420.1. 1HRMN (CDCl3): δ: 8.3 ppm (s, 1H), 8.0 ppm (m, 2H), 7.5 ppm (m, 5H), 7.2 ppm (t, 2H), 5.7 ppm (br m, 1H), 5.0 ppm (dd, 1H), 4.4 ppm (m, 1H), 3.5 ppm (m, 1H), 1.6 ppm (d, 3H).
The variant of the general procedure detailed in example 112 was used for the preparation of the compounds in examples 113 to 257 starting from the appropriate intermediates or commercially available reagents.
[00685] Example no., compound no., compound names, triazolopiperazine intermediates 3 and acyl chloride intermediates 4 are listed in table 2C below. TABLE 2C










BIOLOGY EXAMPLES BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows the effects of a single 10 mg/kg intravenous dose of compound #156 on serum LH levels in castrated male rats measured 60 min and 120 min after dosing. LH hormone levels are expressed as means ± S.E.M. (** p < 0.001 vs. reference, determined by one-way ANOVA and Dunnett's post hoc).
Figure 2 shows the effects of a single intravenous dose of compound #144 (10 mg/kg), compound 71 (15 mg/kg) and compound 114 (20 mg/kg) on serum LH levels in castrated male rats, measured 60 min after dosing. LH hormone levels are expressed as means ± S.E.M. (** p < 0.001 vs. reference, determined by one-way ANOVA and Dunnett's post hoc).
Figure 3 shows the effect of a single intravenous dose of 20 mg/kg of compound No. 156 on plasma testosterone levels in male rats with intact gonads (N = 5 rats/group). Plasma testosterone levels are represented as an integrated testosterone response (AUC) over a 420 min period after dosing. Competitive binding tests
The affinity of the compounds of the invention for tachykinin receptors was determined by measuring the ability of the compounds of the invention to displace a radiolabeled ligand from its specific binding site. 3H-SB222200 binding competition assay with human NK-3 receptor
The ability of the compounds of the invention to inhibit the binding of the selective NK-3 receptor antagonist SB222200 was estimated by an in vitro radioligand binding assay. Membranes were prepared from recombinant Chinese hamster ovary cells expressing the human NK3 receptor. Membranes were incubated with 5 nM of 3H-SB222200_(ARC) in a buffer of 25 mM HEPES / 0.1 M NaCl / 1 mM CaCl2 / 5 Mm MgCl2 / 0.5% BSA / 10 μg/ml Saponin at pH 7 ,4 and various concentrations of the compounds of the invention. The amount of receptor-bound triciated SB222200 was determined after filtration by quantifying membrane-associated radioactivity using a TopCount-NXT reader (Packard). Competition curves were obtained for compounds of the invention and concentrations of compounds that displaced 50% bound radioligand (IC50) were determined and then apparent inhibition constant Ki values were calculated by the following equation: Ki = IC50/(1 +[L]/KD) where [L] is the concentration of free radioligand and KD is its dissociation constant at the receptor, derived from saturation binding experiments (Cheng and Prusoff, 1973) (see results in table 3 below).
[00691] In table 3, the biological results obtained using the 3H-SB222200 binding competition assay with the compounds of the invention are set out in tabulated form. In this table the calculated Ki is given. The Ki value obtained (according to the protocol set out above) is represented as follows: "+++" means Ki < 500 nM; "++" means 500 nM < Ki < 1 µM; "+" means 1 µM < Ki < 5 µM; "#"means Ki > 5 µM. TABLE 3








[125I]-His-MePhe7-Neurokinin B binding competition assay with rat NK-3 receptor
The affinity of the compounds of the invention for the rat NK3 receptor was evaluated in CHO recombinant cells expressing the rat NK3 receptor. Membrane suspensions were prepared from these cells. The following radioligand: [125I]-His-MePhe7-Neurokinin B (PerkinElmer Cat# NEX285) was used in this assay. Binding assays were performed in a buffer of 25 nM HEPES/1 mM CaCh/5 mM MgCh/0.5% BSA/10 µg/ml Saponin, at pH 7.4. Binding assays consisted of 25 μl membrane suspension (approximately 5 μg protein/well in a 96-well plate), 50 μl reference compound or ligand (MePhe7-Neurokinin B) in increasing concentrations (diluted in buffer of assay) and 0.09 nM [125I]-His-MePhe7-Neurokinin B. The plate was incubated 60 min at 25°C in a water bath and then filtered over GF/C filters (Perkin Elmer, 6005174, pre-soaked in saponin-free assay buffer for 2 h at room temperature) with a filtration unit (Perkin Elmer). The radioactivity retained on the filters was measured using a TopCount-NXT reader (Packard). Competition curves were obtained for the compounds of the invention and concentrations of compounds that displaced 50% bound radioligand (IC50) were determined and then apparent inhibition constant Ki values were calculated by the following equation: Ki = IC50/(1+ [L]/KD) where [L] is the concentration of free radioligand and KD is its dissociation constant at the receptor, derived from saturation binding experiments (Cheng and Prusoff, 1973).
When tested in the assay described above, preferred compounds of the invention showed an inhibition constant (Ki) for the rat NK-3 receptor <50 nM. selectivity test
[00694] The selectivity of the compounds of the invention was determined over the other human NK receptors, that is, NK-1 and NK2 receptors. NK1 Human
[00695] The affinity of the compounds of the invention for the NK1 receptor was evaluated in CHO recombinant cells expressing the human NK1 receptor. Membrane suspensions were prepared from these cells. The following radioligand: [3H] substance P (PerkinElmer Cat#NET111520) was used in this assay. Binding assays were performed in a buffer of 50 mM Tris/5 mM MnCl2/150 mM NaCl/0.1% BSA at pH 7.4. Binding assays consisted of 25 µl membrane suspension (approximately 5 µg protein/well in a 96-well plate), 50 µl reference compound or ligand (Substance P) in increasing concentrations (diluted in assay buffer) and 2 nM [3H] substance P. The plate was incubated 60 min at 25°C in a water bath and then filtered over GF/C filters (Perkin Elmer, 6005174, pre-soaked in 0.5% PEI for 2 h at room temperature) with a filtration unit (Perkin Elmer). The radioactivity retained on the filters was measured using a TopCount-NXT reader (Packard). Competition curves were obtained for the compounds of the invention and concentrations of compounds that displaced 50% bound radioligand (IC50) were determined and then apparent inhibition constant Ki values were calculated by the following equation: Ki = IC50/(1+ [L]/KD) where [L] is the concentration of free radioligand and KD is its dissociation constant at the receptor, derived from saturation binding experiments (Cheng and Prusoff, 1973). NK2 Human
[00696] The affinity of the compounds of the invention for the NK2 receptor was evaluated in CHO recombinant cells expressing the human NK2 receptor. Membrane suspensions were prepared from these cells. The following radioligand [125I]-Neurokinin A (PerkinElmer Cat#NEX252) was used in this assay. Binding assays were performed in a buffer of 25 mM HEPES/1 mM CaCl2/5 mM MgCl2/ 0.5% BSA/10 µg/ml saponin, at pH 7.4. Binding assays consisted of 25 µl membrane suspension (approximately 3.75 µg protein/well in a 96-well plate), 50 µl reference compound or ligand (Neurokinin A) in increasing concentrations (diluted in assay buffer ) and 0.1 nM [125I]-Neurokinin A. The plate was incubated 60 min at 25°C in a water bath and then filtered over GF/C filters (Perkin Elmer, 6005174, pre-soaked in GF/C) buffer. assay without saponin for 2 h at room temperature) with a filtration unit (Perkin Elmer). The radioactivity retained on the filters was measured using a TopCount-NXT reader (Packard). Competition curves were obtained for the compounds of the invention and concentrations of compounds that displaced 50% bound radioligand (IC50) were determined and then apparent inhibition constant Ki values were calculated by the following equation: Ki = IC50/(1+ [L]/KD) where [L] is the concentration of free radioligand and KD is its dissociation constant at the receptor, derived from saturation binding experiments (Cheng and Prusoff, 1973).
[00697] The compounds of the invention, which were tested in the NK-1 and NK-2 assays described above, demonstrated a low affinity at the human NK-1 and human NK-2 receptors: 100 to 200-fold Ki shift compared to human NK-3 receptor. Thereby, the compounds according to the invention have been shown to be selective on NK1 and NK2 receptors. In vivo assay to estimate compound activity in rats
[00698] The inhibitory effect of the compounds of the invention on luteinizing hormone (LH) secretion and on circulating steroid levels is determined by the following biological studies. Castrated male rat model to estimate the effect of the compound of the invention on circulating levels of luteinizing hormone (LH).
[00699] In humans and rodents, castration is well preceded to allow persistent, increased GnRH signaling and consequently elevation of circulating LH. Thus, in this animal model, LH is measured in castrated rats as a marker of test compound inhibition of the GnRH signaling pathway.
Adult male castrated Sprague-Dawley (SD) rats (150 to 175 g) were purchased from Janvier (St Berthevin, France). All animals were housed 3 per cage in a room with controlled temperature (22 ± 2°C) and 50 ± 5% relative humidity with a photoperiod of 12 hours light/12 hours dark (lights on at 18 hours). Animals were allowed 2 weeks of post-operative recovery prior to the study. Animals were handled on a daily basis. Standard diet and tap water were provided ad libitum. The straws in the animals' cage were changed once a week. On the day of the study, the animals were acclimated to the procedure room for a period of one hour before the start of the experiment.
The compounds of the invention were formulated as 10% DMSO, 10% Cremophore EL, and 80% saline solutions.
After basal sampling (T0), a single dose of the compounds of the invention or vehicle was administered intravenously to rats. Blood was then collected at 60 min and 120 min after dosing. Blood samples were obtained by bleeding from the tail vein, placed into tubes containing EDTA and centrifuged immediately. Plasma samples were collected and stored in a freezer at -80°C until assayed. Serum LH levels were determined using the IDS radioimmunoassay kit (Liège, Belgium). The reference was defined as the baseline baseline blood sample.
When tested in the castrated male rat model described above, compounds #144, 71, 156 and 114 significantly suppressed the GnRH-mediated elevation of LH (Figures 1 and 2).
[00704] This result also shows that the compounds according to the invention cross the blood-brain barrier and that they are able to block the action of NK-3 receptors in the CNS. The brain to plasma (B/P) values obtained with the compounds according to the invention were generally greater than 0.1 indicating significant brain penetration. Adult male with intact gonads to estimate the effect of compounds of the invention on circulating testosterone levels.
[00705] Adult male Sprague-Dawley (SD) rats with intact gonads (300 to 385 g N=5/group) were housed individually in a room with controlled temperature (22 ± 2°C) and 50 ± 5% relative humidity with a photoperiod of 12 hours light/12 hours dark (lights on at 18 hours). Purina rat food (Ralston Purina Co., St. Louis, MO) and tap water were made available to rats, ad libitum. Chronic intracardiac venous cannulas were implanted under anesthesia with sodium pentobarbital (50 mg/kg, i.p.). After surgery, rats were placed directly into isolation test chambers and supplied with food and water ad libitum until body weight returned to preoperative levels (a period of at least five days). On the test day, the food was removed 1.5 h before the start of sampling and was returned at the end of the experiment. After basal blood sampling, free-moving rats were injected intravenously at time = 0 min with a single dose (20 mg/kg) of compound #156 or vehicle. Blood was then collected through a heparinized line at regular intervals up to 420 min and centrifuged immediately. Plasma samples were collected and stored in a freezer at -80°C until assayed. Plasma testosterone levels were determined using a radioimmunoassay kit (Immunotech).
Compound #156 was formulated as 40% DMA, 50% PEG400, and 10% sterile water solution.
[00707] When tested in male rats with intact gonads, Compound #156 significantly suppressed plasma testosterone levels during the 420 minute test period (Figure 3).

权利要求:
Claims (14)
[0001]
1. Compound, characterized by the fact that it has the formula I:
[0002]
2. Compound according to claim 1, characterized in that it has the formula Ib:
[0003]
3. Compound according to claim 2, characterized in that it has the formula Ic:
[0004]
4. Compound according to claim 3, characterized in that it is selected from the formulas Id-1, Id-2, Id-3 and Id-4:
[0005]
5. A compound according to claim 4, characterized in that it is selected from the formulas Ie-1, Ie-2 and Ie-3: or a pharmaceutically acceptable salt or a solvate thereof, wherein
[0006]
6. Compound according to claim 3, characterized in that it is selected from the formulas If-1, If-2, If-3, If-4, If-5, If-6, If-7 and If-8:
[0007]
7. Compound according to claim 6, characterized in that it is selected from the formulas Ig-1, Ig-2, Ig-3, Ig-4, Ig-5, Ig-6, Ig-7 and Ig-8:
[0008]
8. Compound of the formula If-2 according to claim 6, characterized in that it has the formula Ih-2:
[0009]
9. A compound according to claim 3, characterized in that it is selected from the formulas II-1, II-2, II-3, II-4, II-5, II-6, II-7, II-8, Ij-1, Ij-2, Ij-3, Ij-4, Ij-5, Ij-6, Ij-7, Ij-8, Ik-1, Ik-2, Ik-3, Ik-4, Ik- 5, Ik-6, Ik-7, Ik-8, Ii'-1, Ii'-2, Ii'-3, Ii'-4, Ii'-5, Ii'-6, Ii'-7 and Ii '-8:
[0010]
10. Compound according to claim 9, characterized in that it is selected from the formulas Il-1, Il-2, Il-3, Il-4, Il-5, Il-6, Il-7, Il-8, Il'-1, Il'-2, Il'-3, Il'-4, Il'-5, Il'-6, Il'-7, Il'-8:
[0011]
11. Compound according to claim 10, characterized in that it is selected from the formulas Im-1, Im-2, Im-3, Im-4, Im-5, Im-6, Im-7, Im-8, Im'-1, Im'-2, Im'-3, Im'-4, Im'-5, Im'-6, Im'-7 and Im'-8:
[0012]
12. A compound according to claim 1, characterized in that it is selected from the group consisting of: (4-fluorophenyl)(3-(pyridin-2-yl)-5,6-dihydro-[1,2 ,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone; (4-chlorophenyl)(3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone; (3-(4-chlorophenyl)-1H-pyrazol-5-yl)(3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a ]pyrazin-7(8H)-yl)methanone; (3-(3,4-dichlorophenyl)-1H-pyrazol-5-yl)(3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3 -a]pyrazin-7(8H)-yl)methanone; (3,4-dichlorophenyl)(3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl) methanone; [1,1'-biphenyl]-4-yl(3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7( 8H)-yl)methanone; (4-fluorophenyl)(3-(quinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone; (4-fluorophenyl)(3-(2-phenylthiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl) methanone; (4-fluorophenyl)(3-(2-morpholinothiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl) methanone; (3-(5-chloropyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl) methanone; (4-fluorophenyl)(3-(6-methylpyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl) methanone; (4-fluorophenyl)(8-methyl-3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)- il)methanone; (3-(2,4-dichlorophenyl)-1H-pyrazol-5-yl)(3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3 -a]pyrazin-7(8H)-yl)methanone; (3-(3,4-dichlorophenyl)-1-methyl-1H-pyrazol-5-yl)(3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazole [4,3-a]pyrazin-7(8H)-yl)methanone; (4-fluorophenyl)(3-(isoquinolin-3-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone; (4'-fluoro-[1,1'-biphenyl]-4-yl)(3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazole [4,3 -a]pyrazin-7(8H)-yl)methanone; (3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(3-(4-( trifluoromethyl)phenyl)-1H-pyrazol-5-yl)methanone; (3-(4-phenoxyphenyl)-1H-pyrazol-5-yl)(3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a ]pyrazin-7(8H)-yl)methanone; [1,1'-biphenyl]-4-yl(3-(quinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7( 8H)-yl)methanone; [1,1'-biphenyl]-4-yl(3-(2-morpholinothiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl)methanone; (3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(thiophen-2) -yl)phenyl)methanone; (4-fluorophenyl)(3-(8-fluoroquinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl) methanone; (3-(8-chloroquinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-fluorophenyl) methanone; (4-fluorophenyl)(3-(2-(4-(trifluoromethyl)phenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin -7(8H)-yl)methanone; (4-fluorophenyl)(3-(6-phenylpyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl) methanone; [1,1'-biphenyl]-4-yl(3-(2-phenylthiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl)methanone; (4-fluorophenyl)(3-(4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a ]pyrazin-7(8H)-yl)methanone; (4-fluorophenyl)(3-(2-(3-(trifluoromethyl)phenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin -7(8H)-yl)methanone; (3-(2-(2,4-difluorophenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)- il)(4-fluorophenyl)methanone; (3-(2-(2,3-dichlorophenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)- il)(4-fluorophenyl)methanone; (3-(2-(4-chlorophenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl) (4-fluorophenyl)methanone; (4-fluorophenyl)(3-(2-(4-fluorophenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7( 8H)-yl)methanone; (4-fluorophenyl)(3-(2-(piperidin-1-yl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl)methanone; (4-fluorophenyl)(3-(2-(4-phenylpiperazin-1-yl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a] pyrazin-7(8H)-yl)methanone; (3-(2-(2,4-dichlorophenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)- il)(4-fluorophenyl)methanone; (3-(2-(3,5-dichlorophenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)- il)(4-fluorophenyl)methanone; (4-fluorophenyl)(3-(6-(pyrrolidin-1-yl)pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl)methanone; (4-fluorophenyl)(3-(6-morpholinopyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl) methanone; (4-fluorophenyl)(3-(6-(trifluoromethyl)pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H) -yl)methanone; (3-(2-(3,4-dimethoxyphenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)- il)(4-fluorophenyl)methanone; (4-fluorophenyl)(8-(4-fluorophenyl)-3-(2-phenylthiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin -7(8H)-yl)methanone; (3-(2-(3-chlorophenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl) (4-fluorophenyl)methanone; (4-fluorophenyl)(8-isopropyl-3-(2-phenylthiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H) )-yl)methanone; (R)-(4-fluorophenyl)(8-methyl-3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7 (8H)-yl)methanone; (R)-(4-fluorophenyl)(8-methyl-3-(2-phenylthiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin -7(8H)-yl)methanone; [1,1'-biphenyl]-4-yl(8-methyl-3-(2-morpholinothiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3- a]pyrazin-7(8H)-yl)methanone; (4-fluorophenyl)(3-(2-phenyloxazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl) methanone; (4-fluorophenyl)(8-methyl-3-(2-phenyloxazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H) )-yl)methanone; [1,1'-biphenyl]-4-yl(8-methyl-3-(2-phenyloxazol-4-yl)-5,6-dihydro-[1,2,4]triazolo [4,3- a]pyrazin-7(8H)-yl)methanone; [1,1'-biphenyl]-4-yl(3-(2-phenyloxazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl)methanone; (4-fluorophenyl)(8-(2-hydroxyethyl)-3-(2-phenylthiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin -7(8H)-yl)methanone; (4-fluorophenyl)(8-methyl-3-(2-morpholinothiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H) )-yl)methanone; (4'-fluoro-[1,1'-biphenyl]-4-yl)(8-methyl-3-(2-morpholinothiazol-4-yl)-5,6-dihydro-[1,2,4 ]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone; (3-(2-phenylthiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(thiophene) -2-yl)phenyl)methanone; (3-(2-morpholinothiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(thiophene) -2-yl)phenyl)methanone; (8-methyl-3-(2-morpholinothiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)( 4-(thiophen-2-yl)phenyl)methanone; (4-fluorophenyl)(3-(4-phenylthiazol-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl) methanone; (3-(2-(2-chlorophenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl) (4-fluorophenyl)methanone; (3-(benzo[d]thiazol-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4- fluorophenyl)methanone; (8.8-dimethyl-3-(2-phenylthiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl )(4-fluorophenyl)methanone; (4-fluorophenyl)(8-methyl-3-(quinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)- il)methanone; (8-methyl-3-(2-phenylthiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)( 4-(thiophen-2-yl)phenyl)methanone; (3-(2-phenylthiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(thiophene) -3-yl)phenyl)methanone; (8-methyl-3-(2-phenylthiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)( 4-(thiophen-3-yl)phenyl)methanone; (8-methyl-3-(quinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4- (thiophen-2-yl)phenyl)methanone; (3-(2-(2-chlorophenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl) (4-(thiophen-2-yl)phenyl)methanone; [1,1'-biphenyl]-4-yl(3-(2-(2-chlorophenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3 -a]pyrazin-7(8H)-yl)methanone; (R)-(3-(2-(4-chlorophenyl)thiazol-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin -7(8H)-yl)(4-fluorophenyl)methanone; (3-(quinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(thiophen-2) -yl)phenyl)methanone; (4-fluorophenyl)(3-(2-(4-fluorophenyl)thiazol-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a] pyrazin-7(8H)-yl)methanone; (R)-(4-fluorophenyl)(3-(2-(4-fluorophenyl)thiazol-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4, 3-a]pyrazin-7(8H)-yl)methanone; [1,1'-biphenyl]-4-yl(8-methyl-3-(4-methyl-2-phenylthiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[ 4,3-a]pyrazin-7(8H)-yl)methanone; (3-(2-(4-fluorophenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl) (4-(thiophen-2-yl)phenyl)methanone; (3-(2-(2-chlorophenyl)thiazol-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H) )-yl)(4-fluorophenyl)methanone; (4-fluorophenyl)(8-methyl-3-(4-methyl-2-phenylthiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin -7(8H)-yl)methanone; [1,1'-biphenyl]-4-yl(3-(2-(4-fluorophenyl)thiazol-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazole [4,3-a]pyrazin-7(8H)-yl)methanone; (3-(2-(2,4-difluorophenyl)thiazol-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7 (8H)-yl)(4-fluorophenyl)methanone; (3-(2-(4-fluorophenyl)thiazol-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H )-yl)(4-(thiophen-2-yl)phenyl)methanone; [1,1'-biphenyl]-4-yl(3-(2-(2,4-difluorophenyl)thiazol-4-yl)-8-methyl-5,6-dihydro-[1,2,4 ]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone; (3-(2-(2,4-difluorophenyl)thiazol-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7 (8H)-yl)(4-(thiophen-2-yl)phenyl)methanone; naphthalen-1-yl(3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone; (3-(4-chlorophenyl)-1-methyl-1H-pyrazol-5-yl)(3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4 ,3-a]pyrazin-7(8H)-yl)methanone; (5-(4-chlorophenyl)-1-methyl-1H-pyrazol-3-yl)(3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4 ,3-a]pyrazin-7(8H)-yl)methanone; (8-methyl-3-(5-phenyl-1,2,4-oxadiazol-3-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl)(4-(thiophen-2-yl)phenyl)methanone; (8-methyl-3-(3-phenyl-1,2,4-oxadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl)(4-(thiophen-2-yl)phenyl)methanone; (R)-(3-(2-(4-fluorophenyl)oxazol-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin -7(8H)-yl)(4-(thiophen-2-yl)phenyl)methanone; (5-phenylpyridin-2-yl)(3-(quinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)- il)methanone; (6-phenylpyridin-3-yl)(3-(quinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)- il)methanone; (2-phenylpyrimidin-5-yl)(3-(quinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)- il)methanone; (4-phenylcyclohexyl)(3-(quinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone; cyclohexyl(3-(quinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone; 3-methyl-1-(3-(quinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)butan -1-one; [1,1'-biphenyl]-2-yl(3-(quinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7( 8H)-yl)methanone; (4-(furan-3-yl)phenyl)(3-(quinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7( 8H)-yl)methanone; (4-(pyrimidin-5-yl)phenyl)(3-(quinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7( 8H)-yl)methanone; (9-methyl-9H-carbazol-2-yl)(3-(quinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7 (8H)-yl)methanone; (4-(pyrimidin-2-yl)phenyl)(3-(quinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7( 8H)-yl)methanone; (4-(pyrazin-2-yl)phenyl)(3-(quinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7( 8H)-yl)methanone; (4-(pyridazin-3-yl)phenyl)(3-(quinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7( 8H)-yl)methanone; 4'-(3-(quinolin-2-yl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine-7-carbonyl)-[1,1 '-biphenyl]-4-carbonitrile; 1-(4-(3-(quinolin-2-yl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine-7-carbonyl)phenyl)piperidine -2-one; (4-morpholinophenyl)(3-(quinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone; (4-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl)(3-(quinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4, 3-a]pyrazin-7(8H)-yl)methanone; (3-(2-(4-fluorophenyl)thiazol-4-yl)-6-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H )-yl)(4-(thiophen-2-yl)phenyl)methanone; (3-(2-(4-fluorophenyl)thiazol-4-yl)-5-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H )-yl)(4-(thiophen-2-yl)phenyl)methanone; (3,4-dichlorophenyl)(3-(2-(4-fluorophenyl)thiazol-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3- a]pyrazin-7(8H)-yl)methanone; (3,4-difluorophenyl)(3-(2-(4-fluorophenyl)thiazol-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3- a]pyrazin-7(8H)-yl)methanone; (3-chloro-4-fluorophenyl)(3-(2-(4-fluorophenyl)thiazol-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4, 3-a]pyrazin-7(8H)-yl)methanone; (4-chloro-3-fluorophenyl)(3-(2-(4-fluorophenyl)thiazol-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4, 3-a]pyrazin-7(8H)-yl)methanone; (3-(2-(4-fluorophenyl)thiazol-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H )-yl)(3,4,5-trifluorophenyl)methanone; (8-methyl-3-(2-phenyloxazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)( 4-(thiophen-2-yl)phenyl)methanone; (R)-(4-fluorophenyl)(8-methyl-3-(quinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7 (8H)-yl)methanone; (R)-[1,1'-biphenyl]-4-yl(8-methyl-3-(quinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4, 3-a]pyrazin-7(8H)-yl)methanone; (R)-[1,1'-biphenyl]-4-yl(8-methyl-3-(2-morpholinothiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[ 4,3-a]pyrazin-7(8H)-yl)methanone; (R)-(4-fluorophenyl)(8-methyl-3-(6-phenylpyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin -7(8H)-yl)methanone; (R)-[1,1'-biphenyl]-4-yl(8-methyl-3-(2-phenylthiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[ 4,3-a]pyrazin-7(8H)-yl)methanone; (R)-(4-fluorophenyl)(8-methyl-3-(4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)-5,6-dihydro-[1,2,4 ]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone; (R)-(3-(2-(2,4-difluorophenyl)thiazol-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a ]pyrazin-7(8H)-yl)(4-fluorophenyl)methanone; (R)-(3-(2-(2,3-dichlorophenyl)thiazol-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a ]pyrazin-7(8H)-yl)(4-fluorophenyl)methanone; (R)-(4-fluorophenyl)(8-methyl-3-(2-(4-phenylpiperazin-1-yl)thiazol-4-yl)-5,6-dihydro-[1,2,4] triazolo[4,3-a]pyrazin-7(8H)-yl)methanone; (R)-(3-(2-(2,4-dichlorophenyl)thiazol-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a ]pyrazin-7(8H)-yl)(4-fluorophenyl)methanone; (R)-(3-(2-(3-chlorophenyl)thiazol-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin -7(8H)-yl)(4-fluorophenyl)methanone; (R)-(4-fluorophenyl)(8-methyl-3-(2-phenyloxazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin -7(8H)-yl)methanone; (R)-[1,1'-biphenyl]-4-yl(8-methyl-3-(2-phenyloxazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[ 4,3-a]pyrazin-7(8H)-yl)methanone; (R)-(4-fluorophenyl)(8-(2-hydroxyethyl)-3-(2-phenylthiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3 -a]pyrazin-7(8H)-yl)methanone; (R)-(4'-fluoro-[1,1'-biphenyl]-4-yl)(8-methyl-3-(2-morpholinothiazol-4-yl)-5,6-dihydro-[1 ,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone; (R)-(8-methyl-3-(2-phenylthiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H) -yl)(4-(thiophen-2-yl)phenyl)methanone; (R)-(8-methyl-3-(2-morpholinothiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H) -yl)(4-(thiophen-2-yl)phenyl)methanone; (R)-(4-fluorophenyl)(8-methyl-3-(4-phenylthiazol-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin -7(8H)-yl)methanone; (R)-(3-(2-(2-chlorophenyl)thiazol-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin -7(8H)-yl)(4-fluorophenyl)methanone; (R)-(8-methyl-3-(2-phenylthiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H) -yl)(4-(thiophen-3-yl)phenyl)methanone; (R)-(8-methyl-3-(quinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl )(4-(thiophen-2-yl)phenyl)methanone; (R)-(3-(2-(2-chlorophenyl)thiazol-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin -7(8H)-yl)(4-(thiophen-2-yl)phenyl)methanone; (R)-[1,1'-biphenyl]-4-yl(3-(2-(2-chlorophenyl)thiazol-4-yl)-8-methyl-5,6-dihydro-[1,2 ,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone; (R)-[1,1'-biphenyl]-4-yl(8-methyl-3-(4-methyl-2-phenylthiazol-5-yl)-5,6-dihydro-[1,2, 4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone; (R)-(3-(2-(4-fluorophenyl)thiazol-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin -7(8H)-yl)(4-(thiophen-2-yl)phenyl)methanone; (R)-[1,1'-biphenyl]-4-yl(3-(2-(4-fluorophenyl)thiazol-4-yl)-8-methyl-5,6-dihydro-[1,2 ,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone; (R)-[1,1'-biphenyl]-4-yl(3-(2-(2,4-difluorophenyl)thiazol-4-yl)-8-methyl-5,6-dihydro-[1 ,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone; (R)-(3-(2-(2,4-difluorophenyl)thiazol-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a ]pyrazin-7(8H)-yl)(4-(thiophen-2-yl)phenyl)methanone; (S)-(4-fluorophenyl)(8-methyl-3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7 (8H)-yl)methanone; (S)-(4-fluorophenyl)(3-(2-(4-fluorophenyl)thiazol-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4, 3-a]pyrazin-7(8H)-yl)methanone; (S)-(4'-fluoro-[1,1'-biphenyl]-4-yl)(8-methyl-3-(2-morpholinothiazol-4-yl)-5,6-dihydro-[1 ,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone; (S)-(4-fluorophenyl)(8-methyl-3-(quinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7 (8H)-yl)methanone; (S)-(8-methyl-3-(quinolin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl )(4-(thiophen-2-yl)phenyl)methanone; (S)-(4-fluorophenyl)(3-(2-(4-fluorophenyl)thiazol-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4, 3-a]pyrazin-7(8H)-yl)methanone; (S)-(3-(2-(2,4-difluorophenyl)thiazol-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a ]pyrazin-7(8H)-yl)(4-(thiophen-2-yl)phenyl)methanone; (4-fluorophenyl)(8-methyl-3-(2-phenylthiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H) )-yl)methanone; (S)-(4-fluorophenyl)(8-methyl-3-(2-phenylthiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin -7(8H)-yl)methanone; (S)-(3-(3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[ 4,3-a]pyrazin-7(8H)-yl)(4-(thiophen-2-yl)phenyl)methanone; (R)-(3-(3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[ 4,3-a]pyrazin-7(8H)-yl)(4-(thiophen-2-yl)phenyl)methanone; (3-(2-(2,4-difluorophenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)- yl)(4-(thiophen-2-yl)phenyl)methanone; (3-(5-phenyl-1,2,4-oxadiazol-3-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a] pyrazin-7(8H) -yl)(4-(thiophen-2-yl)phenyl)methanone; (4-fluorophenyl)(3-(3-phenyl-1,2,4-oxadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin -7(8H)-yl)methanone; (4-fluorophenyl)(3-(5-phenyl-1,2,4-oxadiazol-3-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin -7(8H)-yl)methanone; (3-(3-phenyl-1,2,4-oxadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H) -yl)(4-(thiophen-2-yl)phenyl)methanone; (4-fluorophenyl)(3-(3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3 -a]pyrazin-7(8H)-yl)methanone; (3-(3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl)(4-(thiophen-2-yl)phenyl)methanone; (3-(3-(2,4-difluorophenyl)-1,2,4-oxadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a] pyrazin-7(8H)-yl)(4-(thiophen-2-yl)phenyl)methanone; (4-fluorophenyl)(3-(5-phenyl-1H-1,2,4-triazol-3-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a ]pyrazin-7(8H)-yl)methanone; (3-(5-phenyl-1H-1,2,4-triazol-3-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7( 8H)-yl)(4-(thiophen-2-yl)phenyl)methanone; (4-fluorophenyl)(3-(2-(2-fluorophenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7( 8H)-yl)methanone; (3-(2-(2-fluorophenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl) (4-(thiophen-2-yl)phenyl)methanone; [1,1'-biphenyl]-4-yl(3-(2-(2-fluorophenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3 -a]pyrazin-7(8H)-yl)methanone; (4'-fluoro-[1,1'-biphenyl]-4-yl)(3-(2-(2-fluorophenyl)thiazol-4-yl)-5,6-dihydro-[1,2, 4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone; (3-(3-(2,4-difluorophenyl)-1,2,4-oxadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a] pyrazin-7(8H)-yl)(4-(thiophen-2-yl)phenyl)methanone; [1,1'-biphenyl]-4-yl(3-(2-((4,5-dichloro-1H-imidazol-1-yl)methyl)thiazol-4-yl)-5,6-dihydro -[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone; (3-(2-((4,5-dichloro-1H-imidazol-1-yl)methyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4, 3-a]pyrazin-7(8H)-yl)(4'-fluoro-[1,1'-biphenyl]-4-yl)methanone; (3-(2-(4-chlorobenzyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl) (4-fluorophenyl)methanone; (3-(2-(4-chlorobenzyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl) (4-(thiophen-2-yl)phenyl)methanone; (4-fluorophenyl)(3-(2-(p-tolyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7( 8H)-yl)methanone; (4-(thiophen-2-yl)phenyl)(3-(2-(p-tolyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3 -a]pyrazin-7(8H)-yl)methanone; [1,1'-biphenyl]-4-yl(3-(2-(p-tolyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3 -a]pyrazin-7(8H)-yl)methanone; (4-fluorophenyl)(3-(2-(thiophen-2-yl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl)methanone; (4-(thiophen-2-yl)phenyl)(3-(2-(thiophen-2-yl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4 ,3-a]pyrazin-7(8H)-yl)methanone; [1,1'-biphenyl]-4-yl(3-(2-(thiophen-2-yl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4 ,3-a]pyrazin-7(8H)-yl)methanone; (4'-fluoro-[1,1'-biphenyl]-4-yl)(3-(2-(thiophen-2-yl)thiazol-4-yl)-5,6-dihydro-[1, 2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone; (3-(2-(((4-chlorophenyl)sulfonyl)methyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7 (8H)-yl)(4-(thiophen-2-yl)phenyl)methanone; [1,1'-biphenyl]-4-yl(3-(2-(((4-chlorophenyl)sulfonyl)methyl)thiazol-4-yl)-5,6-dihydro-[1,2,4 ]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone; (3-(2-(((4-chlorophenyl)sulfonyl)methyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7 (8H)-yl)(4'-fluoro-[1,1'-biphenyl]-4-yl)methanone; (4-fluorophenyl)(3-(2-(2-methoxyphenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7( 8H)-yl)methanone; (3-(2-(2-methoxyphenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl) (4-(thiophen-2-yl)phenyl)methanone; [1,1'-biphenyl]-4-yl(3-(2-(2-methoxyphenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3 -a]pyrazin-7(8H)-yl)methanone; [1,1'-biphenyl]-4-yl(3-(3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl)-5,6-dihydro-[1,2, 4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone; (4'-fluoro-[1,1'-biphenyl]-4-yl)(3-(3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl)-5,6-di- hydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone; (4-fluorophenyl)(3-(2-(3-fluorophenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7( 8H)-yl)methanone; (3-(2-(3-fluorophenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl) (4-(thiophen-2-yl)phenyl)methanone; (4-fluorophenyl)(3-(2-isopropylthiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl) methanone; (3-(3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3- a]pyrazin-7(8H)-yl)(4-(thiophen-2-yl)phenyl)methanone; (3-(3-phenyl-1,2,4-thiadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H) -yl)(4-(thiophen-2-yl)phenyl)methanone; (4-fluorophenyl)(3-(3-phenyl-1,2,4-thiadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin -7(8H)-yl)methanone; (3-(2-(4-bromophenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl) (4-(thiophen-2-yl)phenyl)methanone; (3-(2-(4-bromophenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl) (4-fluorophenyl)methanone; (3-(2-(4-fluorophenyl)thiazol-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H )-yl)(4-(5-methylthiophen-2-yl)phenyl)methanone; 4-(3-(2-(4-fluorophenyl)thiazol-4-yl)-8-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a] pyrazine -7-carbonyl)benzonitrile; [1,1'-biphenyl]-4-yl(3-(3-phenyl-1,2,4-oxadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[ 4,3-a]pyrazin-7(8H)-yl)methanone; (4-fluorophenyl)(3-(2-(pyridin-4-yl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl)methanone; (3-(2-(quinolin-2-yl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)- yl)(4-(thiophen-2-yl)phenyl)methanone; (3-(1-methyl-3-phenyl-1H-pyrazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H) -yl)(4-(thiophen-2-yl)phenyl)methanone; (3-(2-(4-(dimethylamino)phenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H) -yl)(4-fluorophenyl)methanone; (3-(1-methyl-5-phenyl-1H-pyrazol-3-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H) -yl)(4-(thiophen-2-yl)phenyl)methanone; (4'-fluoro-[1,1'-biphenyl]-4-yl)(3-(3-phenyl-1,2,4-oxadiazol-5-yl)-5,6-dihydro-[1 ,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone; (3-(2-(pyridin-2-yl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)- yl)(4-(thiophen-2-yl)phenyl)methanone; (4-fluorophenyl)(3-(1-methyl-3-phenyl-1H-pyrazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin -7(8H)-yl)methanone; (3-(2-(pyrimidin-2-yl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)- yl)(4-(thiophen-2-yl)phenyl)methanone; (S)-(8-methyl-3-(2-morpholinothiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H) -yl)(4-(thiophen-2-yl)phenyl)methanone; (3-(2-(pyridin-4-yl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)- yl)(4-(thiophen-2-yl)phenyl)methanone; (3-(2-(4-(dimethylamino)phenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H) -yl)(4-(thiophen-2-yl)phenyl)methanone; (4-fluorophenyl)(3-(2-(pyridin-2-yl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl)methanone; phenyl(3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone; (3-(pyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(p-tolyl)methanone; (S)-(3-(2-(4-fluorophenyl)thiazol-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin -7(8H)-yl)(4-(2-methylthiophen-3-yl)phenyl)methanone; (R)-(3-(2-(4-fluorophenyl)thiazol-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin -7(8H)-yl)(4-(2-methylthiophen-3-yl)phenyl)methanone; (3-(2-(pyrazin-2-yl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)- yl)(4-(thiophen-2-yl)phenyl)methanone; 4-(4-(7-(4-(thiophen-2-yl)benzoyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3- yl)thiazol-2-yl)benzonitrile; (4-fluorophenyl)(3-(2-(pyrazin-2-yl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl)methanone; (4-fluorophenyl)(3-(1-methyl-5-phenyl-1H-pyrazol-3-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin -7(8H)-yl)methanone; (3-(2-(4-morpholinophenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl) (4-(thiophen-2-yl)phenyl)methanone; (4-fluorophenyl)(3-(2-(4-morpholinophenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7( 8H)-yl)methanone; (3-(2-(4-(4-methylpiperazin-1-yl)phenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a] pyrazin-7(8H)-yl)(4-(thiophen-2-yl)phenyl)methanone; (4-fluorophenyl)(3-(2-(4-(4-methylpiperazin-1-yl)phenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4 ,3-a]pyrazin-7(8H)-yl)methanone; (3-(2-(4-(piperidin-1-yl)phenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl)(4-(thiophen-2-yl)phenyl)methanone; (4-fluorophenyl)(3-(2-(4-(piperidin-1-yl)phenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3 -a]pyrazin-7(8H)-yl)methanone; (3-(2-(4-(pyrrolidin-1-yl)phenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl)(4-(thiophen-2-yl)phenyl)methanone; (4-fluorophenyl)(3-(2-(4-(pyrrolidin-1-yl)phenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3 -a]pyrazin-7(8H)-yl)methanone; (3-(2-(piperidin-1-yl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)- yl)(4-(thiophen-2-yl)phenyl)methanone; (3-(2-(pyrrolidin-1-yl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)- yl)(4-(thiophen-2-yl)phenyl)methanone; (4-fluorophenyl)(3-(2-(pyrrolidin-1-yl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl)methanone; (3-(2-(4-methylpiperazin-1-yl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H) )-yl)(4-(thiophen-2-yl)phenyl)methanone; (4-fluorophenyl)(3-(2-(4-methylpiperazin-1-yl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a] pyrazin-7(8H)-yl)methanone; (3-(1-methyl-2-phenyl-1H-imidazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H) -yl)(4-(thiophen-2-yl)phenyl)methanone; (4-(dimethylamino)phenyl)(3-(2-(4-fluorophenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin -7(8H)-yl)methanone; (3-(1-(2-methoxyethyl)-3-phenyl-1H-pyrazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl)(4-(thiophen-2-yl)phenyl)methanone; (4-fluorophenyl)(3-(1-(2-methoxyethyl)-3-phenyl-1H-pyrazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3 -a]pyrazin-7(8H)-yl)methanone; (3-(2-isobutylthiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(thiophene) -2-yl)phenyl)methanone; (3-(2-(2-(2-methoxyethyl)morpholino)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7( 8H)-yl)(4-(thiophen-2-yl)phenyl)methanone; (3-(2-(4,4-difluoropiperidin-1-yl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7 (8H)-yl)(4-fluorophenyl)methanone; (4-fluorophenyl)(3-(2-isobutylthiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl) methanone; (3-(2-(2,5-dimethylmorpholino)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)- yl)(4-(thiophen-2-yl)phenyl)methanone; (3-(2-(2-hydroxyphenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl) (4-(thiophen-2-yl)phenyl)methanone; (3-(2-(4,4-difluoropiperidin-1-yl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7 (8H)-yl)(4-(thiophen-2-yl)phenyl)methanone; (3-(2-(2,6-dimethylmorpholino)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)- yl)(4-(thiophen-2-yl)phenyl)methanone; (3-(2-(2,2-dimethylmorpholino)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)- yl)(4-(thiophen-2-yl)phenyl)methanone; (3-(3-phenyl-1H-pyrazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)( 4-(thiophen-2-yl)phenyl)methanone; (3-(2-(4-fluorophenyl)thiazol-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H )-yl)(4-(3-methylthiophen-2-yl)phenyl)methanone; (4-fluorophenyl)(3-(3-phenyl-1H-pyrazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H )-yl)methanone; (R)-(3-(2-(4-fluorophenyl)thiazol-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin -7(8H)-yl)(4-(3-methylthiophen-2-yl)phenyl)methanone; (4-fluorophenyl)(3-(2-(2-hydroxyphenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7( 8H)-yl)methanone; (S)-(3-(2-(4-fluorophenyl)thiazol-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin -7(8H)-yl)(4-(3-methylthiophen-2-yl)phenyl)methanone; (3-(2-(2-methylmorpholino)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl) (4-(thiophen-2-yl)phenyl)methanone; (3-(2-(4,4-dimethylpiperidin-1-yl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7 (8H)-yl)(4-(thiophen-2-yl)phenyl)methanone; (3-(5-methylthiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(thiophene) -2-yl)phenyl)methanone; (3-(2-(4,4-dimethylpiperidin-1-yl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7 (8H)-yl)(4-fluorophenyl)methanone; (4-fluorophenyl)(3-(2-(2-(methoxymethyl)piperidin-1-yl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3 -a]pyrazin-7(8H)-yl)methanone; (4-fluorophenyl)(8-methyl-3-(6-methylpyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H) )-yl)methanone; (3-(2-(2-(methoxymethyl)piperidin-1-yl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl)(4-(thiophen-2-yl)phenyl)methanone; (2-(2-(4-(7-(4-(thiophen-2-yl)benzoyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]) tert-butyl pyrazin-3-yl)thiazol-2-yl)phenoxy)ethyl)carbamate; (3-(2-(2-(2-hydroxyethoxy)phenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7( 8H)-yl)(4-(thiophen-2-yl)phenyl)methanone; (3-(2-(2-(2-aminoethoxy)phenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7( 8H)-yl)(4-(thiophen-2-yl)phenyl)methanone; N-(4-(4-(7-(4-(thiophen-2-yl)benzoyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin -3-yl)thiazol-2-yl)phenyl)methanesulfonamide; (3-(1-(2-hydroxyethyl)-3-phenyl-1H-pyrazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl)(4-(thiophen-2-yl)phenyl)methanone; (3-(1-(2-hydroxyethyl)-5-phenyl-1H-pyrazol-3-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl)(4-(thiophen-2-yl)phenyl)methanone; [1,1'-biphenyl]-4-yl(8-methyl-3-(6-methylpyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3- a]pyrazin-7(8H)-yl)methanone; (8-methyl-3-(6-methylpyridin-2-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)( 4-(thiophen-2-yl)phenyl)methanone; (3-(2-(2,4-difluorophenyl)-5-methylthiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7( 8H)-yl)(4-(thiophen-2-yl)phenyl)methanone; (3-(2-(3-(dimethylamino)phenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H) -yl)(4-(thiophen-2-yl)phenyl)methanone; (3-(2-(3-(dimethylamino)phenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H) -yl)(4-fluorophenyl)methanone; N-(3-(4-(7-(4-(thiophen-2-yl)benzoyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin -3-yl)thiazol-2-yl)phenyl)methanesulfonamide; N-(2-(4-(7-(4-(thiophen-2-yl)benzoyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin -3-yl)thiazol-2-yl)phenyl)methanesulfonamide; (3-(4-chlorophenyl)-1H-pyrazol-5-yl)(3-(2-(4-fluorophenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4] triazolo[4,3-a]pyrazin-7(8H)-yl)methanone; (3-(4-chlorophenyl)-1-methyl-1H-pyrazol-5-yl)(3-(2-(4-fluorophenyl)thiazol-4-yl)-5,6-dihydro-[1, 2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone; (3-(3,4-dichlorophenyl)-1-methyl-1H-pyrazol-5-yl)(3-(2-(4-fluorophenyl)thiazol-4-yl)-5,6-dihydro-[ 1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone; (5-(4-chlorophenyl)-1-methyl-1H-pyrazol-3-yl)(3-(2-(4-fluorophenyl)thiazol-4-yl)-5,6-dihydro-[1, 2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone; (2-(3-phenyl-5-(7-(4-(thiophen-2-yl)benzoyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo [4,3-a tert-butyl ]pyrazin-3-yl)-1H-pyrazol-1-yl)ethyl)carbamate; (2-(5-phenyl-3-(7-(4-(thiophen-2-yl)benzoyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a tert-butyl ]pyrazin-3-yl)-1H-pyrazol-1-yl)ethyl)carbamate; (3-(2-(2-bromophenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl) (4-(thiophen-2-yl)phenyl)methanone; (3-(2-(3-bromophenyl)thiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl) (4-(thiophen-2-yl)phenyl)methanone; 2-(4-(7-(4-(thiophen-2-yl)benzoyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3- yl)thiazol-2-yl)benzonitrile; 3-(4-(7-(4-(thiophen-2-yl)benzoyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazin-3- yl)thiazol-2-yl)benzonitrile; (3-(2-(4-fluorophenyl)thiazol-4-yl)-8-methyl-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H )-yl)(4-(2-methylthiophen-3-yl)phenyl)methanone, and a pharmaceutically acceptable salt or solvate thereof.
[0013]
13. Pharmaceutical composition, characterized in that it comprises a compound as defined in any one of claims 1 to 12 or a pharmaceutically acceptable salt or solvate thereof and at least one pharmaceutically acceptable carrier, diluent, excipient and/or adjuvant.
[0014]
14. Medicine, characterized in that it comprises a compound as defined in any one of claims 1 to 12 or a pharmaceutically acceptable salt or solvate thereof.

类似技术:

---

公开号 | 公开日 | 专利标题

---

US20200125564A1|2020-04-23|Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders

---

US10065960B2|2018-09-04|NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders

---

DK2497470T3|2015-12-07|Imidazotriaziner and imidazopyrimidines as kinase inhibitors

---

CA2825279A1|2012-08-09|New azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors

---

CA2967944C|2020-11-17|Aminopyrazine compounds with a2a antagonist properties

---

BR112020006334A2|2020-09-24|combination of pharmaceutical agents such as rsv inhibitors

---

AU2004255924A1|2005-01-20|Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases

---

CA3038280A1|2017-04-06|Heteroaryl derivatives as sepiapterin reductase inhibitors

---

EP2864330A1|2015-04-29|Pyrrolopyrazone inhibitors of tankyrase

---

US20130023531A1|2013-01-24|Pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors

---

WO2017046737A1|2017-03-23|1-phenylpyrrolidin-2-one derivatives as perk inhibitors

---

WO2014026467A1|2014-02-20|Bicyclic substituted pyrimidine compounds

---

WO2015155624A1|2015-10-15|Dihydropyrrolopyrimidine derivatives

---

CN104995183B|2018-04-06|The inhibitor compound of new phosphodiesterase 10 A types

同族专利:

---

公开号 | 公开日

---

EP2552920A1|2013-02-06|

---

CA2793313C|2018-01-23|

---

LT2552920T|2017-06-12|

---

KR20130021384A|2013-03-05|

---

EA201290940A1|2013-03-29|

---

DK2552920T3|2017-06-12|

---

CA2793313A1|2011-10-06|

---

CN102906093A|2013-01-30|

---

US10544150B2|2020-01-28|

---

AU2011234398A2|2013-01-17|

---

HUE032770T2|2017-10-30|

---

EA023161B1|2016-04-29|

---

KR101878888B1|2018-08-17|

---

ES2627688T3|2017-07-31|

---

RS55997B1|2017-09-29|

---

MX342161B|2016-09-19|

---

AU2011234398B2|2014-10-23|

---

US20140371218A1|2014-12-18|

---

PL2552920T3|2017-08-31|

---

JP2013523697A|2013-06-17|

---

PT2552920T|2017-06-07|

---

SI2552920T1|2017-07-31|

---

AU2011234398B8|2015-03-05|

---

MX2012011132A|2013-03-08|

---

US8871761B2|2014-10-28|

---

US20130023530A1|2013-01-24|

---

AU2011234398A8|2015-03-05|

---

US9926325B2|2018-03-27|

---

AU2011234398A1|2012-09-13|

---

WO2011121137A1|2011-10-06|

---

CN102906093B|2016-01-13|

---

HRP20170712T1|2017-07-28|

---

JP5822911B2|2015-11-25|

---

EP2552920B1|2017-03-15|

---

US20200125564A1|2020-04-23|

---

EP3176171A1|2017-06-07|

---

BR112012025101A2|2017-06-20|

---

AU2011234398C1|2015-02-26|

---

US20180194772A1|2018-07-12|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US1004609A|1911-02-07|1911-10-03|Farbenfab Vorm Bayer F & Co|Triphenylmethane dye.|

---

JP3252483B2|1992-10-20|2002-02-04|東レ株式会社|Method for producing tricyclic triazolo derivative|

---

WO2000043008A1|1999-01-25|2000-07-27|Smithkline Beecham Corporation|Anti-androgens and methods for treating disease|

---

MXPA01009871A|1999-04-01|2002-04-24|Pfizer Prod Inc|Aminopyrimidines as sorbitol dehydrogenase inhibitors.|

---

US7307164B2|2002-03-25|2007-12-11|Merck & Co., Inc.|β-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes|

---

DE60307483T2|2002-08-07|2007-07-05|Novartis Ag|ORGANIC COMPOUNDS AS A MEANS FOR THE TREATMENT OF ALTEROSTERONE-CONDITIONING STATES|

---

MY139563A|2002-09-04|2009-10-30|Squibb Bristol Myers Co|Heterocyclic aromatic compounds useful as growth hormone secretagogues|

---

AR043443A1|2003-03-07|2005-07-27|Merck & Co Inc|PROCEDURE FOR THE PREPARATION OF TETRAHYDROTRIAZOLOPIRAZINS AND INTERMEDIATE PRODUCTS|

---

US7468437B2|2003-09-30|2008-12-23|Merck & Co., Inc.|Phenyl pyrrolidine ether tachykinin receptor antagonists|

---

ES2309718T3|2004-02-18|2008-12-16|Astrazeneca Ab|CONDENSED HETEROCICLICAL COMPOUNDS AND THEIR USE AS ANTAGONISTS OF METABOTROPIC RECEPTORS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS.|

---

GB0509405D0|2005-05-10|2005-06-15|Merck Sharp & Dohme|Therapeutic compounds|

---

TWI378091B|2006-03-09|2012-12-01|Eisai R&D Man Co Ltd|Multi-cyclic cinnamide derivatives|

---

GB0610680D0|2006-05-31|2006-07-12|Istituto Di Ricerche D Biolog|Therapeutic compounds|

---

US7943617B2|2006-11-27|2011-05-17|Bristol-Myers Squibb Company|Heterobicyclic compounds useful as kinase inhibitors|

---

CN101686989B|2007-06-21|2016-10-19|卡拉治疗学股份有限公司|Substituted imidazoheterocycles|

---

CA2702518A1|2007-10-19|2009-04-23|Boehringer Ingelheim International Gmbh|New piperazino-dihydrothienopyrimidine derivatives|

---

AR069526A1|2007-12-03|2010-01-27|Takeda Pharmaceutical|HETEROCICLICAL COMPOUND CONTAINING NITROGEN AND ITS USE|

---

CN104876921A|2008-01-09|2015-09-02|阵列生物制药公司|5H-cyclopenta[d]pyrimidines As AKT Protein Kinase Inhibitors|

---

WO2009090055A1|2008-01-17|2009-07-23|Grünenthal GmbH|Substituted sulfonamide derivatives|

---

EP2085398A1|2008-02-01|2009-08-05|Merz Pharma GmbH & Co. KGaA|Pyrazolopyrimidines, a process for their preparation and their use as medicine|

---

EP2090576A1|2008-02-01|2009-08-19|Merz Pharma GmbH & Co.KGaA|6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor modulators|

---

EP2424869B1|2009-04-29|2016-06-22|Glaxo Group Limited|5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS|

---

GB0907515D0|2009-04-30|2009-06-10|Glaxo Group Ltd|Compounds|

---

EP2455380A4|2009-07-13|2012-11-28|Takeda Pharmaceutical|Heterocyclic compound and use thereof|

---

PT2552920T|2010-04-02|2017-06-07|Ogeda Sa|Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders|

---

US10065960B2|2010-04-02|2018-09-04|Ogeda Sa|NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders|

---

CA2849751C|2011-10-03|2019-06-11|Euroscreen Sa|Chiral n-acyl-5,6,7,-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptormediated disorders and chiral synthesis thereof|

---

CA2907809C|2013-03-29|2021-05-04|Euroscreen Sa|N-acyl---5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders|

---

EP2989103B1|2013-03-29|2019-02-20|Ogeda Sa|N-acyl---5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders|

---

WO2014154896A1|2013-03-29|2014-10-02|Euroscreen Sa|NOVEL N-ACYL--5,6,7,8-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS|JP3316889B2|1992-02-05|2002-08-19|株式会社デンソー|Vehicle direction detector|

---

EP2424869B1|2009-04-29|2016-06-22|Glaxo Group Limited|5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS|

---

WO2011082010A1|2009-12-29|2011-07-07|Eli Lilly And Company|Tetrahydrotriazolopyridine compounds as selective mglu5 receptor potentiators useful for the treatment of schizophrenia|

---

PT2552920T|2010-04-02|2017-06-07|Ogeda Sa|Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders|

---

US10065960B2|2010-04-02|2018-09-04|Ogeda Sa|NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders|

---

CA2849751C|2011-10-03|2019-06-11|Euroscreen Sa|Chiral n-acyl-5,6,7,-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptormediated disorders and chiral synthesis thereof|

---

TWI599567B|2013-03-14|2017-09-21|健生藥品公司|P2x7 modulators|

---

EP3321266A1|2013-03-14|2018-05-16|Janssen Pharmaceutica NV|P2x7 modulators|

---

JP6467404B2|2013-03-14|2019-02-13|ヤンセン ファーマシューティカ エヌ．ベー．|P2X7 modulator|

---

TWI627174B|2013-03-14|2018-06-21|比利時商健生藥品公司|P2x7 modulators|

---

EP2989103B1|2013-03-29|2019-02-20|Ogeda Sa|N-acyl---5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders|

---

CA2907809C|2013-03-29|2021-05-04|Euroscreen Sa|N-acyl---5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders|

---

WO2014154896A1|2013-03-29|2014-10-02|Euroscreen Sa|NOVEL N-ACYL--5,6,7,8-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS|

---

US10183948B2|2013-03-29|2019-01-22|Ogeda Sa|N-acyl---5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists|

---

WO2014170648A1|2013-04-19|2014-10-23|Astrazeneca Ab|A nk3 receptor antagonist compoundfor use in a method for the treatment of polycystic ovary syndrome |

---

GB201315846D0|2013-09-05|2013-10-23|Imp Innovations Ltd|Method for treating or preventing hot flushes|

---

RS59559B1|2014-02-13|2019-12-31|Incyte Corp|Cyclopropylamines as lsd1 inhibitors|

---

US9527835B2|2014-02-13|2016-12-27|Incyte Corporation|Cyclopropylamines as LSD1 inhibitors|

---

PE20161384A1|2014-02-13|2016-12-28|Incyte Corp|CYCLOPROPYLAMINES AS INHIBITORS OF LSD 1|

---

EP3392244A1|2014-02-13|2018-10-24|Incyte Corporation|Cyclopropylamines as lsd1 inhibitors|

---

US9695167B2|2014-07-10|2017-07-04|Incyte Corporation|Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors|

---

US9758523B2|2014-07-10|2017-09-12|Incyte Corporation|Triazolopyridines and triazolopyrazines as LSD1 inhibitors|

---

WO2016007731A1|2014-07-10|2016-01-14|Incyte Corporation|Imidazopyridines and imidazopyrazines as lsd1 inhibitors|

---

WO2016007736A1|2014-07-10|2016-01-14|Incyte Corporation|Imidazopyrazines as lsd1 inhibitors|

---

ES2714048T3|2014-09-12|2019-05-24|Janssen Pharmaceutica Nv|P2X7 modulators|

---

EP3191488B1|2014-09-12|2019-08-14|Janssen Pharmaceutica NV|P2x7 modulating n-acyl-triazolopyrazines|

---

PT3197876T|2014-09-25|2019-02-21|Ogeda Sa|Novel chiral synthesis of n-acyl---5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines|

---

WO2016146712A1|2015-03-16|2016-09-22|Euroscreen Sa|Nk-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat|

---

EA201792205A1|2015-04-03|2018-02-28|Инсайт Корпорейшн|HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS|

---

SG10202001219UA|2015-08-12|2020-03-30|Incyte Corp|Salts of an lsd1 inhibitor|

---

US10166221B2|2016-04-22|2019-01-01|Incyte Corporation|Formulations of an LSD1 inhibitor|

---

WO2017200857A1|2016-05-18|2017-11-23|Merck Sharp & Dohme Corp.|Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders|

---

WO2019145214A1|2018-01-26|2019-08-01|Recordati Industria Chimica E Farmaceutica S.P.A|TRIAZOLE, IMIDAZOLE AND PYRROLE CONDENSED PIPERAZINE DERIVATIVES AND THEIR USE AS MODULATORS OF mGlu5 RECEPTORS|

---

US10968200B2|2018-08-31|2021-04-06|Incyte Corporation|Salts of an LSD1 inhibitor and processes for preparing the same|

---

CN112272670A|2019-04-16|2021-01-26|上海翰森生物医药科技有限公司|Bicyclic derivative-containing inhibitor, preparation method and application thereof|

---

WO2022022680A1|2020-07-30|2022-02-03|上海翰森生物医药科技有限公司|Nitrogen-containing fused ring derivative inhibitor, preparation method therefor and use thereof|

法律状态:
2018-01-23| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|

---

2018-04-10| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|

---

2018-05-15| B25D| Requested change of name of applicant approved|Owner name: OGEDA S.A. (BE) |

---

2019-07-02| B07E| Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |

---

2019-09-03| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|

---

2020-06-02| B06A| Patent application procedure suspended [chapter 6.1 patent gazette]|

---

2020-10-27| B06A| Patent application procedure suspended [chapter 6.1 patent gazette]|

---

2021-02-23| B06A| Patent application procedure suspended [chapter 6.1 patent gazette]|

---

2021-06-22| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|

---

2021-08-31| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/04/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |

优先权:

---

申请号 | 申请日 | 专利标题

---

EP10305343|2010-04-02|

---

EP10305343.5|2010-04-02|

---

US37902810P| true| 2010-09-01|2010-09-01|

---

US61/379,028|2010-09-01|

---

PCT/EP2011/055218|WO2011121137A1|2010-04-02|2011-04-04|Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders|

---